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Abstract: With the onset of prostate-specific antigen (PSA) screening two decades ago the number of
prostate cancer suspicious cases has markedly increased. Due to the lack of specificity men with elevated
PSA levels need to be biopsied to confirm the diagnosis. In order to reduce the number of the unnecessary
taking of biopsies, new specific and non-invasive biomarkers are required to facilitate prostate cancer diag-
nosis. Here, we suggest calcium-activated nucleotidase (CANT) 1 as a novel serum marker candidate for
further validation. As a result of serum PSA measurement, also the number of confirmed prostate cancer
cases has risen. Especially more insignificant carcinomas are detected, which would never have affected
the patients’ life. Thus, overtreatment of these cases and the therapy-induced morbidity is a big issue in
clinical prostate cancer management. Within this study, we identify two potential prognostic biomarkers
to predict the risk of disease recurrence. This risk is reduced in patients with very high CANT1 protein
levels in their prostatectomy specimens. Applying the histochemical score to quantify CANT1 protein
levels, CANT1 is shown to be an independent prognostic biomarker. In contrast, strong forkhead box
(FOX) A1 expression is prognostically unfavourable. Since an ideal prognostic marker should be ap-
plied to pre- treatment samples, analysis of both immunohistochemical markers in large biopsy cohorts
is strongly recommended. Once the tumor has recurred, progression to castration-resistance is likely.
Further elucidation of the underlying mechanisms is necessary to progress in the development of life-
prolonging therapies for these patients. Here, we show that despite ubiquitous overexpression of Golgi
membrane protein (GOLM) 1 in prostate carcinomas, this protein has no functional relevance for the ana-
lyzed cancer cells. In contrast, knockdown of FOXA1 reduces in vitro tumorigenicity. Moreover, FOXA1
expression increases with prostate cancer progression and is associated with poor prognosis, especially in
cases with low androgen receptor levels. Thus, we conclude that FOXA1 upregulation is a novel mecha-
nism of castration-resistance for prostate cancer cells. Additionally, we reveal that CANT1 expression is
already elevated in the precursor lesion prostatic intraepithelial neoplasia. In vitro experiments establish
the secretion of CANT1 as well as the reduction of in vitro tumorigenicity accompanied by G1 cell cycle ar-
rest upon CANT1 knockdown. Furthermore, induction of selected unfolded protein response target genes
and enhancement of CANT1 mRNA expression upon stress induction in the endoplasmic reticulum (ER)
are indicated. We thus propose that CANT1 is upregulated in prostate carcinomas to counteract tumor-
associated ER stress. According to our model, this might be achieved by the interplay between soluble
truncated CANT1, which prevents calcium release from the ER, and full- length CANT1, which regulates
protein folding. Since knockdown of CANT1 heavily impaired proliferation of the hormone-independent
cell line PC-3, which is a model for castration- resistant prostate carcinomas, CANT1 might be an interest-
ing therapeutic target for this group of prostate carcinomas. Zusammenfassung Seit Beginn des prostata-
spezifischen Antigen (PSA)-Screenings vor zwei Jahrzehnten ist die Zahl der Prostatakrebs-Verdachtsfälle
deutlich angestiegen. Aufgrund der fehlenden Spezifität müssen Männer mit einem erhöhten PSA-Level
biopsiert werden, um die Diagnose zu bestätigen. Zur Reduktion der unnötigen Entnahmen von Biopsien
werden neue spezifische und nicht-invasive Biomarker benötigt, die die Prostatakrebsdiagnose verein-
fachen. In der vorliegenden Arbeit schlagen wir Calcium-aktivierte Nukleotidase (CANT) 1 als neuen
Serummarkerkandidaten für die weitere Evaluierung vor. Als Folge der Serum-PSA-Messung ist auch
die Zahl bestätigter Prostatakarzinomfälle gestiegen. Dabei werden hauptsächlich mehr insignifikante
Karzinome detektiert, die niemals das Leben der Patienten beeinträchtigt hätten. Daher ist die Über-
behandlung dieser Fälle und die therapieinduzierte Morbidität ein großes Thema im klinischen Manage-
ment von Prostatakrebs. In dieser Studie identifizieren wir zwei potentielle prognostische Biomarker zur
Vorhersage des Rezidivrisikos. Dieses Risiko ist in Patienten, deren Prostatektomie- präparate sehr hohe
CANT1-Proteinmengen aufweisen, reduziert. Es wird gezeigt, dass CANT1 unter Anwendung des histo-
chemischen Scores für die Quantifizierung von CANT1- Proteinmengen ein unabhängiger prognostischer
Biomarker ist. Im Gegensatz dazu ist eine starke Expression von Forkhead Box (FOX) A1 prognostisch
ungünstig. Da ein idealer prognostischer Marker an Proben, die vor der ersten Behandlung entnom-
men wurden, angewendet werden sollte, wird die Analyse von beiden immunhistochemischen Markern
in großen Biopsiekohorten empfohlen. Sobald ein Rezidiv des Tumors auftritt, ist die Progression zur
Kastrationsresistenz sehr wahrscheinlich. Die weitere Aufklärung der darunterliegenden Mechanismen ist
notwendig, um die Entwicklung lebensverlängernder Therapien für diese Patienten voranzutreiben. Hier
zeigen wir, dass Golgimembranprotein (GOLM) 1 trotz ubiquitärer Überexpression in Prostatakarzi-
nomen keine funktionelle Relevanz für die analysierten Krebszellen hat. Im Gegensatz dazu reduziert
die Herunterregulierung von FOXA1 die in vitro-Tumorigenität. Darüber hinaus steigt die Expression
von FOXA1 mit der Progression des Prostatakarzinoms und ist mit einer schlechten Prognose assoziiert,
besonders in Fällen mit niedrigen Androgenrezeptormengen. Daher schlussfolgern wir, dass FOXA1-
Aufregulation einen neuartigen Mechanismus der Kastrationsresistenz von Prostatakrebszellen darstellt.
Zusätzlich weisen wir eine erhöhte CANT1-Expression schon in der Vorläuferläsion der prostatischen
intraepithelialen Neoplasie nach. In vitro-Experimente zeigen die Sekretion von CANT1 sowie eine Re-
duktion der in vitro-Tumorigenität nach CANT1-Herunterregulierung, die von einem G1-Zellzyklusarrest
begleitet wird. Weiterhin deutet sich eine Induktion von ausgewählten Zielgenen der sogenannten „un-
folded protein response“ sowie eine Verstärkung der CANT1-mRNA-Expression nach Stressinduktion
im endoplasmatischen Retikulum (ER) an. Daher postulieren wir, dass CANT1 in Prostatakarzinomen
aufreguliert ist, um dem tumorassoziierten ER-Stress entgegenzuwirken. Unserem Modell zufolge könnte
dies erreicht werden durch ein Zusammenspiel zwischen löslichem abgespaltenem CANT1, welches die
Calcium-Freisetzung im ER verhindert, und membranverankertem CANT1, welches die Proteinfaltung
reguliert. Da die Herunterregulierung von CANT1 die Proliferation der hormonunabhängigen Zelllinie
PC-3, welche als Modell für kastrationsresistente Prostatakarzinome gilt, sehr stark beeinträchtigt, könnte
CANT1 ein interessantes therapeutisches Zielprotein für diese Gruppe von Prostatakarzinomen sein.
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Summary 
With the onset of prostate-specific antigen (PSA) screening two decades ago the number of 
prostate cancer suspicious cases has markedly increased. Due to the lack of specificity men 
with elevated PSA levels need to be biopsied to confirm the diagnosis. In order to reduce the 
number of the unnecessary taking of biopsies, new specific and non-invasive biomarkers are 
required to facilitate prostate cancer diagnosis. Here, we suggest calcium-activated 
nucleotidase (CANT) 1 as a novel serum marker candidate for further validation.  
 
As a result of serum PSA measurement, also the number of confirmed prostate cancer cases 
has risen. Especially more insignificant carcinomas are detected, which would never have 
affected the patients’ life. Thus, overtreatment of these cases and the therapy-induced 
morbidity is a big issue in clinical prostate cancer management. Within this study, we identify 
two potential prognostic biomarkers to predict the risk of disease recurrence. This risk is 
reduced in patients with very high CANT1 protein levels in their prostatectomy specimens. 
Applying the histochemical score to quantify CANT1 protein levels, CANT1 is shown to be an 
independent prognostic biomarker. In contrast, strong forkhead box (FOX) A1 expression is 
prognostically unfavourable. Since an ideal prognostic marker should be applied to pre-
treatment samples, analysis of both immunohistochemical markers in large biopsy cohorts is 
strongly recommended. 
 
Once the tumor has recurred, progression to castration-resistance is likely. Further 
elucidation of the underlying mechanisms is necessary to progress in the development of life-
prolonging therapies for these patients. Here, we show that despite ubiquitous 
overexpression of Golgi membrane protein (GOLM) 1 in prostate carcinomas, this protein 
has no functional relevance for the analyzed cancer cells. In contrast, knockdown of FOXA1 
reduces in vitro tumorigenicity. Moreover, FOXA1 expression increases with prostate cancer 
progression and is associated with poor prognosis, especially in cases with low androgen 
receptor levels. Thus, we conclude that FOXA1 upregulation is a novel mechanism of 
castration-resistance for prostate cancer cells. Additionally, we reveal that CANT1 
expression is already elevated in the precursor lesion prostatic intraepithelial neoplasia. In 
vitro experiments establish the secretion of CANT1 as well as the reduction of in vitro 
tumorigenicity accompanied by G1 cell cycle arrest upon CANT1 knockdown. Furthermore, 
induction of selected unfolded protein response target genes and enhancement of CANT1 
mRNA expression upon stress induction in the endoplasmic reticulum (ER) are indicated. We 
thus propose that CANT1 is upregulated in prostate carcinomas to counteract tumor-
associated ER stress. According to our model, this might be achieved by the interplay 
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between soluble truncated CANT1, which prevents calcium release from the ER, and full-
length CANT1, which regulates protein folding. Since knockdown of CANT1 heavily impaired 
proliferation of the hormone-independent cell line PC-3, which is a model for castration-
resistant prostate carcinomas, CANT1 might be an interesting therapeutic target for this 
group of prostate carcinomas. 
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Zusammenfassung 
Seit Beginn des prostata-spezifischen Antigen (PSA)-Screenings vor zwei Jahrzehnten ist 
die Zahl der Prostatakrebs-Verdachtsfälle deutlich angestiegen. Aufgrund der fehlenden 
Spezifität müssen Männer mit einem erhöhten PSA-Level biopsiert werden, um die Diagnose 
zu bestätigen. Zur Reduktion der unnötigen Entnahmen von Biopsien werden neue 
spezifische und nicht-invasive Biomarker benötigt, die die Prostatakrebsdiagnose 
vereinfachen. In der vorliegenden Arbeit schlagen wir Calcium-aktivierte Nukleotidase 
(CANT) 1 als neuen Serummarkerkandidaten für die weitere Evaluierung vor.  
 
Als Folge der Serum-PSA-Messung ist auch die Zahl bestätigter Prostatakarzinomfälle 
gestiegen. Dabei werden hauptsächlich mehr insignifikante Karzinome detektiert, die niemals 
das Leben der Patienten beeinträchtigt hätten. Daher ist die Überbehandlung dieser Fälle 
und die therapieinduzierte Morbidität ein großes Thema im klinischen Management von 
Prostatakrebs. In dieser Studie identifizieren wir zwei potentielle prognostische Biomarker 
zur Vorhersage des Rezidivrisikos. Dieses Risiko ist in Patienten, deren Prostatektomie-
präparate sehr hohe CANT1-Proteinmengen aufweisen, reduziert. Es wird gezeigt, dass 
CANT1 unter Anwendung des histochemischen Scores für die Quantifizierung von CANT1-
Proteinmengen ein unabhängiger prognostischer Biomarker ist. Im Gegensatz dazu ist eine 
starke Expression von Forkhead Box (FOX) A1 prognostisch ungünstig. Da ein idealer 
prognostischer Marker an Proben, die vor der ersten Behandlung entnommen wurden, 
angewendet werden sollte, wird die Analyse von beiden immunhistochemischen Markern in 
großen Biopsiekohorten empfohlen. 
 
Sobald ein Rezidiv des Tumors auftritt, ist die Progression zur Kastrationsresistenz sehr 
wahrscheinlich. Die weitere Aufklärung der darunterliegenden Mechanismen ist notwendig, 
um die Entwicklung lebensverlängernder Therapien für diese Patienten voranzutreiben. Hier 
zeigen wir, dass Golgimembranprotein (GOLM) 1 trotz ubiquitärer Überexpression in 
Prostatakarzinomen keine funktionelle Relevanz für die analysierten Krebszellen hat. Im 
Gegensatz dazu reduziert die Herunterregulierung von FOXA1 die in vitro-Tumorigenität. 
Darüber hinaus steigt die Expression von FOXA1 mit der Progression des Prostatakarzinoms 
und ist mit einer schlechten Prognose assoziiert, besonders in Fällen mit niedrigen 
Androgenrezeptormengen. Daher schlussfolgern wir, dass FOXA1-Aufregulation einen 
neuartigen Mechanismus der Kastrationsresistenz von Prostatakrebszellen darstellt. 
Zusätzlich weisen wir eine erhöhte CANT1-Expression schon in der Vorläuferläsion der 
prostatischen intraepithelialen Neoplasie nach. In vitro-Experimente zeigen die Sekretion von 
CANT1 sowie eine Reduktion der in vitro-Tumorigenität nach CANT1-Herunterregulierung, 
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die von einem G1-Zellzyklusarrest begleitet wird. Weiterhin deutet sich eine Induktion von 
ausgewählten Zielgenen der sogenannten „unfolded protein response“ sowie eine 
Verstärkung der CANT1-mRNA-Expression nach Stressinduktion im endoplasmatischen 
Retikulum (ER) an. Daher postulieren wir, dass CANT1 in Prostatakarzinomen aufreguliert 
ist, um dem tumorassoziierten ER-Stress entgegenzuwirken. Unserem Modell zufolge könnte 
dies erreicht werden durch ein Zusammenspiel zwischen löslichem abgespaltenem CANT1, 
welches die Calcium-Freisetzung im ER verhindert, und membranverankertem CANT1, 
welches die Proteinfaltung reguliert. Da die Herunterregulierung von CANT1 die Proliferation 
der hormonunabhängigen Zelllinie PC-3, welche als Modell für kastrationsresistente 
Prostatakarzinome gilt, sehr stark beeinträchtigt, könnte CANT1 ein interessantes 
therapeutisches Zielprotein für diese Gruppe von Prostatakarzinomen sein. 
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1 Introduction 
1.1 The clinical aspects of prostate cancer 
1.1.1 An overview of prostate histology  
The prostate surrounds the urethra and the healthy organ weighs 30 to 40 g in adult men. It 
is organized in three zones, the inner transition zone and the outer peripheral and central 
zones. Histologically, the prostate contains epithelial and stromal parts, whereas the 
epithelial cells are arranged in glands. These consist of ducts that branch out from the 
urethra. Each gland is framed by a secretory (inner) and basal (outer) cell layer. Prostatic 
intraepithelial neoplasia (PIN), which is believed to be the precursor lesion of prostate cancer 
[3, 4], is characterized by a benign architecture with large and branched glands. However, 
nuclei are atypic, they are enlarged and hyperchromatic and have prominent nucleoli.  
A B
C D
Fig. 1 Prostate histology. 
Hematoxylin & eosin stainings of human prostatic tissues. (A) Benign prostate gland with 
secretory and basal cells surrounded by stroma. (B) High grade PIN (HGPIN), note the 
prominent nucleoli. (C) Prostate adenocarcinoma with small glands (center) infiltrating 
between benign glands. (D) Prostate adenocarcinoma showing enlarged nuclei with nucleoli. 
Note the mitotic figure (arrow). A benign gland is seen in the lower right. A, C and D from [5], 
B from [4]. 
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The main characteristic of prostate adenocarcinoma is the absence of basal cells. Further, 
glands are small, tend to crowd and infiltrate between benign glands. Nuclei look similar to 
PIN, additionally, mitotic figures and apoptotic bodies are observed. Mucinous secretions can 
be found in the lumina of the glands [5] (Fig. 1).  
1.1.2 Epidemiology, risk factors and general course of the disease 
Prostate cancer is diagnosed 5500 to 6000 times a year in Switzerland and is therefore the 
most common malignancy in men. However, regarding mortality, with 1300 deaths per year 
prostate cancer stays behind lung cancer, which has a death rate of 2000 cases per year [6]. 
Similar incidence and mortality rates are observed in other western countries [7]. Yet, in 
Afroamericans incidence is up to 34 % higher and mortality is even two fold elevated 
compared to Caucasians [8]. This difference is probably genetically determined, as it is 
reflected in the American population [9]. In contrast, the clearly lower incidence of prostate 
cancer among Japanese is believed to be related to their low-fat diet with high 
concentrations of phytoestrogens [9]. 
Independent on the ethnic origin, age is the major risk factor for prostate cancer [9]. 
Autopsies revealed that actually 80 % of men above 80 have prostate cancer [10] (Fig. 2). 
The fact, that most of these tumors are never diagnosed, reflects the disease course. 
Prostate cancer is usually slowly growing and most of the tumors never affect the patient and 
are therefore called insignificant carcinomas. However, a significant fraction of the cases 
progresses and metastasizes or relapses after initial surgery or radiotherapy. These tumors 
are generally treated by hormonal therapy, which leads to tumor shrinkage in the beginning. 
Finally, basically all of these tumors start growing again within two years and are then called 
castration-resistant prostate carcinomas (CRPC) [9]. 
Further, family history influences the risk for prostate cancer. Men, whose brother or father 
suffers from the disease, have a double risk to develop prostate cancer theirselves [11]. 
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Fig. 2 Prevalence of prostate cancer. 
Relation between prevalence of prostate cancer at autopsy, clinically diagnosed cases and 
prostate cancer deaths. *Prostate cancer at autopsy implies examination of prostate in men 
dying from reasons other than prostate cancer and undergoing autopsy. From [9]. 
 
1.1.3 Diagnosis  
1.1.3.1 Diagnostic scheme at the University Hospital Zurich 
The initial indication to conduct a more elaborate diagnostic procedure for prostate cancer is 
usually a positive digital rectal examination (DRE) or elevated levels of prostate-specific 
antigen (PSA) in serum. The threshold at the University Hospital Zurich ranges from 2.5 to 
4 ng/ml, depending on the age of the patient and the difference compared to the previous 
measurement [11]. However, increased PSA secretion into the blood also occurs in benign 
prostatic hyperplasia (BPH) or prostatitis. Further, serum PSA levels depend on age, body 
mass index and race. Hence, most of the men with increased PSA levels actually do not 
have prostate cancer [8]. Therefore, for further discrimination, ten systematic needle biopsies 
are taken transrectal, analyzed histologically and the Gleason score is determined. For the 
final diagnosis of suspicious lesions, immunohistochemistry is applied. The presence of 
basal cells in normal prostate glands is proven by expression of the marker proteins p63 or 
cytokeratin 5/6, whereas tumor cells can be identified by strong staining with alpha-
methylacyl-CoA racemase (AMACR), Golgi membrane protein (GOLM) 1 and fatty acid 
synthase (FASN) antibodies. In the case of a positive prostate cancer diagnosis, additional 
imaging techniques are employed to detect metastases. Since no unified diagnostic 
guidelines exist for prostate cancer, the scheme varies between hospitals and countries [9]. 
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In 2004, the World Health Organization called to search for novel biomarkers with a higher 
specificity than serum PSA [9], which specifically detect prostate cancer but are not elevated 
in benign prostatic diseases. Until now, our and other groups examined myriad patient 
samples including blood, urine and tissue concerning changes in transcriptomics, miRNA 
expression, proteomics and metabolomics [12-19]. However, no marker has been identified 
so far, which has generally been accepted as being superior to PSA. The most promising 
novel candidate is the non-coding RNA prostate cancer antigen (PCA) 3, for which a 
diagnostic kit has been developed [20]. 
1.1.3.2 PSA screening 
The serine protease PSA is important to liquify seminal fluid. Increased PSA levels in the 
serum are a hallmark of prostate cancer. PSA is one of the few molecular markers that are 
routinely used in the diagnosis of common types of cancer. Also prognosis and monitoring of 
prostate cancer rely on serum PSA levels. Notably, this increase is not due to overpression 
of the enzyme by tumor cells, rather, increased secretion is the cause [8]. Since 1994 a 
screening for prostate cancer based on PSA detection in the serum was introduced in 
various countries [21, 22]. In Switzerland a regular check-up is recommended for men with a 
life expectancy of more than 10 years [11]. Thus, the increasing number of tests resulted in 
an increase of incidence during the past two decades [9, 23, 24]. Simultaneously, the 
percentage of patients below 70 as well as of low-grade tumors has increased, probably 
because these tumors do not show any symptoms and therefore remained undetected 
before [9, 11]. Because this group of tumors often does not affect the patient’s health, benefit 
of the screening has been questioned. Two studies including 200.000 patients claim that the 
risk to die from prostate cancer is decreased by 50 and 20 %. However, 293 and 1410 men 
need to be screened of which 12 and 48 men, respectively, need to be treated to save one 
life [23, 24]. A third study did not reveal any benefit in the screening cohort [25]. These trials 
substantiate the need of novel non-invasive diagnostic tools to minimize the number of 
biopsies as well as of novel prognostic biomarkers to better distinguish insignificant 
carcinomas that do not need to be treated. 
1.1.3.3 Clinicopathological parameters 
In general, staging of malignant tumors is done according to the TNM classification, which 
describes the circumference of the primary tumor (T) and the existence of regional lymph 
node metastases (N) and/or distant metastases (M). Tumors can be classified according to 
clinical (TNM classification) or pathological (pTNM classification) standards [26]. In Tab. 2, 
the criteria of each category for prostate carcinomas are listed. 
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Tab. 2 TNM classification for prostate carcinomas. 
stage criteria 
T1 tumor not palbable and not detectable with imaging techniques 
T1a tumor ≤ 5 % of the resected tissue 
T1b tumor > 5 % of the resected tissue 
T1c tumor identified by needle biopsy 
T2 tumor confined to prostate 
T2a tumor ≤ 50 % of one lobe 
T2b tumor > 50 % of one lobe 
T2c tumor involves both lobes 
T3 tumor extends through the prostate capsule 
T4 tumor is fixed or invades adjacent structures other than seminal vesicles 
N1 regional lymph node metastases 
M1 distant metastases  
 
Grading of prostate cancer is done according to the Gleason score, which was established 
by Donald Gleason. He described five patterns of prostate gland organization and 
designated these patterns Gleason grade one to five. Gleason grade one corresponds to 
small, uniform glands, whereas Gleason grade five corresponds to poorly differentiated 
tumors with lack of any glandular structure and single tumor cells (Fig. 3 a). In radical 
prostatectomy (RPE) specimens, the Gleason score is built of the sum of the two most 
common patterns, resulting in possible values from two to ten (reviewed in [27], examples in 
Fig. 3 b, c). In needle biopsies, the highest value is always included, independent of the area 
[9]. A further clinicopathological parameter is the resection margin being either free of tumor 
cells (R0) or not (R1). 
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A B
C
Fig. 3 Gleason grading. 
(A) Gleason grades: standard drawing. (B) Hematoxylin & eosin staining of prostate 
adenocarcinoma Gleason score 3+4=7, gleason pattern 4 left. (C) Hematoxylin & eosin 
staining of prostate adenocarcinoma Gleason score 3+5=8, gleason pattern 5 left. A from 
[27], C and D from [5]. 
 
1.1.4 Prognosis  
Prognosis for the patient mainly depends on the tumor stage at the time of diagnosis. 
Patients with so called localized carcinomas without metastases, generally have the highest 
chance not to die from their tumor. Based on the PSA level, Gleason score and T-stage, 
these patients are sub-divided into a low risk (PSA level < 10 ng/ml, Gleason score ≤ 6, T1c-
2a, in Zurich maximal two of ten biopsies positive), intermediate risk (PSA level 10 to 20 
ng/ml, Gleason score 7, T2b) and high risk group (PSA level > 20 ng/ml, Gleason score ≥ 8, 
T2c). The 5 year-survival rate for these three groups is 85 %, 60 % and 30 %, respectively 
[28, 29]. For patients with metastases to regional lymph nodes (stage N1) the median 
cancer-specific survival is eight years. In contrast, patients with distant metastases (stage 
M1) die within 24 to 48 months upon diagnosis [9]. Especially for the intermediate risk group 
with Gleason score 7, novel biomarkers that are able to predict the risk of recurrence, are 
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needed. In general, the main challenge concerning prognosis is to distinguish insignificant 
carcinomas from such cases that have a high probability to progress in order to decide for 
the optimal treatment. 
1.1.5 Treatment 
Generally, selection of the therapeutic strategy is very individual. Patient’s age, disease 
stage, medical condition and will are the parameters that determine the treatment modality. 
Possible options are active surveillance, RPE, radiotherapy, hormonal therapy, chemo-
therapy, immunotherapy and various other approaches. Active surveillance is mainly applied 
for early-stage cancer patients (high probability to be insignificant) with a live expectancy of 
less than ten years [9] to avoid treatment side-effects [30]. RPE and radiotherapy are the 
major options for localized tumors, whereas radiotherapy is additionally administered to 
patients with locally advanced disease. Hormonal therapy is the treatment of choice for 
patients with distant metastases at the first diagnosis, after a PSA-relapse or adjuvant to 
radiotherapy in case of locally advanced tumors [9]. Chemotherapy and immunotherapy are 
the main options for treatment of CRPC. In 2004, clinicians succeeded for the first time to 
prolong overall survival of CRPC patients using chemotherapeutics [31, 32]. Recently, the 
first immunotherapeutic, Sipuleucel-T, was approved by the US Food and Drug 
Administration for patients with asymptomatic or minimally symptomatic CRPC. Peripheral 
blood mononuclear cells are harvested from the patient, incubated with a chimeric protein 
and reinfused into the patient’s blood. The protein is composed of granulocyte-macrophage 
colony-stimulating-factor (GM-CSF) to activate antigen presentation and prostatic acid 
phosphatase (PAP) as tumorassociated antigen. Median survival was prolonged from 21.7 to 
25.8 months [33]. 
1.1.5.1 Hormonal therapy 
Efficacy of androgen ablation by orchiectomy or estrogen injection was first proven 60 years 
ago [34]. Further approaches at the stage of pituitary hormone secretion, androgen synthesis 
in the testes and adrenal glands and androgen receptor (AR) action in the tumor cells were 
addressed in several studies. Gonadotropin-releasing hormone antagonists and agonists 
block the corresponding receptors in the pituitary gland and thus prevent release of follicle-
stimulating hormone and luteinizing hormone which normally trigger testosterone production 
in the testes. The pregnenolone derivative arbiraterone acetate (currently phase III) blocks 
steroid synthesis in the adrenal glands and testes. Similarly the glucocorticoid prednisone 
inhibits androgen synthesis in the adrenal glands. Finally antiandrogens are widely used to 
block the AR function within the prostate cells. Bicalutamide and MDV3100 (currently phase 
III) belong to the group of competing androgen antagonists that interact with the ligand 
binding domain of AR. Such compounds prevent androgens from binding to AR and thus 
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inhibit AR-mediated transcriptional activation by disabling AR from either nuclear 
translocation, DNA binding or coactivator recruitment [35] (Fig. 4).  
Usually a combination treatment of androgen depletion and antiandrogens is applied, called 
combined androgen blockade [35]. Overall, hormonal therapy initially reduces the disease 
symptoms in 70-80 % of the patients [9]. However, after a certain period of quiescence, PSA 
levels rise again indicating relapse of the tumor, which is then castration-resistant (CRPC) 
[35]. 
 
Fig. 4 The androgen-signaling axis and its inhibitors.  
Androgen synthesis is regulated by the hypothalamus-pituitary axis and takes place in the 
testes and adrenal glands. Within the prostate dihydrotestosterone (DHT) is generated from 
testosterone and activates AR signaling. The mode of action of various agents to block 
androgen synthesis or signaling is illustrated. For further explanations concerning AR 
signaling see chapter 1.2.1. From [35]. CRH = corticotropin-releasing hormone, ACTH = 
adrenocorticotropic hormone, DHEA = dehydroepiandrosterone, DHEA-S = DHEA-sulphate, 
ARE = androgen responsive element. 
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1.2 The molecular biology of prostate cancer 
1.2.1 Steroid hormones and their receptors 
Prostate cell growth and survival generally depend on androgens, which are provided by the 
testes and the adrenal glands. Androgen signaling is induced by binding of dihydro-
testosterone (DHT) to the ligand-binding domain of AR. DHT is the active derivative of 
testosterone and is generated by reduction of the hormone, this reaction is catalyzed by the 
5α-reductase in the stromal cells of the prostate. Upon ligand binding, the active steroid 
hormone receptor dimerizes, translocates into the nucleus and binds to corresponding 
androgen responsive elements (ARE) in the promoter or enhancer regions of target genes 
via its DNA-binding domain. Following recruitment of coactivators via the N-terminal domain, 
transcription is initialized [36, 37] (Fig. 5). Also prostate cancer cells rely on androgen 
signaling, even in cancer cells of CRPC AR is detected in the nucleus and androgen 
responsive genes are expressed [38].  
 
Fig. 5 Androgen signaling in a prostatic cell.  
Modified from [36]. HSP = heat-shock protein, ARA70 = 70 kDa AR-activator, GTA = general 
transcription apparatus, P = phosphate. 
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Estrogens play a dual role during development of prostate cancer. On the one hand, 
estrogens have been shown to delay prostate cancer progression, which was related to their 
antiandrogenic effect by preventing luteinizing hormone release in the pituitary [34, 39]. On 
the other hand, several studies indicate a promoting role of estrogens in prostate 
carcinogenesis, which is probably mediated by ERα. Comparison of estrogen and 
testosterone levels during aging and between ethnicities substantiates the positive 
correlation between estrogen levels and prostate carcinogenesis. At the age when prostate 
cancer starts to develop, testosterone levels decline, however, estrogen levels remain 
unchanged or even increase. Further, testosterone levels are similar in men of different 
ethnic background, in contrast estrogen levels are higher in African Americans compared to 
Caucasian Americans and very low in Japanese, strikingly correlating with prostate cancer 
incidence rates (reviewed in [40, 41]).  
ERβ has a high affinity to phytoestrogens. Soy products, which are staple food in Japan, 
contain high concentrations of these agents. Phytoestrogens were shown to reduce serum 
PSA levels, activity of 5α-reductase and expression of AR and thus to inhibit cell proliferation 
and angiogenesis. Probably these reactions are mediated by ERβ. Altogether, ERα is 
designated the “bad” and ERβ the “good” estrogen receptor concerning prostate cancer 
development (reviewed in [9, 41]). Both receptors have a similar, highly conserved DNA 
binding domain. However, ligand-specificity and N-terminal domains are different and 
important for signal processing [42]. 
1.2.2 Epithelial-stromal interactions 
Interactions between epithelial and stromal cells are of great importance within the prostate. 
The stromal cells express 5α-reductase and AR and thus process androgen signals, which 
are forwarded to the epithelial cells via paracrine factors and their corresponding receptors. 
These factors include extracellular matrix proteins, transforming growth factor (TGF) β, 
platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), insulin-like 
growth factor (IGF), fibroblast growth factor (FGF), hepatocyte growth factor (HGF), 
epidermal growth factor (EGF) and chemokine (C-X-C motif) ligand (CXCL) 12. Although 
epithelial AR expression increases during prostate cancer development, these interactions 
still remain essential for tumor survival (reviewed in [43, 44]). 
1.2.3 Genomic alterations 
In general, prostate cancer is a very heterogenous and complex disease [45]. However, 
there are two specific genomic alterations that are frequently observed: phosphatase and 
tensin homolog (PTEN) deletion and gene fusion between a prostate-specific androgen-
regulated gene and an avian erythroblastosis virus E26 (v-ets) oncogene homolog (ETS) 
gene. PTEN deletion was detected in 23 % of HGPIN and 68 % of primary carcinomas [46]. 
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Gene fusions occur in 56 % of prostate carcinomas [47], the most frequent fusion transcript 
is the one between transmembrane protease, serine 2 and the ETS family member ERG 
(TMPRSS2:ERG) for which our group revealed a prevalence of 41 % [48]. In two cases, 
calcium-activated nucleotidase (CANT) 1 was identified as 5’ androgen-regulated fusion 
partner [47, 49]. The promoters of these genes are used to induce expression of the 
oncogenic ETS transcription factors [50] in the prostate. Interestingly, serine peptidase 
inhibitor, Kazal type (SPINK) 1 was reported to be exclusively overexpressed in fusion 
negative carcinomas and to be related to poor prognosis. Cell culture and mouse studies 
revealed an association between SPINK1 expression and tumorigenic potential [51, 52]. 
Mutations or amplifications of the AR gene are barely found in primary prostate carcinomas. 
In contrast, 58 % of metastatic lesions display alterations regarding AR, which is either 
mutated, amplified or overexpressed [53].  
1.2.4 Gene and protein expression in prostate cancer 
The heterogeneity of prostate cancer becomes obvious also on the level of gene expression. 
Various gene expression studies have been conducted and identified many genes that are 
up- or downregulated in the cancer cells [54-57]. Our group performed a gene array study 
including matched normal and cancerous tissue, which was microdissected, from 42 patients 
and identified non-conding RNA PCA3, prostate-specific G-protein coupled receptor (PSGR), 
ATP-binding cassette sub-family C member (ABCC) 4, GOLM1, T-cell receptor gamma 
alternate reading frame protein (TARP), CANT1, FASN, anterior gradient homolog (AGR) 2, 
forkhead box (FOX) A1 and a disintegrin and metallopeptidase domain (ADAM) 9 amongst 
the top ugregulated genes in prostate cancer [15]. The overexpression on protein level was 
confirmed for GOLM1, TARP, FASN and ADAM9 [16, 17, 58, 59] so far. The detailed 
analysis of the protein expression pattern of CANT1 and FOXA1 in prostatic tissues is part of 
this thesis. 
1.3 CANT1 
1.3.1 CANT1 gene and protein 
The CANT1 gene is located on chromosome 17q25.3 [60], two alternative first exons (exon 1 
and 1a) have been described [49]. 
The corresponding transcripts result in the same full-length protein, which consists of 401 
amino acids and was detected at 37 to 42 kDa by Western Blot analysis [60, 61]. Analysis of 
the protein sequence predicted two internal start codons, one N-glycosylation site, one 
tyrosine sulfation site, two N-myristoylation sites, one cyclic AMP- and cyclic GMP-
dependent protein kinase phosphorylation site, one cysteine residue, and six protein kinase 
(PK) C and casein kinase II phosphorylation sites [60, 62]. Further, a weak and a strong 
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hydrophobic stretch were identified, suggesting full-length CANT1 to be a transmembrane 
protein, most likely a single pass transmembrane protein of type II with the strong 
hydrophobic stretch crossing the membrane and the long C-terminus facing the extracellular 
space. However, also a model with both protein termini facing the extracellular space and 
two transmembrane domains is discussed [62, 63]. Treatment with peptide: N-glycosidase 
(PNGase) F confirmed glycosylation of the protein. Yet, also after deglycosylation, a double 
band was seen in Western Blots, indicating further modifications of the protein or use of an 
internal start codon [60, 62]. Post-translational modifications as well as the transmembrane 
domain appear not to have any functional relevance as the truncated soluble form of CANT1, 
which was expressed in bacteria, displayed similar nucleotidase activity compared to its full-
length counterpart, which was expressed in mammalian cells [61]. 
1.3.2 CANT1 enzymatic activity 
1.3.2.1 CANT1 is an apyrase 
CANT1 was discovered in the human expressed sequence tag GenBank database as a 
homologous clone of the apyrase cDNA clone from the blood-sucking insect C.lectularius 
(bed bug) and therefore its functionality as apyrase was examined [60]. Apyrases (Enzyme 
Commission number 3.6.1.5, ATP-diphosphohydrolases) hydrolyze ADP and ATP to AMP 
and inorganic phosphate. While also other di- and triphosphates can be substrates, 
monophosphates or nonnucleoside phosphates are not dephosphorylated. The activity of this 
enzyme class is dependent on divalent cations [64]. Indeed, calcium-dependent ADPase and 
ATPase activity was detected in CANT1-transfected cells [60, 61]. Analysis of further 
potential substrates revealed UDP as preferred target for CANT1, followed by IDP and GDP. 
Weak hydrolytic activities were also measured for UTP, GTP, ITP, CDP and CTP. In 
comparison to UDP, hydrolytic activities for ADP and ATP were weak as well. No 
monophosphates were hydrolyzed by CANT1 [60-62]. 
Enzymatic activity of CANT1 was shown to be dependent on homodimerization of the 
protein, which in turn is dependent on calcium [61, 63, 65, 66]. Dimerization has been 
demonstrated for the truncated soluble as well as for the full-length transmembrane form of 
CANT1 [63]. 
1.3.2.2 Apyrase families  
Two families of apyrases have been described so far, based on their primary amino acid 
similarity. The first family of so called NTPDases is characterized by five invariant apyrase-
conserved regions that are essential for enzymatic function. Eight family members with 
different substrate-specificities have been identified so far. The ectoenzymes NTPDase 1, 2, 
3 and 8 are highly glycosylated and are expressed on the surface of vessels, nerves and in 
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the liver. NTPDase 1 and 2 are critical regulators of blood vessel homeostasis. Less 
research has been carried out on NTPDases 4 to 7. NTPDase 5 and 6 are usually expressed 
intracellular, although they are secreted upon heterologous expression. NTPDase 4 and 7 
are localized in intracellular organelles (reviewed in [67]). 
The second family consists of apyrases from blood-feeding insects and their vertebrate 
homologs. CANT1 is a member of this latter family and besides the bed bug apyrase further 
homologs are known in C.elegans (APYrase [apy]-1), X.laevis, rat and mouse [62, 68, 69]. 
No traditional apyrase-conserved regions or nucleotide-binding domains were found in this 
class of enzymes, however, eight nucleotidase-conserved regions could be identified [65, 70, 
71]. 
Both families show no amino acid homology and are evolutionarily unrelated to each other, 
however, their enzymatic function is highly analogous. For example, NTPDase 1 efficiently 
hydrolyzes ADP [72], which usually induces coagulation by activating purinergic receptors on 
platelets. Hence, this enzyme is an important regulator of blood fluidity [67]. Similarly, the 
bed bug apyrase is secreted into the host’s wound to hydrolyze ADP [73] and thus to inhibit 
platelet clotting and enable the insect to blood-feed for extended times. This feature of 
apyrases could be useful in treating thrombosis. In fact, NTPDase 1 is tested as thrombosis 
drug [74]. However, the disadvantage of this enzyme is that it also hydrolyzes ATP to ADP 
which promotes thrombosis [75]. Therefore, approaches to modify CANT1 in a way that it 
effectively hydrolyzes ADP but not ATP are under investigation. Indeed, certain CANT1 
mutants were generated that inhibited coagulation, dissolved existing platelet aggregates 
and inhibited thrombosis in a mouse model [76, 77]. 
1.3.3 CANT1 expression 
CANT1 mRNA was detected in a variety of human organs. Strongest expression was 
revealed in testis, small intestine, placenta and prostate. Additionally, the transcript was 
detected in the lung, stomach, salivary glands, colon, spleen, ovary, thymus and trachea [49, 
60]. Transcript-specific measurement revealed the transcript starting at exon 1a to be 
prostate-specific [49]. 
Yet, both transcripts were shown to be inducible by treatment of LNCaP cells with the 
synthetic androgen R1881 [49]. As demonstrated by chromatin immunoprecipitation analysis 
this was caused by direct binding of AR to the promoter of CANT1 [47]. 
1.3.4 CANT1 mutations in a chondrodysplasia 
Desbuquois dysplasia is a rare autosomal recessive chondrodysplasia. It is a severe skeletal 
disorder characterized by short limbs, spondylometaphyseal abnormalities, osteopenia, 
advanced carpotarsal ossification, ligamentous joint laxity, flat midface, cleft palate and  
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progressive scoliosis [78]. Mutations in the CANT1 gene were revealed to be causative for 
most of the cases. Several nonsense or missense mutations in the nucleotidase-conserved 
regions were identified. All mutations resulted in CANT1 loss-of-function [70, 79-81].  
1.4 FOXA1 
FOXA1 was first detected in nuclear extracts of rat liver and hepatoma cells (HepG2) and 
therefore named initially hepatocyte nuclear factor 3α (HNF3α). It was identified as the 
transcription factor that induces expression of transthyretin and α1-antitrypsin [82-84]. The 
gene is located on chromosome 14q12-q13. 
1.4.1 The FOX family 
Due to the similarity between the DNA binding domains of HNF3α and the D.melanogaster 
protein fork head, Weigel et al. suggested to designate this domain “forkhead box” and to 
found a corresponding family of transcription factors [85, 86]. HNF3α as the first member of 
the first subfamily was later renamed into FOXA1 [87, 88]. Meanwhile the forkhead 
transcription factor family comprises 19 subfamilies and 50 members [89]. These are 
characterized by a so called „winged helix“ 3D-structure similar to that of linker histones [90-
93] (Fig. 6). This enables FOX proteins to open highly compacted chromatin [94] and thus to 
facilitate the binding of other transcription factors, which prompted researchers to call this 
class of proteins “pioneer factors”. Hence, with a few exceptions, these proteins activate 
target gene transcription [95].  
 
Fig. 6 Comparison of the structure of HNF3 (= FOXA) proteins to that of linker 
histones. 
Schematics of the tertiary structure of the DNA binding domain of HNF3y (= FOXA3, amino 
acid 107-223), which is very similar to that of FOXA1 [84], and the globular domain of linker 
histone H5 (GH5). Both proteins are viewed looking towards the DNA-binding surface as if 
the target DNA was running vertically. Modified from [90]. N = N-terminus, C = C-terminus, 
H = α-helix, S = β-strand, W = loop region. 
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In general, FOX transcription factors are important during early vertebrate development and 
organogenesis. In the adult organisms, these proteins play a role in glucose and lipid 
metabolism and energy balance [95]. Several family members, amongst others also FOXA1, 
are involved in the development and progression of various carcinomas [96]. 
1.4.2 FOXA1 in development and metabolism 
FOXA1 in particular is involved in the organogenesis of the prostate, lung, liver, pancreas 
and breast [97-102]. In adult rodents expression of FOXA1 was detected in the brain, 
gastrointestinal tract, respiratory tract, thyroid glands and urogenital tract including the 
prostate [95, 103, 104]. FOXA1 knockout mice die early after birth due to hypoglycaemia, 
which indicates that the major function of FOXA1 in the adult organism is glucose 
homeostasis. Accordingly, dramatically reduced glucagon levels in the blood and 
proglucagon levels in pancreatic islets were measured [105, 106]. 
1.4.3 FOXA1 in the prostate 
FOXA1 is essential for prostate development and is still expressed in the adult prostate [98, 
99, 103, 104]. The protein has been shown to be responsible for activating transcription of 
prostatic genes specifically in the prostate but not in other tissues, e.g. probasin [107], the 
transcription factor homeobox (HX) B13, which is important during prostate development 
[108] and NK3 homeobox (NKX3.) 1 [98]. 
A small study on whole mount RPE sections from 20 primary prostate carcinomas, which 
included benign and malignant tissue, revealed a strong expression of FOXA1 in normal 
tissue and no upregulation in PIN or carcinoma tissue [109]. Very recently, analysis of a 
cohort of 80 primary and 28 metastatic prostate carcinomas revealed a much higher 
prevalence of strongly stained cases in the metastatic group and positive correlation of 
FOXA1 with tumor  size, extraprostatic extension, angiolymphatic invasion, lymph node 
metastases at diagnosis and AR staining [110]. 
1.4.4 FOXA1 regulation and signaling 
The consensus DNA binding sequence for FOXA transcription factors is 
A(A/T)TRTT(G/T)RYTY (R = purine, Y = pyrimidine) [111]. Lupien et al. [112] suggested that 
the methylation status of histones H3 at lysine 4 is critical for binding of FOXA1 to chromatin, 
which was confirmed by Wang et al. [113]. Thus, histone methylation is critical for lineage-
specific FOXA1 transcriptional regulation (Fig. 7). 
Once bound to chromatin, FOXA1 recruits various other transcription factors to activate gene 
transcription, amongst others ERα [114], AR [98, 115, 116], breast cancer (BRCA) 1 [117] 
and CCCTC-binding Factor (CTFC) [118]. However, interaction with for example transducin-
like enhancer of split (TLE) 3 represses expression of usually positively regulated target 
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genes and interaction with NKX2.1 can influence target gene transcription in both ways [117-
122]. 
FOXA1 itself can be induced by GATA binding protein (GATA) 3, ERα, SRY (sex determining 
region Y)-box (SOX) 17, β-Catenin and SOX 4 [123-126]. 
1.4.5 The relationship between FOXA1 and steroid hormone receptors  
The relationship between FOXA1 and ERα was best investigated in breast cells so far. A 
correlation between FOXA1 and ERα expression in breast cell lines and tissue was revealed 
[117]. In the same study, these two transcription factors were identified as downstream 
targets of GATA3. Together, these three proteins build a hormonal transcription factor 
network, which is specific for the luminal cell type in the breast [101, 123, 127]. The overlap 
between FOXA1 and ERα binding to chromatin was more than 50 % in three breast cancer 
cell lines [114].  
Fig. 7 Lineage-specific transcriptional regulation by FOXA1 in breast and prostate 
cancer cells.  
FOXA1 binds to genomic regions harbouring the FOXA binding motif and carrying the 
activating histone methylation (histone 3 lysine 4). Subsequent chromatin remodelling opens 
the DNA and allows estrogen receptor and AR to bind and to induce estrogen and androgen-
dependent target gene transcription, respectively. From [128]. H = histone, K = lysine, me = 
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methylated, E2 = estradiol, ER = estrogen receptor, ERE = estrogen responsive element. 
Accordingly, FOXA1 was shown to be needed for the recruitment of ERα to the promoters of 
50 % of ERα target genes [114, 125, 129, 130] and for ERα transcriptional activity [114]. 
Thus, FOXA1 is essential for hormonal responsiveness of luminal breast cells during 
mammary development as well as in breast cancer [101, 123, 127] (Fig. 7). FOXA1 itself is 
also inducible by estrogens [125] and ERα expression in turn is regulated by FOXA1 [101]. 
The binding motif for FOXA1  is also enriched in the AR cistrome [131]. FOXA1 binding to 
ARE independent of androgen concentrations as well as a direct physical interaction 
between FOXA1 and AR was reported [115, 116, 132, 133]. Hence, various androgen-
regulated genes are not expressed in the prostate of FOXA1 deficient mice [98] (Fig. 7). 
1.5 GOLM1 
GOLM1 was first described in a patient suffering from acute adult giant-cell hepatitis as Golgi 
protein, which was detected at 73 kDa by Western Blot analysis, and therefore named GP73 
[134]. Another designation is GOLPH2 (Golgi phosphoprotein 2). The function of the protein 
is still unknown.  
1.5.1 GOLM1 gene and protein 
The gene GOLM1 is located on chromosome 9q21.33. Two transcript variants exist that 
result in the same protein with a theoretical mass of 45 kDa. Due to glycosylation in 
combination with additional post-translational modifications or abnormal migration because of 
the high rate of acidic amino acids, the protein is detected at a molecular weight of 73 kDa in 
Western Blot analyses [134, 135]. Sequence analysis suggests a mainly hydrophilic protein 
with a hydrophobic N-terminus, a single transmembrane domain, a signal peptidase 
cleavage site, a N-myristoylation site, several coiled-coil domains after the transmembrane 
domain, five glycosylation sites and no enzymatic activity [134]. Indeed, GOLM1 was found 
to be a transmembrane protein of type II with a short cytoplasmic N-terminus and a long 
luminal C-terminus, which is structurally similar to p63, 130 kDa Golgi-localized 
phosphoprotein (GPP130) and Golgin-84 [134, 136, 137].  
1.5.2 Expression of GOLM1 
Several organs were shown to express GOLM1, amongst others stomach, colon, prostate 
and trachea, the expression is weaker in testes, spleen and liver [134].  
A Golgi targeting sequence was identified within the coiled-coil domains [136, 137]. 
Consistently, in immunofluorescence studies the protein was detected in the cis- and medial-
compartments of the Golgi apparatus [134]. Additionally, it was detected at the cell surface 
and in sorting endosomes, from where it is directly transported to the trans-Golgi network 
bypassing late endosomes [136]. Further, a truncated soluble form is detectable in serum. A 
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concordant consensus sequence for proprotein convertases was identified 20 amino acids 
away from the transmembrane domain on the luminal side of the protein and cleavage by 
furine was proven [138].  
1.5.3 GOLM1 in the liver 
In the healthy liver, GOLM1 is only expressed in epithelial cells, however, elevated levels 
were detected in diseased hepatocytes, either due to cirrhosis, hepatitis or hepatitis C virus-
infection [137, 139]. In liver cell lines GOLM1 was shown to be induced by adenoviral 
infection [134, 140]. 
It is further upregulated in hepatocellular carcinoma (HCC) [141-143] and serves as serum 
marker for the diagnosis and disease surveillance of HCC that is superior to alpha-
fetoprotein (AFP) in certain applications [138, 141, 142, 144]. Hyperfucosylation of GOLM1 in 
HCC was reported [141], followed by the discovery that GOLM1 expression in Hep3B cells 
can be induced by overexpression of the fucosyltransferase 8 [145]. 
1.5.4 GOLM1 in prostate cancer 
GOLM1 mRNA was shown to be elevated in prostate cancer in several studies [15, 54, 146-
148] and applicability of GOLM1 mRNA as urinary marker was proven [147, 149].  
N
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Fig. 8 GOLM1 immunohistochemistry of human prostatic tissues. 
(A) Gleason 3+3=6 adenocarcinoma (center) infiltrating in between normal glands (N). Note 
the upregulation of GOLM1 in comparison to normal glands. (B) The same case at a higher 
magnification. Note the characteristic Golgi pattern. From [16]. 
 
Corresponding augmented GOLM1 protein levels in prostate cancer were revealed in a small 
cohort of 40 patients [146] and confirmed by our group in a study including 640 patients. 
Although a weak staining was detected in normal tissue, GOLM1 expression was increased 
in 92 % of the tumors. Thus, GOLM1 was suggested as novel histological biomarker for the 
diagnosis of prostate cancer and is already applied in the University Hospital Zurich. The  
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difference in the staining intensity being low in normal tissue, intermediate in PIN and high in 
carcinoma was highly significant. However, no correlation with pT stage, Gleason score, pre-
operative (pre-OP) serum PSA level or PSA-relapse was found [16] (Fig. 8). 
1.5.5 GOLM1 in other diseases 
In lung cancer, a strong association between GOLM1 expression and adenocarcinomas in 
contrast to squamous carcinomas was revealed [150]. In seminomas, GOLM1 is 
overexpressed in comparison to normal tissue and was therefore suggested as novel 
diagnostic biomarker [151]. Further, GOLM1 expression is more frequent in the hepatic 
phenotype of Wilson disease compared to the neurologic phenotype [152]. Finally, a 
polymorphism in the GOLM1 gene is discussed as risk factor for Alzheimer disease [153-
155]. 
1.6 Protein glycosylation 
Protein glycosylation, here defined as adding of sugar molecules to peptide chains, plays a 
role in three cellular processes: synthesis of glycoproteins and proteoglycans and protein 
folding. This chapter gives an overview of these processes and the associated unfolded 
protein response (UPR). 
1.6.1 Glycoproteins 
Glycoproteins are defined as proteins that are covalently linked to more or less branched 
oligosaccharides, which are composed of miscellaneous monosaccharides. Depending on 
the sugar-peptide bond, glycoproteins are subdivided into N- and O-glycosylated proteins. In 
N-glycosylated proteins the oligosaccharide is bound to the amido-group of asparagine, 
whereas in O-glycosylated proteins the oligosaccharide is bound to the hydroxy group of 
serine or threonine (reviewed in [156]). 
1.6.1.1 N-glycosylated proteins 
N-glycosylation takes place in the endoplasmic reticulum (ER) and the Golgi apparatus. The 
consensus-sequence for N-glycosylation is asparagine-X-serine/threonine, whereas X can 
be any amino acid except proline. In all eukaryotes, the sugar-peptide bond is built between 
the asparagine and N-acetylglucosamine (GlcNAc), which is part of the core oligosaccharide 
GlcNAc2Man9Glc3 (Glc = glucose, Man = mannose). This core oligosaccharide is synthesized 
by transferring the monosaccharides to dolicholphosphate (Dol-PP), which is integrated in 
the ER-membrane. This biosynthesis takes place in the cytoplasm and in the ER, whereby 
cytoplasmic sugar donors are UDP-GlcNAc, GDP-Man and UDP-Glc and ER-sugar donors 
are Dol-P-Man and Dol-P-Glc. The core oligosaccharide is added to the nascent peptide 
chain, which is translocated into the ER during protein synthesis. Next, the three Glc and one 
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Man are trimmed, the polypeptide chain is folded into its native 3D-structure and the protein 
is transported into the Golgi apparatus. There, diverse sugar molecules are removed and 
added in a protein- and tissue-specific manner. The used monosaccharides are GlcNAc, 
galactose (Gal), sialic acid and fucose that are donated by the nucleotides CMP, GDP and 
UDP (reviewed in [156], Fig. 9). 
Fig. 9 N-glycosylation of proteins.  
For explanations of the quality control step see chapter 1.6.2. Green ellipse symbolizes 
correctly folded glycoprotein. Modified from [156]. UGGT = UDP-Glc glycoprotein 
glucosyltransferase, Sia = sialic acid, Fuc = fucose. 
 
1.6.1.2 O-glycosylated proteins 
O-glycosylation takes as well place in the ER and the Golgi apparatus. The first sugar can 
either be Man, which is derived from Dol-P-Man in the ER, or N-acetylgalactosamine, which 
is donated by UDP in the cis-Golgi apparatus. All the following sugar molecules are added in 
the Golgi apparatus and are transferred from nucleotides (reviewed in [156]).  
1.6.2 Protein folding and quality control  
As described in chapter 1.6.1.1, a core oligosaccharide is added to freshly translated 
proteins as soon as the consensus sequence enters the ER lumen. Subsequently all three 
Glc are hydrolyzed. The question is why does the core oligosaccharide contain Glc 
molecules that are removed shortly after transfer? These Glc have two important functions: 
Firstly, they are a signal for correct transfer of the core oligosaccharide. Secondly, 
glucosylation status is a marker of the protein’s folding status [156]. 
Immediately after transfer of the core oligosaccharide, the outermost two Glc are removed 
and the polypeptide chain associates with calnexin or calreticulin. These two chaperones 
assist protein folding and most of the proteins leave the complex in their native 3D-structure. 
Subsequently, also the innermost Glc is cleaved and the protein can leave the ER towards 
the Golgi apparatus. However, if the protein is not folded correctly, which is sensed by the 
enzyme UDP-Glc glycoprotein glucosyltransferase (UGGT), the polypeptide chain is 
reglucosylated by this enzyme and enters another calnexin/calreticulin cycle. In this case, 
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UDP-Glc is the donor for the Glc molecule. Terminally misfolded proteins are unfolded, 
retrotranslocated into the cytoplasm and degraded in the proteasome, a pathway called ER-
associated degradation (ERAD) (reviewed in [157], Fig. 10).  
 
Fig. 10 Protein folding and quality control.  
From [158]. EDEM = ER degradation enhancer, mannosidase alpha-like. 
 
1.6.3 UPR 
In case of overload of the ER with newly synthesized unfolded and/or misfolded proteins the 
capacity of the folding machinery is exceeded, which triggers a signaling pathway named 
UPR. Simultaneously, general protein synthesis is stopped to reduce the amount of unfolded 
proteins and expression of specific proteins, that handle unfolded proteins, is promoted. 
“Handle” means either folding of the proteins or degradation of misfolded proteins (ERAD). If 
the cell fails to re-establish the balance between unfolded and misfolded proteins on the one 
side and capacity of the folding machinery on the other side, cell death is initiated.  
The three major mediators of this signaling pathway are inositol-requiring protein (IRE) 1, 
activating transcription factor (ATF) 6 and protein kinase RNA-like endoplasmic reticulum 
kinase (PERK). IRE1 mainly activates X-box binding protein (XBP) 1, which induces 
transcription of ERAD genes. A truncated form of ATF6 directly enters the nucleus and 
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induces transcription of UPR genes. PERK phosphorylates and thus inactivates eukaryotic 
translation initiation factor (eIF) 2, which leads to general translational inhibition. Yet, 
translation of the transcription factor ATF4 is specifically activated, which induces 
transcription of further UPR- as well as cell death-related genes. In its function as ER 
chaperone, heat-shock protein (HSP) A5 is the main sensor of overload with misfolded 
proteins and is in turn upregulated in the course of the UPR (reviewed in [159, 160], Fig. 11).  
Fig. 11 Signaling during the UPR.  
From [160]. Bip = HSPA5, CHOP = CCAAT/enhancer-binding protein homologous protein.  
 
1.6.4 Proteoglycans 
In contrast to glycoproteins, proteoglycans are defined as proteins that are covalently linked 
to long unbranched polysaccharides, which consist of repeating disaccharides. The 
polysaccharide chains are designated glycosaminoglycans because the disaccharide unit is 
composed of an amino sugar that alternates with an acidic sugar. Hence, these chains are 
highly negatively charged. Proteoglycan synthesis takes place in the Golgi apparatus and is 
initiated by adding the tetrasaccharide Xyl-Gal-Gal-GlcA (Xyl = xylose, GlcA = glucuronic 
acid) to the hydroxyl group of serine (compare chapter 1.6.1). Afterwards the respective 
monosaccharides are added alternating (reviewed in [161]). In all reactions donor molecules 
are again nucleotides. 
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1.6.5 Nucleotide sugar transporters 
As explained above sugar molecules have to be activated by addition to nucleotides or 
dolicholphosphate before they can be transferred to proteins. Sugar donors for 
dolicholphosphate-sugar conjugates are again nucleotide sugars. These nucleotide sugar 
molecules are generally synthesized in the cytoplasm, except CMP-sialic acid, which is 
synthesized in the nucleus. In any case, they need to be imported into the lumen of the ER 
and Golgi apparatus, which is catalyzed by a family of nucleotide sugar transporters. These 
proteins are antiporters that exchange one nucleotide sugar molecule for the corresponding 
nucleotide monophosphate, e.g. UDP-Glc for UMP in the ER (reviewed in [162, 163], Fig. 
12). Thus, for being exported, the nucleotide diphosphates need to be hydrolyzed after 
transfer of the sugar. 
 
Fig. 12 Import of nucleotide sugars into the ER or Golgi apparatus.  
After transfer of the sugar to the protein, the remaining NDP is hydrolyzed by an NDPase 
and the emerging NMP is exported into the cytosol in exchange for an incoming nucleotide 
sugar. From [164]. 
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2 Aims of the study 
This study addressed the challenges of prostate cancer diagnosis, prognosis and treatment 
by the description of novel diagnostic and/or prognostic biomarkers for prostate cancer and 
the functional characterization of these proteins. From a previous gene array study published 
by our group, CANT1, FOXA1 and GOLM1 were selected for further analyses due to 
overexpression of these genes in prostate cancer specimens.  
Recently, overexpression of GOLM1 was confirmed on protein level. Immunohistochemical 
analysis of GOLM1 protein expression in tissue specimens as well as GOLM1 mRNA 
measurement in urine were suggested to be applied in prostate cancer diagnostics. In the 
first part of this study, similar analyses were conducted for CANT1 and FOXA1. The 
expression patterns of both proteins were analyzed immunohistochemichally in tissue 
specimens of different stages of prostate cancer development. For CANT1, protein secretion 
was evaluated in the supernatant of prostate cancer cells as well as serum samples. The 
diagnostic and prognostic potential of the candidate markers was evaluated by comparing 
CANT1 and FOXA1 protein expression levels between normal and cancer samples and by 
analysing the correlation between protein expression and clinicopathological and survival 
data, respectively.  
For each protein, the tumorbiological relevance was investigated. Therefore, expression of 
the protein was analyzed in benign and malignant prostatic cell lines and specific knockdown 
and/or overexpression protocols were established in the corresponding cell lines with high or 
low endogenous protein levels. Of these cells, cell proliferation and migration rate and cell 
cycle distribution were studied in in vitro assays in comparison to control cells. 
Finally, the underlying mechanism responsible for the involvement of CANT1 in tumor 
initiation was examined in more detail. This will help to better understand the molecular 
processes during prostate cancer development and thus contribute to the identification of 
novel therapeutic targets and finally to the design of more effective treatments. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Reagent lists 
3.1.1.1 Primary antibodies 
 
Tab. 3 Primary antibodies.  
WB = Western Blot, IHC = immunohistochemistry, IF = immuofluorescence, ELISA = 
enzyme-linked immunosorbent assay, GFP = green fluorescent protein. 
protein company, clone species clonality application 
Actin Millipore (MAB1501, 
Billerica, MA, USA) 
mouse monoclonal WB 
CANT1 Abnova (clone 2D3, 
Taipei, Taiwan) 
mouse monoclonal WB, IHC, IF, 
ELISA 
CANT1 Sigma-Aldrich 
(HPA019639, St. 
Louis, MO, USA) 
rabbit polyclonal ELISA 
FOXA1/2 
(HNF3α/β) 
Santa Cruz Biotech-
nologies (clone C-20, 
Santa Cruz, CA, USA) 
goat polyclonal WB, IHC, IF 
GOLM1 
(GOLPH2) 
Abnova (clone 3B10) mouse monoclonal WB 
GOLM1 
(GOLPH2) 
Abcam (Cambridge, 
UK) 
rabbit polyclonal IF 
tGFP OriGene (Rockville, 
MD, USA) 
mouse monoclonal WB 
HSPA5 Sigma-Aldrich 
(HPA038846) 
rabbit polyclonal WB 
NTPDase5 
(ENTPD5) 
Sigma-Aldrich 
(HPA002927) 
rabbit polyclonal WB 
AR BioGenex (clone 
F39.4.1, San Ramon, 
CA, USA) 
mouse monoclonal IHC, IF 
ERα Ventana Medical 
Systems (clone SP1, 
Tucson, AZ, USA) 
rabbit monoclonal IHC 
ERβ AbD Serotec (clone 
57/3, Oxford, UK) 
mouse monoclonal IHC 
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3.1.1.2 Secondary antibodies 
 
Tab. 4 Secondary antibodies. 
antibody, conjugate company application 
goat anti mouse – horseradish peroxidase Pierce Biotechnology 
(Rockford, IL, USA) 
WB 
goat anti rabbit – horseradish peroxidase Pierce Biotechnology WB 
donkey anti goat – horseradish peroxidase Santa Cruz 
Biotechnologies 
WB 
goat anti mouse – Alexa 488 Invitrogen (Carlsbad, 
CA, USA) 
IF 
goat anti rabbit – Alexa 546 Invitrogen IF 
donkey anti goat – Alexa 546 Invitrogen IF 
goat anti rabbit – horseradish peroxidase Sigma-Aldrich ELISA   
 
3.1.1.3 Primers 
 
Tab. 5 Primers. 
ALAS = aminolevulinate, delta-, synthase, HPRT = hypoxanthine phosphoribosyltransferase, 
TRIB = tribbles homolog, Herpud = homocysteine-inducible, endoplasmic reticulum stress-
inducible, ubiquitin-like domain member,  
gene forward primer reverse primer probe # 
ALAS1 5’ TAA TGA CTA CCT 
AGG AAT GAG TCG 3’ 
5’ CCA TGT TGT TTC 
AAA GTG TCC A 3’ 
43 
HPRT1 5’ TGA CCT TGA TTT 
ATT TTG CAT ACC 3’ 
5’ CGA GCA AGA CGT 
TCA GTC CT 3’ 
73 
CANT1 5’ CTG GGT GTC CAA 
CTA CAA CG 3’ 
5’ ACT CCA GCA GGC 
AGA CTC AT 3’ 
42 
FOXA1 5’ AGG GCT GGA TGG 
TAT TG 3’ 
5’ ACC GGG ACG 
GAG GAG TAG 3’ 
1 
GOLM1 5’ AAC AAC GAC CAG 
AGA CAG CA 3’ 
5’ CCT TGT GGC ACC 
TCT GTG T 3’ 
64 
HSPA5 5’ CAG CCT GGC GAC 
AAG AGT 3’ 
5’ CCT TGG GCA GTA 
TTG GAT TC 3’ 
39 
TRIB3 5’ GTC TTC GCT GAC 
CGT GAG A 3’ 
5’ CAG TCA GCA CGC 
AGG AGT C 3’ 
67 
Herpud1 5’ CAA AAA TGC CAG 
AAA TCA ACG 3’ 
5’ CTG TCC CCG ATT 
AGA ACC AG 3’ 
82 
NTPDase5 5’ TTT GGA TTG AAA 
GCT GCA AG 3’ 
5’ GAA AGT GTG CCC 
ATC AGT CC 3’ 
80 
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All probes were labeled with a FAM reporter dye. Primers and probes were purchased from 
Microsynth (Balgach, Switzerland) and Roche Applied Science (Mannheim, Germany), 
respectively. 
3.1.1.4 SiRNAs 
 
Tab. 6 SiRNAs. 
gene # siRNA target sequence 
unspecific  5’ AAT TCT CCG AAC GTG TCA CGT 3’ 
CANT1 #1 
#2 
5’ CCA GAT CAT TGT GGC CCT CAA 3’ 
5’ ACC CGG AAT GGA ATG AGT CTA 3’ 
FOXA1 #1 
#2 
#3 
5’ CCA GAC GGG TTT CAT TAT TAT 3’ 
5’ CAA ACC GTC AAC AGC ATA ATA 3’ 
5’ CTC CTC CGT CCC GGT CAG CAA 3’ 
GOLM1 #1 
#2 
#3 
5’ AAG CGG AAT CAT ACA CTC TGA 3’ 
5’ CAT GTT TAA TTT GTA CGC ATA 3’  
5’ TAG GCT CTT ACC ACT TGC AAA 3’ 
NTPDase5  5’ CTG CCT AAC CAC TCA AGA GTA 3’  
 
SiRNAs were purchased from Qiagen (Hilden, Germany) and were applied in a final 
concentration of 10 nM.  
3.1.2 Patients material 
3.1.2.1 Tissue samples for the study on CANT1 
Two patient cohorts were used to follow CANT1 expression during prostate cancer 
development and to evaluate the diagnostic and prognostic potential of CANT1 immuno-
histochemistry.  
Cohort #1 consists of formalin-fixed paraffin-embedded prostate tissues from 529 patients, 
who were diagnosed at the Institute of Surgical Pathology, University Hospital Zurich, 
between 1993 and 2006 [18]. Clinical follow-up data were available for 201 patients following 
RPE. Seventy-nine patients (39 %) experienced a PSA-relapse, defined as a rising PSA level 
exceeding 0.1 ng/ml, having reached a nadir after surgery. The median follow-up time (of all 
patients) was 67 months. This study was approved by the Cantonal Ethics Committee of 
Zurich (approval number StV 25-2007). The clinicopathological data for evaluable (see 
chapter 3.2.1.1) primary carcinoma cases are given in Tab. 7. 
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Tab. 7 Clinicopathological data of primary prostate carcinoma specimens (RPE) in 
cohort #1 (n=238). 
Only the cases are included that were evaluable for CANT1 staining. 
parameter median (range) / 
cases (percentage) 
age  65 (50-77) 
pre-OP PSA  12.3 (0.2-209) 
Gleason score  
5-6 37 (15.5 %) 
7 138 (58 %) 
8-10 63 (26.5 %) 
pT stage   
pT2 142 (59.7 %) 
pT3/4 96 (40.3 %) 
margin status   
R0 150 (63 %) 
R1 85 (35.7 %)  
 
Formalin-fixed paraffin-embedded RPE specimens from 640 patients who underwent RPE 
between 1999 and 2005 at the Department of Urology, Charité–Universitätsmedizin Berlin, 
were included in cohort #2 (Tab. 8), which was approved by the Charité University Ethics 
Committee (approval number EA1/06/2004) on 20 September 2004. Eighty-five patients 
(14.6 %) experienced a PSA-relapse. The median follow-up time of all cases was 47.5 
months. 
 
Tab. 8 Clinicopathological data of primary prostate carcinoma specimens (RPE) in 
cohort #2 (n=640). 
parameter median (range) / 
cases (percentage) 
age  62 (43-74) 
pre-OP PSA  7.2 (0.8-39) 
Gleason score   
5-6 234 (36.6 %) 
7 293 (45.8 %) 
8-10 112 (17.5 %) 
pT stage  
pT2 442 (69.1 %) 
pT3/4 197 (30.8 %) 
margin status   
R0 463 (72.3 %) 
R1 173 (27 %)  
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3.1.2.2 Tissue samples for the study on FOXA1 and steroid hormone receptors 
For the analysis of FOXA1, AR, ERα and ERβ expression in prostatic tissue cohort #1 with 
updated patient data was applied. Ninety-two patients (44.4 %) experienced a biochemical 
(PSA) relapse after a median time of 24 months. The median follow-up time of all patients 
was 60 months. The clinicopathological data for evaluable (see chapter 3.2.1.1) primary 
carcinoma cases are given in Tab. 9. 
 
Tab. 9 Clinicopathological data of primary prostate carcinoma specimens (RPE) in 
cohort #1 (n=288). 
Only the cases are included that were evaluable for FOXA1 staining. 
parameter median (range) / 
cases (percentage) 
age  65 (46-57) 
pre-OP PSA  11.1 (0.4-357) 
Gleason score   
5-6 35 (16.9 %) 
7 119 (57.5 %) 
8-10 53 (25.6 %) 
pT stage  
pT2 129 (62.3 %) 
pT3/4 78 (37.7 %) 
margin status   
R0 131 (63.9 %) 
R1 74 (35.7 %)  
 
Additionally, 23 cases of CRPC patients that were transurethrally resected for palliation and 
one bone trephine of a CRPC metastasis from the archives of the Institute of Surgical 
Pathology, University Hospital Zurich, were enclosed. This study was approved by the 
Cantonal Ethics Committee of Zurich (approval number StV 25-2007). 
3.1.2.3 Patients sera 
Serum samples (n=38) were collected from 15 healthy individuals and 23 prostate cancer 
patients who were treated at the Clinic and Policlinic for Oncology, University Hospital Zurich, 
between 2008 and 2010 and gave informed consent.  
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3.2 Methods 
3.2.1 Studies on patients material 
3.2.1.1 Tissue microarray (TMA) construction 
The TMA of cohort  #1 was constructed as described [18], each case was represented by a 
single 0.6 mm core of tissue. Three-hundred-fourty-nine of 529 cores were evaluable for 
CANT1 staining. These cases represent 30 BPH, 269 primary prostate carcinomas, 29 lymph 
node and distant metastases and 21 CRPC. 
FOXA1 staining was analyzable in 288 cores. The distribution was as follows: 15 cases of 
BPH, 207 primary prostate carcinomas, 39 lymph node and distant metastases and 27 
CRPC. Because FOXA1 staining was much lower in the transitional zone (data not shown), 
where BPH is derived from, adjacent normal tissue around the tumor that was of peripheral 
zone origin was analyzed instead, enough evaluable normal tissue was present in 204 of the 
primary carcinomas. 
The TMA of cohort #2 was constructed as described before [16, 17, 58]. Briefly, each case 
was represented by five cores of 2 mm in diameter each, encompassing BPH of the 
transitional zone, normal tissue from the peripheral zone, PIN if present (otherwise another 
core from the peripheral zone), and two cores of invasive carcinoma, ideally of primary and 
secondary Gleason score. CANT1 staining of normal and cancerous cores was evaluable for 
618 patients, the PIN core was evaluable for 467 patients. 
3.2.1.2 Immunohistochemistry and immunofluorescence 
Freshly cut sections (3 µm) from the TMAs or cell blocks were analyzed by 
immunohistochemistry using the Ventana Benchmark automated staining system and 
Ventana reagents (Ventana Medical Systems) according to the manufacturer’s 
recommendations. Following antigen retrieval using the “CC1 protocol”, primary antibodies 
(CANT1 mouse, FOXA1/2, AR, ERα, ERβ) were detected by the UltraVIEW DAB detection 
kit. Subsequently, the slides were counterstained with haematoxylin, dehydrated and 
mounted.  
To prove specificity of the CANT1 antibody, two consecutive slides were stained as 
described above. The antibody solution for one slide was pre-incubated with CANT1 
recombinant protein (Q1, Abnova) 100 times in excess overnight at 4 °C. 
Double immunofluorescence stainings were performed as described previously [16] using the 
same CANT1, FOXA1/2 and AR antibody as for immunohistochemistry and the GOLM1 
rabbit antibody. 
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3.2.1.3 Evaluation of immunohistochemistry 
On the slides of TMA #1 and additional CRPC cases, CANT1, FOXA1, AR, ERα and ERβ 
staining intensity was evaluated using a scoring system that differentiates between negative 
(0), weak (1), moderate (2) and strong (3) staining.  
Since TMA #2 with its multiple cores and the larger diameter per core allowed a better 
estimation of intratumoral heterogeneity, a more differentiated evaluation scheme was 
applied to evaluate CANT1 staining intensity in addition to the simpler 0-3 rating. A 
Histochemical score (H-score) was set up to include the percentages of weak, moderate and 
strong expression and to sum these up in a weighted manner (H-score = (1 * percentage 
weak) + (2 * percentage moderate) + (3 * percentage strong)). 
3.2.2 Cell biological methods 
3.2.2.1 Cell culture 
Three prostate cancer cell lines derived from a lymph node metastasis (LNCaP), bone 
metastasis (PC-3) and brain metastasis (DU-145), one immortalized prostate epithelium cell 
line (RWPE-1) and one embryonic kidney cell line (HEK293) were used. All cell culture 
consumables were purchased from Invitrogen if not otherwise indicated. LNCaP cells 
(DSMZ, Braunschweig, Germany) were cultivated in RPMI-1640 Medium, PC-3 cells (ATCC, 
Manassas, VA, USA) were cultivated in Ham’s F-12 Medium/Kaighn’s Modification, DU-145 
and HEK293 (ATCC) cells were cultivated in Eagle’s Minimal Essential Medium, all of these 
media were supplemented with 10 % fetal bovine serum (FBS). RWPE-1 cells (ATCC) were 
grown in Keratinocyte Serum Free Medium mixed with bovine pituitary extract and human 
recombinant EGF. All cell lines were cultivated in cell culture flasks (TPP, Trasadingen, 
Switzerland) at 37 °C and 5 % CO2. For experiments cell culture test plates of different sizes 
(all TPP) were applied. 
To passage the cells, PC-3 and DU-145 cells were washed with phosphate buffered saline 
(PBS), trypsinized for 10 min at 37 °C, resuspended in medium and seeded in new flasks. 
LNCaP cells were trypsinized for 15 min and centrifuged for 3 min at 1.200 rpm and room 
temperature (RT) before seeding. RWPE-1 cells were washed with PBS, trypsinized for 10 
min at 37 °C and centrifuged for 3 min at 1.200 rpm and RT before seeding. HEK293 cells 
were detached by tapping the flask and centrifuged for 3 min at 1.200 rpm and RT before 
seeding. All cell lines were passaged maximal 30 times upon receipt. 
PC-3, DU-145, RWPE-1 and HEK293 cells were frozen in complete medium supplemented 
with additional 10 % FBS and 10 % DMSO (Dimethylsulfoxid, Merck, Darmstadt, Germany). 
LNCaP cells were frozen in complete medium supplemented with additional 20 % FBS and 
5 % DMSO. Frozen cells were stored at -70 °C overnight and at -170 °C for long-time 
storage.  
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3.2.2.2 Cell counting 
Cell counting was performed using the Nucleocounter and the corresponding cassettes, 
which are filled with propidium iodide (PI). The signal was detected by a camera. Thus, if 
applied to untreated cell suspensions, dead cells were counted. The total cell number was 
measured by lysing the cells before with lysis buffer and treating them with stabilizing buffer 
(machine and consumables chemometec, Allerød, Denmark). The number of living cells was 
then calculated. 
3.2.2.3 Generation of cell blocks 
A pellet of 1 x 107 cells was mixed with four drops blood plasm (blood bank) and one drop 
thrombin (Diagnotec, Liestal, Switzerland) and fixed with 4 % formalin (Kantonsapotheke 
Zürich, Zurich, Switzerland). The coagulum was dehydrated overnight and embedded in 
paraffin (Paraplast, McCormick Scientific, Richmond, IL, USA).  
3.2.2.4 Transient gene knockdown and overexpression 
For transient gene knockdown PC-3 cells were transfected using Lipofectamine 2000 
(Invitrogen). The transfection mix was prepared according to the manufacturer’s instructions 
and added to the cells immediately after seeding. Twenty-four hours later the transfection 
medium was removed and the cells were cultivated in complete medium. For transfection of 
CANT1 and FOXA1 siRNAs LNCaP cells were transfected using HiPerFect transfection 
reagent (Qiagen) following the FastForward Protocol provided by the manufacturer. For 
GOLM1 and NTPDASE5 siRNAs, the transfection efficiency in LNCaP cells was higher with 
Lipofectamine 2000. A similar protocol as for PC-3 cells was applied, due to weaker 
adhesion to the test plate surface, no medium was changed 24 h after transfection. Higher 
cell numbers were needed compared to transfection with HiPerFect, because Lipofectamine 
2000 was more aggressive to the cells and decreased vitality. DU-145 cells were transfected 
with HiPerFect, twice as much transfection reagent was necessary for efficient knockdown. 
The variable parameters in the transfection protocol are listed in Tab. 10. 
 
Tab. 10 Parameters for siRNA transfection. 
cell line target gene test plate cell number transfection reagent 
6-well plate 2 x 105 5 µl Lipofectamine 2000 PC-3 all 
6 cm-dish 4 x 105 10 µl Lipofectamine 2000 
6-well plate 3 x 105 6 µl HiPerFect CANT1, FOXA1 
6 cm-dish 6 x 105 10 µl HiPerFect 
LNCaP 
GOLM1, NTPDase5, 
double knockdown of 
CANT1 and NTPDase5 
6 cm-dish 8 x 105 10 µl Lipofectamine 2000 
DU-145 GOLM1 6 cm-dish 2.5 x 105 20 µl HiPerFect 
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For transient overexpression, cells were seeded in 6 cm-dishes and grown for the indicated 
time periods until a confluence of ~80 % was reached. Then, cells were transfected with 
pCMV6-AN-GFP (named GFP) or pCMV6-XL6-CANT1 (named CANT1, both OriGene) or a 
mixture of both in the ratio 2:1 using Lipofectamine 2000 or FuGENE 6 (Roche Applied 
Science, Mannheim, Germany) according to the manufacturers’ protocols. Five hours after 
transfection of DU-145 medium was changed.  
To rescue CANT1 expression, CANT1 knockdown PC-3 cells (PC-3 siRNA) were transfected 
with CANT1 vectors. Therefore, CANT1 was knocked down using siRNA as described above 
and 3 days later the cells were transfected with CANT1 DNA vector. Due to decreased 
vitality of siRNA treated cells, more cells were seeded in comparison to untreated PC-3 cells 
(PC-3 untr). The variable transfection parameters of the vector transfection protocol are 
given in Tab. 11. 
 
Tab. 11 Parameters for vector transfection. 
cell line days before 
transfection 
cell number amount of DNA transfection reagent 
RWPE-1 3 1.2 x 106 8 µg 20 µl FuGENE 6 
DU-145 2 5 x 105 4 µg 20 µl Lipofectamine 2000 
HEK293 1 2 x 106 8 µg 24 µl Lipofectamine 2000 
PC-3 untr 3 2.5 x 105 8 µg 40 µl FuGENE 6 
PC-3 siRNA 3 5 x 105 8 µg 40 µl FuGENE 6  
 
All transfection mixes were prepared in Opti-MEM (Invitrogen). 
3.2.2.5 DNA synthesis rate 
DNA synthesis rate measurement was conducted using the Cell Proliferation ELISA, 
bromodeoxyuridine (BrdU) kit (Roche Applied Science) according to the manufacturer’s 
instructions. The kit is based on brome-labeled uridine (BrdU), which is incorporated into 
newly synthesized DNA strands instead of thymidine. Briefly, cells were seeded (Tab. 12) in 
96-well plates, after 6 h, BrdU labeling reagent was added to the medium and cells were 
incubated at 37 °C overnight. Subsequently, cells were fixed and stained with an anti-BrdU 
antibody, which was detected with substrate solution. The color reaction was stopped by 
adding H2SO4 (Sigma-Aldrich) and the optical density (OD) was measured at 450 nm and at 
595 nm as reference wavelength using the infinite F200 microplate reader (Tecan, 
Männedorf, Switzerland). 
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Tab. 12 Cell number for proliferation assay. 
cell line cell number 
LNCaP 2 x 104 
PC-3 knockdown cells 5 x 103 
PC-3 overexpression cells (untr) 5 x 103 
PC-3 overexpression cells (siRNA) 1 x 104 
RWPE-1 2 x 104 
DU-145 5 x 103 
HEK293 2 x 104  
 
3.2.2.6 Cell cycle analysis 
Cells were cultivated in 6 cm-dishes and detached as described in chapter 3.2.2.1, washed 
twice with sample buffer (1 % glucose [Merck] in PBS) and fixed with 70 % ethanol (Merck) 
overnight at 4 °C. The next day, 1 x 106 cells were incubated with 50 µg/ml PI (Sigma-
Aldrich), 0.3 mg/ml RNaseA (Qiagen) and 0.05 % Triton X-100 (Sigma-Aldrich) in sample 
buffer for 30 min at RT and analyzed by flow cytometry using the FACSCalibur (BD, Franklin 
Lakes, NJ). Proportion of cells in gap (G) 1-, synthesis (S) - and G2/mitotic (M)-phase was 
determined applying the Dean/Jett/Fox-model provided by the FlowJo 6.3 software (Tree 
Star, Ashland, OR, USA). 
For cell cycle analyses it is of special importance that the cells have not reached 100 % 
confluence at the time of analysis, else they would undergo G1-arrest. Thus, to circumvent 
this phenomenon, lower numbers of untransfected cells were seeded because these cells 
proliferated stronger than transfected cells (Tab. 13). 
 
Tab. 13 Cell number for cell cycle analyis. 
cell number cell line 
untr siRNA 
LNCaP HiPerFect 5 x 105 6 x 105 
LNCaP Lipofectamine 2000 6 x 105 8 x 105 
PC-3 2 x 105 4 x 105 
DU-145 1.5 x 105 2.5 x 105  
 
3.2.2.7 Transmigration assay 
Haptotactic cell migration was analyzed in a modified boyden chamber assay. Transwell 
chambers (Corning, Corning, NY, USA) were coated at the bottom side with 10 µg/ml 
fibronectin (Roche Applied Science) for 2 h at RT in a humid chamber. Then, the inserts 
were placed into 24-well plates, the lower chamber was filled with 600 µl serum free RPMI-
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1640 Medium supplemented with 0.5 % bovine serum albumine (BSA, Sigma-Aldrich) and 
the cells were seeded (Tab. 14) in 200 µl of this migration medium in the upper chamber. In 
the case of RWPE-1 cells Keratinocyte Serum Free Medium without supplements with 0.5 % 
BSA was used. After 24 h incubation at 37 °C non-migrated cells were removed with a cotton 
swab and the remaining cells were fixed by placing the inserts in 600 µl of methanol/acidic 
acid (both Simga-Aldrich) in a 3:1 ratio. After the inserts had been air-dried, they were 
incubated in a DAPI (4′,6-Diamidino-2-phenylindole dihydrochloride) solution (2.5 µg/ml DAPI 
[Sigma-Aldrich] in PBS) for 15 min at RT on a shaker. Afterwards the wells were washed 
twice with PBS and the amount of migrated cells was analyzed under the microscope 
(magnification 25x). Pictures were taken at nine defined places of the membrane and 
analyzed with ImageJ 1.4 software (National Institutes of Health, Bethesda, MD, USA). The 
migration rate was quantified by determining the area of the membrane that was covered 
with stained nuclei. A negligible small number of cells, which was not quantified, had 
migrated through the membrane, detached from the membrane and attached to the bottom 
of the well. 
 
Tab. 14 Cell number for transmigration assay. 
cell line cell number 
LNCaP 5 x 104 
PC-3 knockdown cells 5 x 104 
PC-3 overexpression cells (untr) 3 x 104 
PC-3 overexpression cells (siRNA) 5 x 104 
RWPE-1 1 x 105 
DU-145 5 x 104 
HEK293 7 x 104  
 
3.2.2.8 Scratch wound assay 
DU-145 cells were seeded in 6 cm-dishes and transfected with siRNAs as described in 
chapter 3.2.2.4. A total of 4 x 105 cells were seeded to reach confluence after 72 h, 
transfection efficiency was similar as with 2.5 x 105 seeded cells (data not shown). Then, a 
wound was introduced into the cell monolayer using a yellow pipette tip and pictures were 
taken at the marked areas after 0 and 8 h. Because the full knockdown efficiency of PC-3 
cells was reached already after 8 h (data not shown) and PC-3 cells close the wound slowlier 
than DU-145 cells do, the protocol was adapted accordingly. The cells were grown to ~95 % 
confluence before they were transfected with siRNAs as described in chapter 3.2.2.4 and 
pictures were taken after 0 and 24 h. In both cases, the area of the wound was measured 
using ImageJ 1.4 software. 
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3.2.2.9 Ultracentrifugation and precipitation of supernatants 
Cells were cultivated in 75 cm² cell culture flasks in 10 ml complete medium to ~70 % 
confluence, then the medium was changed to serum-free medium. Therefore, PC-3 cells 
were washed three times with PBS, LNCaP cells were washed twice with prewarmed serum-
free medium. To enrich secreted proteins only 7.5 ml serum-free medium were added. After 
24 h cell supernatants were centrifuged for 20 min at 1.200 rpm and 4 °C, transferred to new 
tubes and centrifuged again for 20 min at 4.000 rpm and 4 °C to pellet detached cells and 
cell debris. Afterwards ~16 ml supernatant were transferred to Ultra-Clear centrifuge tubes 
and vesicles were separated by ultracentrifugation in a SW32.1 Ti rotor (both Beckman 
Coulter, Palo Alto, CA, USA) for 2.5 h at 24.000 rpm and 4 °C. The ultracentrifugation pellet 
was resuspended in 30 µl 1x Lämmli-buffer or NuPAGE LDS sample buffer (Invitrogen) and 
incubated for 5 min at 95 °C. Supernatants were then precipitated by adding trichloroacetic 
acid (Simga-Aldrich) to a final concentration of 10 % and centrifugation for 15 min at 14.000 
rpm and 2 °C. Pellets were washed with icecold acetone (Simga-Aldrich) by centrifugation for 
15 min at 14.000 rpm and 2 °C, air-dried, resuspended in 1x sample buffer and incubated for 
5 min at 95 °C. 
  
5x Lämmli-buffer: 
17.5 ml glycerine  
8 mg SDS 
16 ml 1M TrisHCL pH 6.8 
 
All ingredients were purchased from Sigma-Aldrich. SDS = sodium dodecyl sulfate. 
3.2.2.10 ER stress induction 
To induce ER stress, cells were grown in 6 cm-dishes to ~50 % confluence (Tab. 15) and 
treated with 30 nM thapsigargin (AppliChem, Darmstadt, Germany) or 1 µM tunicamycin 
(Sigma-Aldrich) for 8 to 48 h as indicated. The stock solution (300 µM) of thapsigargin was 
dissolved in 70 % ethanol, this stock was further diluted 1:10 in cell culture medium freshly 
before usage. The stock solution (1.2 mM) of tunicamycin was dissolved in DMSO. This 
solution was directly added to the cells. As negative control, the cells were treated with 70 % 
ethanol freshly diluted 1:10 in cell culture medium or pure DMSO, respectively. 
 
Tab. 15 Cell seeding for ER stress induction. 
cell line cell number days before treatment 
RWPE-1 1.2 x 106 2 
LNCaP 1 x 106 2 
DU-145 4 x 105 1 
PC-3 6 x 105 1  
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3.2.3 Molecular biological methods 
3.2.3.1 Cell lysis 
Cells were detached as described in chapter 3.2.2.1 and washed with PBS before lysis in a 
buffer containing 60 mM n-Octyl-ß-D-glucopyranoside (Sigma-Aldrich) and protease 
inhibitors (complete, Mini, EDTA-free, Protease Inhibitor cocktail tablets; Roche Applied 
Science) for 30 min on ice. Lysates were centrifuged for 15 min at 14.000 rpm and 4 °C, 
supernatants were supplemented with 5x Lämmli-buffer or 4x NuPAGE LDS sample buffer 
and incubated for 5 min at 95 °C. 
 
20x PBS: 
160 g NaCl 
6 g KCl 
28.8 g Na2HPO4 x 2 H2O 
4 g KH2PO4 
add 1 l H2O 
 
The pH was adjusted to pH 7.4. NaCl was obtained from the Kantonsapotheke Zürich, the 
other ingredients were purchased from Merck. This self-made PBS was only used for non-
cell culture experiments. 
3.2.3.2 Measurement of protein concentration 
Cell lysates without sample buffer were diluted 1:200 in Quick-Start Bradford Dye Reagent 
(Bio-Rad, Hercules, CA, USA) and incubated for 5 min at RT. A standard curve with 
increasing concentrations of BSA was included in the same 96-well plate. The optical density 
at 595 nm was measured using the infinite F200 microplate reader (Tecan). 
3.2.3.3 Western Blot analysis 
Before Western Blot analysis, β-Mercaptoethanol (Sigma-Aldrich) was added freshly to a 
final concentration of 5 % and lysates were incubated again for 5 min at 95 °C. Twenty 
microgram of lysates were separated by SDS-polyacrylamid gelelectrophoresis (Mini-
PROTEAN Tetra Electrophoresis System, Bio-Rad). Depending on the size of the protein to 
be detected, gels containing 10 % or 12.5 % acrylamide were used. In parallel, a protein 
standard was loaded (Precision Plus Protein Kaleidoscope standard [Bio-Rad] or MagicMark 
XP Western Protein Standard mixed with SeeBlue Prestained Standard [Invitrogen]). 
Subsequently, proteins were transferred (Mini Trans-Blot Cell, Bio-Rad) onto a polyvinylidene 
fluoride-membrane (Bio-Rad). The membrane was blocked for 1-2 h at RT with 3 % skim milk 
(Rapilait, MIGROS, Zurich, Switzerland) or 1 % BSA in PBS-Tween (0.5 % Tween 20 
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[Sigma-Aldrich] in PBS) or in 1x Roti-Block (Carl Roth, Karlsruhe, Germany) and incubated 
overnight at 4 °C in primary antibody solution, which was diluted in the corresponding 
blocking buffer (in case of Roti-Block in 1:10 diluted Roti-Block in PBS-Tween). The next day, 
the membrane was washed four times in PBS-Tween, incubated in the secondary antibody 
solution, which was diluted as the primary antibody solution, and washed again four times in 
PBS-Tween. To detect the horseradish peroxidase signal, the membrane was either 
incubated for 1 min in Amersham ECL Western Blotting Detection Reagents (GE Healthcare, 
Fairlield, CT, USA; for Actin, tGFP) or for 5 min in SuperSignal West Dura Extended Duration 
Substrate (Pierce Biotechnology; all remaining primary antibodies). Subsequently, the 
membrane was either exposed to X-ray films (Amersham Hyperfilm ECL, GE Healthcare) or 
a camera system (ChemiDoc XRS+ System, Bio-Rad) was used to record the signal.  
As loading control, membranes were reprobed with anti-Actin antibody. 
 
resolving gel  
10 % 12.5 % stacking gel 
H2O 4.6 ml 3.7 ml 1.8 ml 
Resolving buffer 2.8 ml 2.8 ml  
Stacking buffer    960 µl 
Protogel 3.7 ml 4.6 ml 280 µl 
10 % APS 32 µl 32 µl 13 µl 
TEMED 2.8 µl 2.8 µl 4 µl 
 
Resolving buffer, Stacking buffer, Protogel, ammonium persulfate (APS) and tetramethyl-
ethylenediamine (TEMED) were purchased from national diagnostics (Atlanta, GA, USA). 
 
10x running buffer: 
60.6 g Tris 
288.3 g glycine 
10 g SDS 
add 2 l H2O 
 
The pH was adjusted to pH 8.3. All ingredients were purchased from Sigma-Aldrich. 
 
10x blotting buffer:  1x blotting buffer: 
48.5 g Tris  100 ml 10x blotting buffer 
225.5 g glycine  200 ml methanol 
add 2 l H2O  add 1 l H2O 
 
The pH was adjusted to pH 8.3.  
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3.2.3.4 RNA isolation and quantitative real-time polymerase chain reaction (qRT-PCR)  
Cells were detached as described in chapter 3.2.2.1 and washed with PBS. RNA was 
isolated using the RNeasy kit (Qiagen), DNA was digested on-column with the RNase free 
DNase Set (Qiagen). For cDNA synthesis the High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, Foster City, CA, USA) was applied, 200 ng total RNA were transcribed 
per 20 µl-reaction. QRT-PCR was performed using TaqMan Universal PCR MasterMix 
(Applied Biosystems) and the Universal Probe Library (Roche Applied Science). Gene 
expression was normalized to aminolevulinate, delta-, synthase (ALAS) 1, if not otherwise 
indicated. In certain experiments hypoxanthine phosphoribosyltransferase (HPRT) 1 was 
used as second housekeeping gene to achieve increased robustness of the results. Both 
genes are stably expressed in prostate cancer cells [165]. All reactions were run in 96- or 
384-well plates (Applied Biosystems) on the 7900HT Fast Real-Time PCR System or Viia7 
Real-Time PCR System (both Applied Biosystems). Kits and reagents were used according 
to the manufacturer’s instructions. 
3.2.3.5 ELISA  
Patients sera and cell culture supernatants were submitted to an ELISA assay for detection 
of soluble CANT1. The ELISA was performed as a sandwich ELISA as follows: Maxisorb 
plates (NUNC, Langenselbold, Germany) were coated overnight at 4°C with monoclonal 
mouse CANT1 antibody. The following day, plates were washed with PBS and blocked using 
10 % BSA and 0.5 % Tween 20 for 1 h at RT. Samples were diluted 1:10 and applied in 
triplicates to the plate for 1.5 h at RT. Recombinant CANT1 protein (P01, Abnova) was plated 
in increasing concentrations (0.05 µg/ml, 0.1 µg/ml, 0.2 µg/ml, 0.5 µg/ml, 1 µg/ml, 2 µg/ml, 
10 µg/ml and 20 µg/ml). Then, plates were incubated with polyclonal rabbit CANT1 antibody 
for 1 h at RT that was detected by the horseradish peroxidase-linked secondary antibody for 
45 min. Inbetween each incubation step, plates were extensively washed. Wells were 
replenished with 100 μl staining solution (TMBsolution, Pierce Biotechnology) per well and 
left at RT in the dark for 20 min. The colour reaction was stopped by adding 50 μl 2 N H2SO4. 
The absorbance at 450 nm was measured using an Emax microplate reader and analyzed 
with Softmax Pro V3.0 software (both Molecular devices, Sunnyvale, CA, USA).  
3.2.3.6 PNGase F treatment 
PNGase F (New England BioLabs, Ipswich, MA, USA) treatment was performed according to 
the manufacturer’s protocol, 20 µg of cell lysate (cell lysis described in chapter 3.2.3.1) 
without sample buffer were used per reaction. After treatment sample buffer and 
β-Mercaptoethanol were added and samples were incubated as described in chapters 
3.2.3.1 and 3.2.3.3. 
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3.2.4 Statistical analyses 
Mean immunohistochemical staining intensities were compared between different groups of 
tumor stage using the Mann-Whitney Test for TMA #1 and the Wilcoxon Matched-pairs Test 
for TMA #2. For analysis of the association of staining intensity with clinicopathological 
parameters cross tables were calculated (chi square test, 2-tailed Fisher’s exact test). 
Univariate survival analyses were conducted according to Kaplan-Meier (log rank test). For 
correlation significance tests Spearman’s rho test (2-tailed) has been used. These statistics 
were calculated with PASW18 (SPSS, Chicago, IL, USA). Mean optical density values from 
the ELISA assay were compared with help of the 2-tailed unpaired t-test. 
The cell culture results are displayed as mean ± standard deviation, each experiment was 
repeated at least three times if not otherwise indicated. Significance was tested in a 2-tailed 
paired or unpaired t-test depending on the experiment. If necessary, Welch’s correction was 
applied. 
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4 Results 
4.1 The role of CANT1 in prostate cancer 
4.1.1 The expression of CANT1 in human prostatic tissue 
Previously, our group has reported an overexpression of CANT1 mRNA in human prostate 
carcinoma tissue compared to adjacent normal tissue [15]. To confirm the results on protein 
level and to evaluate the diagnostic and prognostic potential of CANT1 expression, two 
TMAs representing a total of 989 patients were stained with the CANT1 mouse antibody. The 
specificity of this antibody was verified by preincubation with CANT1 recombinant protein, 
which led to the complete blocking of the immunohistochemical staining (Fig. 13). 
1 mm1 mm
CANT1 antibody CANT1 antibody + CANT1 recombinant protein
Fig. 13 Blocking of CANT1 immunohistochemical staining by antigen preincubation. 
Consecutive slides from a prostate adenocarcinoma case were stained with CANT1 antibody 
or with CANT1 antibody, which was pre-incubated with CANT1 recombinant protein. 
Magnification 25x. 
 
4.1.1.1 CANT1 protein is overexpressed in human prostate cancer 
To compare protein expression levels among different tumor stages and to evaluate the 
potential of CANT1 as diagnostic marker, the staining intensity of each core was analyzed. In 
general, CANT1 was only detected in epithelial cells, stroma cells did not express the 
protein. The pattern of CANT1 immunoreactivity appeared semigranular and was detected 
perinuclear at the apical side of the epithelium, resembling a typical Golgi apparatus staining 
pattern (Fig. 14 a). Additionally, a diffuse cytoplasmic staining was observed in some cases 
(Fig. 14 c), which was recorded separately on TMA #1. In normal tissue, CANT1 staining 
was only detected in secretory epithelial cells, whereas basal cells were generally negative 
for CANT1 (Fig. 14 a).  
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Fig. 14 CANT1 immunohistochemistry of human prostatic tissues.  
Immunohistochemistry of human prostatic tissues, magnification 200x if not otherwise 
indicated. (A) Normal prostate glands, magnification 400x. (B) Prostate adenocarcinoma 
infiltrating inbetween normal glands (N). (C) Prostate adenocarcinoma; note the strong 
diffuse cytoplasmic staining. (D) Prostate cancer metastasis in a lymph node; note the 
lymphocytes in the upper left corner. 
 
On TMA #1, which contained samples from 30 normal cases, 269 primary carcinomas, 29 
metastases and 21 CRPC, CANT1 staining intensity was monitored throughout carcinoma 
progression. The mean intensity of Golgi and cytoplasmic staining was 1.4 and 0.4 in normal 
tissue, 2.3 and 1.2 in primary carcinomas, 2.3 and 1.3 in metastases (lymph node metastasis 
in Fig. 14 d) and 1.9 and 0.7 in CRPC, respectively. The difference in the mean staining 
intensity of CANT1 between normal tissues and primary carcinomas, metastases as well as 
all cancerous tissues was highly significant for Golgi staining as well as for cytoplasmic 
staining. However, only the Golgi staining intensity was significantly different between normal 
tissues and CRPC (Fig. 15). 
On TMA #2 the mean intensity of CANT1 Golgi staining was 1.0 in normal cores, 1.7 in PIN 
cores and 1.8 in carcinoma cores (Fig. 15). In addition, the composition of TMA #2 allowed 
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the direct comparison of CANT1 staining intensity between cancerous and adjacent normal 
tissue from each patient. To detect also subtle differences between carcinoma and normal 
cores that would in some cases be assigned the same staining score, it was also reported if 
the cancer area was stained stronger than adjacent normal glands. This was found in 97.2 % 
of the cases (example in Fig. 14 b). 
no
rm
al
pr
im
ary
 C
a
me
tas
tas
is
CR
PC
0
1
2
3
4
Golgi staining
cytoplasmic staining
st
ai
ni
ng
 in
te
ns
ity
TMA #1 TMA #2
no
rm
al PIN
pr
im
ary
 C
a
0.0
0.5
1.0
1.5
2.0
2.5 p<0.0001
p<0.0001
p<0.0001
st
ai
ni
ng
 in
te
ns
ity
Golgi staining normal primary Ca metastasis CRPC tumor 
normal - <0.0001* <0.0001* 0.009* <0.0001* 
primary Ca  - 0.889 0.008* - 
metastasis   - 0.053 - 
      
cytoplasmic staining normal primary Ca metastasis CRPC tumor 
normal - <0.0001* 0.001* 0.152 <0.0001* 
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Fig. 15 CANT1 staining intensity in human prostatic tissue samples.  
Mean CANT1 staining intensity during neoplasia development and progression on TMA #1 
and #2. P-values for TMA #1 are put together in the tables below. Ca = carcinoma. 
 
Altogether, these data confirm the overexpression of CANT1 in human prostate carcinomas 
compared to normal prostate epithelium on protein level, which was reported on mRNA level 
before [15]. We additionally showed that this upregulation occurs already in PIN lesions. 
Further, CANT1 expression was slightly reduced in CRPC. 
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4.1.1.2 Relationship of CANT1 staining to clinicopathological parameters and survival 
analysis 
For analysis of the prognostic value of CANT1, the relationship between staining intensities 
and corresponding clinicopathological and survival data was examined. For these statistical 
analyses (crosstables and survival analyses) both staining qualities of TMA #1 were 
dichotomized by the median. No correlations of Golgi and cytoplasmic CANT1 staining with 
patient age, Gleason score, pT stage and margin status were found. However, cytoplasmic 
CANT1 staining correlated inversely with pre-OP serum PSA-levels (p=0.026) (Tab. 16). 
 
Tab. 16 Relationship between CANT1 expression and clinicopathological data of 
primary prostate carcinoma specimens (RPE) in cohort #1. 
* statistically significant 
 Golgi staining cytoplasmic staining 
parameter CANT1 
low 
CANT1 
high 
p-value CANT1 
low 
CANT1 
high 
p-value 
age    0.894   0.782 
≤ 64 years 68 46  78 36  
> 64 years 76 48  82 42  
pre-OP PSA    0.669   0.026* 
≤ 10 ng/ml 55 35  51 39  
> 10 ng/ml 67 49  84 32  
Gleason score    0.764   0.823 
5-6 21 16  24 13  
7 86 52  95 43  
8-10 37 26  41 22  
pT stage    0.893   0.069 
pT2 85 57  102 40  
pT3/4 59 37  58 38  
margin status    0.583   0.563 
R0 92 58  100 50  
R1 49 36  60 25   
 
On TMA #2 CANT1 staining intensity values were dichotomized by H-score 1.9, they did not 
correlate with patient age, serum PSA-levels and margin status. A trend between high 
Gleason grade and low H-score was noted as well as a significant correlation between high 
pT stage and low H-score (Tab. 17). 
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Tab. 17 Relationship between CANT1 expression and clinicopathological data of 
primary prostate carcinoma specimens (RPE) in cohort #2. 
* statistically significant 
 
parameter 
CANT1 
low 
CANT1 
high 
p-value 
age    0.273 
≤ 62 years 196 116  
> 62 years 205 100  
pre-OP PSA    0.701 
≤ 10 ng/ml 293 153  
> 10 ng/ml 104 59  
Gleason score    0.054 
5-6 136 84  
7 185 103  
8-10 80 29  
pT stage    0.014* 
pT2 262 162  
pT3/4 139 54  
margin status    0.569 
R0 287 159  
R1 113 55  
 
 
On univariate analysis of PSA-relapse free survival times no association of CANT1 tissue 
levels with disease relapse was found on TMA #1, neither for the Golgi nor the cytoplasmic 
staining (Fig. 16). However, due to the larger cores of TMA #2 it was possible to also 
consider heterogeneity of CANT1 staining and to derive a more differentiated H-score. A 
careful analysis of these data revealed a good prognosis of patients with the highest CANT1 
expression (the upper quartile), whereas the majority of the patients experienced a PSA-
relapse much earlier (Fig. 16). This prognostic value is maintained in a multivariate analysis 
including pT stage, Gleason score, margin status and pre-OP serum PSA levels (p-value 
CANT1 = 0.034). However, this survival difference was not detectable, when only the simpler 
overall intensity score (0-3) was analyzed (data not shown). 
In summary, a prognostic value of CANT1 staining intensity and a corresponding association 
with pT stage was revealed on TMA #2 using the H-score. 
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Fig. 16 Univariate survival analysis dependent on CANT1 staining intensity. 
Kaplan-Meier curves of CANT1 Golgi and cytoplasmic expression on TMA #1 (dichotomized 
by the median in low [blue] and high [green] levels) and of CANT1 Golgi expression on 
TMA #2 (green: upper quartile, blue: lower three quartiles of H-score).  
 
4.1.2 The influence of CANT1 knockdown and overexpression on in vitro 
tumorigenicity 
4.1.2.1 Characterization of CANT1 expression in prostatic cell lines 
To test if CANT1 overexpression has a functional relevance in prostate cancer, prostatic cell 
lines were evaluated for endogenous CANT1 expression levels and selected for subsequent 
functional studies. The expression on gene and protein level was determined in the 
immortalized epithelial cell-line, RWPE-1, and in three metastasis-derived cancer cell lines, 
LNCaP, DU-145 and PC-3. As observed by Western Blot analysis CANT1 protein was 
strongly expressed in LNCaP and PC-3 cells whereas the band was much weaker in the 
lysates of DU-145 and RWPE-1 cells. In all four cell lysates a clear double band was visible. 
Similarly, mRNA expression was strongest in LNCaP and PC-3 cells. High levels of CANT1 
mRNA were also detected in DU-145 and RWPE-1 cells (Fig. 17).  
Thus, two prostate cancer cell lines with high CANT1 levels and a third prostate cancer cell 
line with low endogenous levels of the protein were identified. Weak expression of CANT1 
was detected in the selected benign prostatic cell line. 
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Fig. 17 Expression of CANT1 in prostatic cell lines. 
RWPE-1, LNCaP, DU-145 and PC-3 cells were cultivated in 75 cm² cell culture flasks to 
70-80 % confluence. CANT1 mRNA and protein expression was determined by qRT-PCR 
(top) and Western Blot analysis (bottom), respectively.  
 
4.1.2.2 Transient knockdown of CANT1 in prostate cancer cell lines with high endogenous 
CANT1 levels 
The goal of this part of the study was to investigate if endogenous CANT1 overexpression 
contributes to tumorigenicity of prostate cancer cells. According to the strong CANT1 
expression on mRNA and protein level (see chapter 4.1.2.1), LNCaP and PC-3 cells were 
selected for these studies. A knockdown protocol based on RNA interference was 
established for both cell lines using two CANT1-specific siRNAs. QRT-PCR and Western 
Blot analysis revealed a potent CANT1 knockdown on mRNA and protein level 72 h after 
siRNA transfection. The mRNA levels were reduced to 28 % and 49 % in LNCaP cells and to 
2 % and 13 % in PC-3 cells, using CANT1 siRNA #1 and #2, respectively. No differences in 
knockdown efficiency were visible on protein level (Fig. 18).  
Thus, CANT1 expression was efficiently downregulated using two specific siRNAs in LNCaP 
and PC-3 cells. 
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Fig. 18 Knockdown of CANT1 in LNCaP and PC-3 cells. 
LNCaP and PC-3 cells were cultivated in 6-well plates and left untreated or transfected with 
unspecific or CANT1-specific siRNAs as indicated. After 72 h CANT1 mRNA and protein 
expression was determined by qRT-PCR (top) and Western Blot analysis (bottom). untr = 
untreated, unspec = unspecific. 
 
The strong reduction of the Western Blot band upon transfection with both CANT1-specific 
siRNAs further substantiated the specificity of the CANT1 antibody, which was used as well 
for immunohistochemistry and in the ELISA assay, and confirmed that there is no cross-
reactivity with other molecules. 
4.1.2.3 CANT1 knockdown reduces cell proliferation 
One of the main hallmarks of cancer cells is uncontrolled proliferation [166]. To determine if 
CANT1 expression has an influence on prostate cancer cell proliferation, LNCaP and PC-3 
cells were transfected with CANT1-specific or control siRNAs. Compared to unspecific siRNA 
transfected cells, the cell number of CANT1 siRNA #1 and #2 transfected LNCaP cells was 
reduced significantly by 17 % and 21 %. Although siRNA treatment itself strongly affected the 
propagation of PC-3 cells, the number of CANT1 siRNA #1 and #2 transfected cells was 
further decreased by 38 % and 26 % compared to control cells (Fig. 19).  
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Fig. 19 Cell number of LNCaP and PC-3 cells upon CANT1 knockdown.  
LNCaP and PC-3 cells were seeded in 6-well plates, left untreated or transfected with 
siRNAs as indicated, and counted after 72 h.  
 
To test whether the reduction of cell number upon CANT1 knockdown was caused by a 
reduction of cell proliferation rate, DNA synthesis rate was determined by measuring BrdU 
incorporation. As shown in Fig. 20, 32 % and 36 % less BrdU was detected after transfection 
of LNCaP cells with CANT1 siRNA #1 and #2, respectively. The DNA synthesis rate of PC-3 
cells was decreased highly significantly by 67 % and 30 % in CANT1 siRNA #1 and #2 
transfected cells compared to unspecific siRNA transfected cells (Fig. 20). 
Taken together, these results show a potent reduction of proliferation of LNCaP and PC-3 
cells after CANT1 knockdown. 
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Fig. 20 DNA synthesis rate of LNCaP and PC-3 cells upon CANT1 knockdown.  
LNCaP and PC-3 cells were seeded in 6 cm-dishes and left untreated or transfected with 
siRNAs as indicated. After 72 h DNA synthesis rate measurement was performed. 
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4.1.2.4 Recuded cell proliferation is associated with G1-arrest 
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Fig. 21 Cell cycle distribution of LNCaP and PC-3 cells upon CANT1 knockdown.  
LNCaP cells (A, C, E, G) and PC-3 cells (B, D, F, H) were left untreated or transfected with 
siRNAs as indicated. After 72 h, cell cycle analysis was performed. (A, B) Representative 
histogram of cells that were treated either with unspecific siRNA (red) or CANT1 siRNA #1 
(blue); note the higher G1-phase peak and lower S-phase plateau and G2-phase peak in the 
CANT1 siRNA histogram compared to the unspecific siRNA histogram. (C, D) 
Representative distribution of G1-, S-, and G2/M-phase cells. (E, F) Proportion of cells in G1-
phase from all replicates. (G, H) Proportion of cells in S-phase from all replicates. 
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The observed reduction of cell proliferation upon CANT1 knockdown provoked the question, 
if this was reflected in a change of cell cycle distribution. Hence, the proportion of cells in 
G1-, S- and G2/M-phase was determined by flow cytometry of PI-stained cells. The 
proportion of LNCaP cells in G1-phase rose from 68 % in control cells to 76 % in CANT1 
knockdown cells, whereas the proportion of cells in S-phase declined from 20 % to 13 % in 
the respective groups. The mean proportion of cells in G2/M-phase remained unchanged 
(Fig. 21 a, c, e, g). These differences were even more pronounced in PC-3 cells: Sixty-three 
percent of the cells treated with unspecific siRNA were in G1-phase in contrast to 81 % and 
76 % of the cells treated with CANT1-specific siRNA #1 and #2, respectively. Different from 
the LNCaP cells, the proportion of cells in S- as well as G2/M-phase was altered in PC-3 
knockdown cells. S-phase cells decreased from 19 % in the control cells to 6 % and 12 % in 
the knockdown cells, in parallel G2/M-phase cells decreased from 17 % to 11 % in the 
corresponding groups (Fig. 21 b, d, f, h).  
In summary, these data clearly demonstrate G1-arrest upon CANT1 knockdown in LNCaP 
and PC-3 cells. 
4.1.2.5 Cell migration is inhibited upon CANT1 knockdown 
With regard to the concept suggested by Hanahan and Weinberg, elevated migratory 
potential is another feature that cells adapt during transformation to malignant cancer cells 
[166]. The relevance of CANT1 expression during cell migration was therefore elucidated in a 
transmigration assay. In particular, haptotactic migration towards the extracellular matrix 
component fibronectin was investigated. Downregulation of CANT1 reduced highly 
significantly migration of LNCaP cells through the porous membrane by 55 % and 20 % 
using siRNA #1 and #2 compared to control cells. The reduction of PC-3 cell migration 
accounted for 61 % and 13 % with the respective siRNAs (Fig. 22).  
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Fig. 22 Haptotactic transmigration of LNCaP and PC-3 cells upon CANT1 knockdown.  
LNCaP and PC-3 cells were seeded in 6 cm-dishes and left untreated or transfected with 
siRNAs as indicated. After 72 h, the transmigration assay was performed. Below, 
representative pictures of the DAPI-stained membranes are displayed (magnification 100x). 
 
Additionally, migration of PC-3 cells on a plain, non-coated surface was assessed in a 
scratch wound assay. This assay is less reliably applicable to LNCaP cells as these do not 
build a confluent monolayer. 
The area, which was not recovered with migrated cells within 24 h after introducing the 
wound, was 1.4 and 1.6 times larger following CANT1 downregulation with specific siRNA #1 
and #2, respectively, compared to unspecific siRNA treatment (Fig. 23), further confirming a 
diminished cell motility after loss of CANT1 expression.  
Altogether, these data show that the reduction of CANT1 expression induces strong inhibition 
of LNCaP and PC-3 cell migration. 
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Fig. 23 Wound healing of PC-3 cells upon CANT1 knockdown. 
PC-3 cells were seeded in 6 cm-dishes and the scratch wound assay was conducted. On the 
right, representative pictures of the wounds are shown (magnification 25x). 
 
4.1.2.6 Transient overexpression of CANT1 
Having shown that loss of endogenous CANT1 expression results in reduced proliferation 
and migration of prostate cancer cells, we next examined if enforced expression of CANT1 is 
sufficient to induce or enhance in vitro tumorigenicity. Therefore, the benign prostatic cell line 
RWPE-1 and the prostate cancer cell line DU-145, which both express little endogenous 
CANT1 protein (see chapter 4.1.2.1), were transfected with a CANT1-encoding vector. 
Further, it was evaluated, whether similar CANT1-related effects could be observed in the 
HEK293 cell line, which is a benign cell line of non-prostatic origin and expresses similar 
CANT1 protein amounts as RWPE-1 cells (Fig. 24). Additionally, it was examined if a further 
increase of CANT1 expression in PC-3 cells, which showed a clear response to CANT1 
knockdown (see chapters 4.1.2.3 to 4.1.2.5), would induce the contrary effects. Finally, 
CANT1 downregulation by RNA interference and the resulting effects were attempted to be 
rescued by subsequent transfection with a CANT1-encoding vector. In all cases, increasing 
amounts of CANT1 DNA were introduced into the cells by transfecting the cells with a GFP 
vector alone as negative control, with a mixture of GFP and CANT1 vector, which consisted 
of 33 % CANT1 vector and 67 % GFP vector to keep the DNA content constant, and with 
pure CANT1 vector.  
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Fig. 24 Expression of CANT1 in HEK293 cells. 
HEK293, RWPE-1 and LNCaP cells were cultivated in 75 cm² cell culture flasks to 70-80 % 
confluence. CANT1 mRNA and protein expression was determined by qRT-PCR (top, n=2) 
and Western Blot analysis (bottom, n=1). 
 
A dose-dependent increase of CANT1 expression on mRNA and protein level was achieved 
in RWPE-1, DU-145 and HEK293 cells. On mRNA level, the fold change upon transfection of 
pure CANT1 vector was 186, 16 and 562 times in these cell lines, respectively (Fig. 25). 
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Fig. 25 Overexpression of CANT1 in RWPE-1, DU-145 and HEK293 cells. 
RWPE-1 (n=3), DU-145 (n=4) and HEK293 (n=2) cells were left untreated or transfected with 
GFP vector, CANT1 vector or a mixture of both in a 2:1 ratio as indicated. After 24 h CANT1 
mRNA and protein expression was determined by qRT-PCR (top) and Western Blot analysis 
(bottom), respectively. The mRNA levels for HEK293 cells were normalized to that of 
untreated cells. 
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Transfection of wildtype PC-3 cells with CANT1 vector resulted as well in elevated 
expression levels of CANT1 compared to endogenous levels (fold change 6.8). In CANT1 
knockdown PC-3 cells endogenous mRNA levels were restored upon transfection with 
CANT1 vector, fold change compared to GFP transfected knockdown cells was 12.5. 
However, the protein was not reexpressed (Fig. 26).  
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Fig. 26 Overexpression of CANT1 in wildtype and CANT1 knockdown PC-3 cells. 
PC-3 cells were left untreated or transfected with unspecific or CANT1-specific siRNA #1 
and/or GFP vector, CANT1 vector or a mixture of both in a 2:1 ratio as indicated. In the case 
of combination siRNAs were transfected 3 days before DNA vectors. Twenty-four hours after 
transfection of DNA vectors CANT1 mRNA and protein expression was determined by qRT-
PCR (top) and Western Blot analysis (bottom), respectively. MRNA expression was 
measured twice for transfection of wildtype PC-3 cells and once for CANT1 knockdown PC-3 
cells. 
 
Summarized, strongly augmented expression of CANT1 was achieved in RWPE-1, DU-145, 
HEK293 and wildtype PC-3 cells. Rescue of CANT1 expression following RNA interference 
was successful on mRNA level. However, protein levels could not be restored. 
4.1.2.7 CANT1 overexpression does not change cell proliferation rate 
Cell proliferation upon CANT1 overexpression was assessed by measuring the DNA 
synthesis rate. RWPE-1, DU-145 and HEK293 cells were slightly affected by the treatment 
(compare bars of untreated and GFP transfected cells), however, the DNA synthesis rate 
was independent of CANT1 levels (Fig. 27). 
RESULTS │ The role of CANT1 in prostate cancer 
- 60 - 
un
tr
GF
P
GF
P/C
AN
T1
CA
NT
1
0.0
0.2
0.4
0.6
0.8
1.0
O
D
 4
50
-5
95
 n
m
un
tr
GF
P
GF
P/C
AN
T1
CA
NT
1
0.0
0.2
0.4
0.6
0.8
O
D
 4
50
-5
95
 n
m
un
tr
GF
P
GF
P/C
AN
T1
CA
NT
1
0.0
0.5
1.0
1.5
O
D
 4
50
-5
95
 n
m
RWPE-1 DU-145 HEK293
Fig. 27 DNA synthesis rate of RWPE-1, DU-145 and HEK293 cells upon CANT1 
overexpression. 
RWPE-1, DU-145 and HEK293 cells were left untreated or transfected with DNA vectors as 
indicated. After 24 h DNA synthesis rate measurement was performed. 
 
Similar results were obtained in PC-3 cells. Neither in wildtype cells nor in CANT1 
knockdown cells, forced expression of CANT1 changed the DNA synthesis rate (Fig. 28). 
Yet, reduced DNA synthesis activity upon CANT1 knockdown was confirmed (compare 
chapter 4.1.2.3). 
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Fig. 28 DNA synthesis rate of wildtype and CANT1 knockdown PC-3 cells upon CANT1 
overexpression. 
PC-3 cells were left untreated or transfected with siRNAs and/or DNA vectors as indicated. In 
the case of combination siRNAs were transfected 3 days before DNA vectors. Twenty-four 
hours after transfection of DNA vectors, DNA synthesis rate measurement was performed. 
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4.1.2.8 CANT1 overexpression does not influence cell migration 
Next, the influence of increased CANT1 expression on transwell migration was examined. 
Similar to DNA synthesis rate, also transwell migration was decreased upon vector 
transfection in RWPE-1, DU-145 and particularly in HEK293 cells. In all of these cell lines, 
the effect on the migration rate was independent of CANT1 overexpression (Fig. 29). 
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Fig. 29 Haptotactic transmigration of RWPE-1, DU-145 and HEK293 cells upon CANT1 
overexpression. 
RWPE-1, DU-145 and HEK293 cells were left untreated or transfected with DNA vectors as 
indicated. After 24 h, the transmigration assay was performed. 
 
In wildtype PC-3 cells, neither the transfection process nor exogenous CANT1 expression 
affected the migration rate (Fig. 30). Upon CANT1 knockdown, transwell migration was 
reduced as observed before (compare chapter 4.1.2.5). However, transfection with CANT1 
vector had no influence on cell motility (Fig. 30).  
Summarized, these results show that increased expression of CANT1 does not increase the 
tumorigenic potential of prostatic and non-prostatic, cancerous and non-cancerous cell lines.  
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Fig. 30 Haptotactic transmigration of wildtype and CANT1 knockdown PC-3 cells upon 
CANT1 overexpression. 
PC-3 cells were left untreated or transfected with siRNAs and/or DNA vectors as indicated. In 
the case of combination siRNAs were transfected 3 days before DNA vectors. Twenty-four 
hours after transfection of DNA vectors, the transmigration assay was performed. 
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4.1.3 Characterization of CANT1 
4.1.3.1 Endogenous CANT1 is glycosylated 
Smith et al. demonstrated that human CANT1, which was transfected into COS-1 cells, was 
glycosylated. Upon PNGase F treatment the band was shifted by 2 kDa, showing that the 
protein is N-glycosylated [60]. To test, if this is also the case for endogenous CANT1, lysates 
of LNCaP and PC-3 cells were incubated with PNGase F and analyzed by Western Blot 
analysis. In both cell lines a shift of the double band by ~2 kDa was observed (Fig. 31), 
indicating that, similar to artificially expressed CANT1, endogenous CANT1 is 
N-glycosylated.  
PNGaseF - + - +
LNCaP   PC-3
CANT1
Actin
 
Fig. 31 N-glycosylation of CANT1. 
A total of 6 x 105 LNCaP and 4 x 105 PC-3 cells were seeded in 6 cm-dishes. After 3 days 
cells were lysed, parts of the lysates were treated with PNGase F and treated and untreated 
lysates were analyzed by Western Blot analysis. 
 
4.1.3.2 Intracellular localization of CANT1 
In transfected CHO cells the full-length rat homolog of CANT1 localizes to the membranes of 
the ER and pre-Golgi intermediates [62], whereas a truncated form of human CANT1 was 
detected in the supernatant of transfected COS-1 cells, indicating cleavage and secretion 
[60]. As shown in chapter 4.1.1.1, the main immunohistochemical staining pattern resembled 
a Golgi apparatus staining pattern. Therefore, double immunofluorescence stainings of 
normal and cancerous prostate tissue with GOLM1, which is known as Golgi resident protein 
[134], were performed. An extensive overlap of both staining patterns was seen, illustrating 
that CANT1 is predominantly localized in the Golgi apparatus. Similar to 
immunohistochemistry, also an additional diffuse CANT1 staining was observed in the 
cytoplasm in some cases (Fig. 32).  
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Fig. 32 Intracellular localization of endogenous CANT1 in prostatic tissue.  
Double immunofluorescence of CANT1 (green) and GOLM1 (red) in human prostate 
adenocarcinoma and normal prostate epithelium, magnification 400x. 
 
Similar analyses were performed in LNCaP and PC-3 cells. Cellblock slides were stained 
immunohistochemically. The granular staining on one side of the nucleus suggested 
localization in the Golgi apparatus. This was confirmed by double immunofluorescence 
staining with GOLM1 (Fig. 33). 
Hence, it was demonstrated that CANT1 is mainly localized in the Golgi apparatus in human 
prostatic tissue as well as in prostate cancer cell lines.  
RESULTS │ The role of CANT1 in prostate cancer 
- 64 - 
IHC CANT1
GOLM1
Merge + DAPI
IHC CANT1
GOLM1
Merge + DAPI
LNCaP
PC-3
Fig. 33 Intracellular localization of endogenous CANT1 in LNCaP and PC-3 cells. 
LNCaP and PC-3 cell blocks were immunohistochemically stained with CANT1 (IHC) and a 
double immunofluorescence staining with CANT1 (green) and GOLM1 (red) was performed. 
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4.1.3.3 Secretion of CANT1 
To examine if CANT1 is also secreted by cells that express the protein endogenously, the 
supernatants of LNCaP and PC-3 cells were analyzed. Therefore, the cells were cultivated in 
serum-free medium for 24 h and soluble proteins in the supernatants were separated from 
vesicles by ultracentrifugation. Supernatants before and after ultracentrifugation were 
precipitated and analyzed by Western Blot analysis in comparison to lysates from the 
corresponding cells and the vesicle pellet derived from ultracentrifugation. 
The Western Blot analysis showed that a truncated form of CANT1, which was approximately 
2 kDa smaller compared to the lowest band from the cell lysate, was detectable in the 
supernatants of both cell lines before as well as after ultracentrifugation. This band was 
clearly singular, in contrast to the triple band in the lysates. In the lysate of LNCaP cells an 
additional weak band of the same molecular weight as the band observed in the supernatant 
was detected. In the ultracentrifugation pellet of LNCaP supernatant no CANT1 was 
detected. A weak double band was visible in the ultracentrifugation pellet of PC-3 cell 
supernatant at the same size as in the cell lysate (Fig. 34 a). 
To further evaluate the secretion and quantify the amount of CANT1 in serum-free cell 
culture supernatants, an ELISA assay was established. When testing commercially available 
antibodies, the combination of mouse monoclonal CANT1 antibody for capturing the antigen 
and rabbit polyclonal CANT1 antibody for detection was found to be the most reproducible 
design. In two independent experiments, 0.4 and 0.15 µg/ml CANT1 protein were measured 
in the supernatant of PC-3 cells. The CANT1 concentrations in LNCaP supernatant were 
0.08 and 0.1 µg/ml (Fig. 34 b). 
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Fig. 34 Secretion of endogenous CANT1. 
PC-3 and LNCaP cells were cultivated in 75 cm² cell culture flasks to ~70 % confluence 
before incubation in serum-free medium for 24 h. (A) Supernatants from 3 flasks each were 
pooled and 16 ml were ultracentrifuged. In parallel, cells were lysed. Supernatants before 
(supernatant) and after ultracentrifugation (supernatant ultra) were precipitated. Cell lysate, 
supernatants and the ultracentrifugation pellet were analyzed by Western Blot analysis. 
Pictures from a short (top) and long (bottom) exposed film are depicted. (B) CANT1 levels in 
the supernatants were measured in an ELISA-assay (n=2). ultra = ultracentrifugation. 
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Thus, secreted endogenous CANT1 was detected using two different approaches. The 
soluble form of the protein is ~2 kDa smaller than the full-length form. 
4.1.3.4 CANT1 is detectable in blood serum 
The confirmation of the secretion of CANT1 prompted us to clarify if CANT1 is detectable in 
human blood serum and if the levels are different in prostate cancer patients compared to 
healthy individuals. Thus, the same ELISA assay as for CANT1 detection in cell culture 
supernatans was applied to human sera. Serum CANT1 levels appeared to be too low for 
quantification with this ELISA assay, which had a detection range from 0.1 to 20 µg/ml. 
Therefore results are shown as measurement of absorbance at 450 nm. Serum CANT1 
levels in 23 tested prostate carcinoma patients were slightly higher than in 15 healthy test 
persons, however, this difference failed statistical significance (median patients: 0.096, 
median controls: 0.061; Fig. 35). No correlation was noted between serum PSA and serum 
CANT1 levels (data not shown). 
In conclusion, CANT1 protein was detectable in human blood samples, however, the 
amounts were not quantifiable with the current method. 
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Fig. 35 CANT1-ELISA of human blood serum. 
Serum CANT1 levels of 23 prostate carcinoma patients and 15 healthy individuals were 
measured in an ELISA assay. 
 
4.1.4 The involvement of CANT1 in the UPR 
CANT1, being an apyrase with preference for UDP and GDP and being located in the ER or 
Golgi apparatus, is believed to hydrolyze these nucleotide disphosphates, which are sugar 
carriers in these organelles, and thus to indirectly drive nucleotide sugar antiporters. By 
thereby ensuring sugar supply, CANT1 is speculated to be an important player in protein 
glycosylation [62, 68, 80]. An involvement in glycoprotein or proteoglycan synthesis would be 
reflected in a reduced amount of these molecules upon CANT1 knockdown. Presuming that 
CANT1 plays a role in protein folding, CANT1 knockdown would induce an increased ratio of 
misfolded to correctly folded proteins, which would trigger the UPR, while CANT1 would in 
turn be a target gene of the UPR.  
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Experimental results, which support the latter scenario, were published previously. Uccelletti 
et al. demonstrated constitutive activation of the UPR upon knockdown of the C.elegans 
CANT1 homolog apy-1, whereas apy-1 expression was upregulated upon tunicamycin 
treatment, which is a chemical inducer of the UPR [68]. Similarly, in LNCaP cells Fang et al. 
observed activation of the UPR upon knockdown of NTPDase5, a UDPase that is located in 
the ER [167]. To test if also human CANT1 is involved in protein folding, the expression of 
UPR target genes following CANT1 knockdown as well as the expression of CANT1 
following ER stress induction was measured. 
4.1.4.1 UPR activation upon CANT1 and NTPDase5 single or double knockdown 
To analyze UPR activation, three established UPR target genes were selected. The 
expression of HSPA5, tribbles homolog (TRIB) 3 and homocysteine-inducible, endoplasmic 
reticulum stress-inducible, ubiquitin-like domain member (Herpud) 1 was measured on RNA 
level, HSPA5 expression was additionally evaluated on protein level. This was not only done 
for CANT1 knockdown but also for double knockdown with the before mentioned ER-
UDPase NTPDase5 to evaluate a putative redundancy of these two proteins. As positive 
control of UPR activation, LNCaP and PC-3 cells were treated with thapsigargin or 
tunicamycin. Thapsigargin prevents calcium pumping into the ER and thus induces calcium 
depletion in the organelle [168]. The resulting ER stress leads to UPR induction. Differently, 
tunicamycin inhibits transfer of the core oligosaccharide to newly synthesized peptide chains 
[169]. Thus, protein folding and quality control are disturbed, which leads to accumulation of 
misfolded proteins and finally to UPR induction.  
As shown in Fig. 36, expression of all three genes was strongly increased in both cell lines 
upon ER stress induction by both agents, also HSPA5 protein amounts were clearly higher 
after treatment. Thus, UPR activation can be detected via measurement of HSPA5, TRIB3 
and Herpud1 expression. 
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Fig. 36 UPR activation upon induction of ER stress in LNCaP and PC-3 cells. 
LNCaP and PC-3 cells were treated with thapsigargin (n=3) and tunicamycin (n=2) or ethanol 
and DMSO as corresponding negative controls for 24 h. MRNA expression of HSPA5, TRIB3 
and Herpud1 and protein expression of HSPA5 were determined by qRT-PCR and Western 
Blot analysis. MRNA expression levels were normalized to ALAS1 and HPRT1. 
 
Next, single knockdown of NTPDase5 and double knockdown of CANT1 and NTPDase5 
were established in the same cell lines. CANT1 mRNA levels were reduced to approximately 
30 % in LNCaP cells and 5 % in PC-3 cells, while NTPDase5 mRNA levels were reduced to 
approximately 30 % in both cell lines. Knockdown on protein level was very efficient for both 
proteins in both cell lines.  
Further, in PC-3 cells NTPDase5 mRNA was increased 1.8 fold following knockdown of 
CANT1 and also a weak tendency towards increased CANT1 expression was seen in 
NTPDase5 knockdown cells on mRNA level. However, protein levels were unaffected by 
mutual knockdown of both apyrases (Fig. 37).  
Hence, an efficient knockdown of CANT1 and NTPDase5 alone and together was 
established in LNCaP and PC-3 cells. Additionally, a redundancy of these two genes was 
indicated in PC-3 cells. 
RESULTS │ The role of CANT1 in prostate cancer 
- 69 - 
LNCaP PC-3
0.0
0.5
1.0
1.5
CANT1
Actin
CANT1re
la
tiv
e 
RN
A 
ex
pr
es
si
on
p=0.0058
p=0.0488
0.0
0.5
1.0
1.5
2.0
2.5
CANT1
Actin
CANT1
p<0.0001
p=0.0262
re
la
tiv
e 
RN
A 
ex
pr
es
si
on
un
tr
un
sp
ec
CA
NT
1#
1
NT
PD
as
e5
CA
NT
1#
1/N
TP
Da
se
5
0.0
0.5
1.0
1.5
NTPDase5
Actin
NTPDase5re
la
tiv
e 
RN
A 
ex
pr
es
si
on
p=0.0347
p=0.0068
un
tr
un
sp
ec
CA
NT
1#
1
NT
PD
as
e5
CA
NT
1#
1/N
TP
Da
se
5
0.0
0.5
1.0
1.5
NTPDase5
Actin
NTPDase5
p=0.0534
re
la
tiv
e 
RN
A 
ex
pr
es
si
on
p=0.0789
p=0.0007
Fig. 37 Single and double knockdown of CANT1 and NTPDase5 in LNCaP and PC-3 
cells. 
LNCaP and PC-3 cells were cultivated in 6 cm-dishes and left untreated or transfected with 
unspecific or CANT1 and/or NTPDase5-specific siRNA as indicated. After 72 h CANT1 and 
NTPDase5 mRNA and protein expression was determined by qRT-PCR (top) and Western 
Blot analysis (bottom). MRNA levels were normalized to that of untreated cells 48 h after 
seeding, house-keeping genes were ALAS1 and HPRT1. To measure CANT1 and Actin 
protein expression, the same samples were loaded on different gels in a different order.  
 
The measurement of UPR target gene and protein expression upon CANT1 and NTPDase5 
knockdown revealed no changes in LNCaP cells. However, in PC-3 cells HSPA5 expression 
was increased on RNA level following NTPDase5 knockdown, which was significant for the 
single knockdown. The amount of protein was clearly augmented upon CANT1/NTPDase5 
double knockdown. MRNA expression of TRIB3 was significantly enhanced in CANT1 single 
knockdown PC-3 cells. Further, higher mRNA levels of Herpud1 were detected in all three 
knockdown samples, a statistical trend was observed for CANT1 single knockdown (Fig. 38). 
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Summarized, while UPR is not activated in LNCaP cells upon knockdown of CANT1 and/or 
NTPDase5, evidence for UPR activation reflected in the upregulation of corresponding 
marker genes was observed in PC-3 cells following downregulation of CANT1 and 
NTPDase5. 
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Fig. 38 UPR activation upon CANT1 and NTPDase5 single and double knockdown in 
LNCaP and PC-3 cells. 
LNCaP and PC-3 cells were seeded in 6 cm-dishes and left untreated or transfected with 
siRNAs as indicated. After 72 h mRNA expression of HSPA5, TRIB3 and Herpud1 and 
protein expression of HSPA5 were determined by qRT-PCR and Western Blot analysis. 
MRNA levels were normalized to that of untreated cells 48 h after seeding, house-keeping 
genes were ALAS1 and HPRT1. To measure HSPA5 and Actin protein expression in PC-3 
cells, the same samples were loaded on different gels in a different order. 
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4.1.4.2 CANT1 expression upon ER stress induction 
To clarify if CANT1 is a UPR target gene, i.e. if CANT1 expression is upregulated upon UPR 
induction, a kinetic analysis of CANT1 expression upon ER stress induction by thapsigargin 
or tunicamycin in comparison to known UPR target genes was performed in three cell lines 
differing in endogenous CANT1 expression and malignancy status. In the benign cell line 
RWPE-1 with low CANT1 levels, expression of HSPA5 was strongly augmented on RNA 
level during the whole experiment, whereas the corresponding protein was only increased 
after 24 h and 48 h of treatment with tunicamycin. This clearly showed that the UPR was 
activated upon thapsigargin and tunicamycin treatment. However, TRIB3 expression was 
unaffected indicating that this gene is not involved in UPR signaling in this cell line. Herpud1 
mRNA was strongly upregulated 8 h after treatment, within the following 40 h the levels 
decreased, yet, the expression was still much higher compared to ethanol or DMSO treated 
control cells. Similarly, CANT1 mRNA was slightly increased 8 h after thapsigargin as well as 
tunicamycin treatment. At later timepoints, the mRNA levels were similar to untreated cells 
and protein expression decreased in comparison to ethanol or DMSO treated cells (Fig. 39). 
In the malignant cell line DU-145 with low CANT1 levels, expression of all three UPR target 
genes and HSPA5 protein was strongly increased over the whole treatment period. After 
48 h, treatment with ethanol also induced expression of HSPA5, TRIB3 and Herpud1. A 
similar but weaker effect was observed upon DMSO treatment. CANT1 mRNA expression 
was unaffected by ER stress induction via thapsigargin as well as tunicamycin. However, 
after 14 h of treatment, CANT1 protein level was reduced which was also observed at later 
time points (Fig. 40). 
UPR activation proceeded very similar in the malignant cell line PC-3 with high CANT1 
levels. HSPA5 mRNA and protein expression as well as TRIB3 and Herpud1 mRNA 
expression were strongly enhanced during the whole period of thapsigargin and tunicamycin 
treatment. After 48 h of treatment with DMSO, the mRNA levels of these UPR target genes 
were increased as well. This effect was less pronounced for the treatment with ethanol. 
CANT1 mRNA levels increased continuously from 14 h to 48 h after thapsigargin and 
tunicamycin treatment compared to control treatment. Similar to the UPR target genes, 
expression was also elevated 48 h after ethanol and DMSO treatment. However, CANT1 
protein expression is lower in thapsigargin and tunicamycin treated samples compared to 
ethanol and DMSO treated samples during the whole experiment (Fig. 41). 
In summary, CANT1 protein expression was decreased in all three cell lines upon ER stress 
induction. On mRNA level, CANT1 changed in a similar but less pronounced manner as the 
established UPR target gene Herpud1 in the case of RWPE-1 cells and as all three analyzed 
UPR target genes in the case of PC-3 cells. Thus, some evidence for CANT1 being a novel 
UPR target gene was seen in these two cell lines. 
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Fig. 39 CANT1 expression upon ER stress induction in RWPE-1 cells. 
RWPE-1 cells were treated with thapsigargin and tunicamycin or ethanol and DMSO as 
corresponding negative controls for the indicated time periods. MRNA expression of CANT1, 
HSPA5, TRIB3 and Herpud1 and protein expression of CANT1 and HSPA5 were determined 
by qRT-PCR and Western Blot analysis. EtOH = ethanol, Thg = thapsigargin, Tu = 
tunicamycin. 
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Fig. 40 CANT1 expression upon ER stress induction in DU-145 cells. 
DU-145 cells were treated with thapsigargin and tunicamycin or ethanol and DMSO as 
negative control, respectively, for the indicated time periods. MRNA expression of CANT1, 
HSPA5, TRIB3 and Herpud1 and protein expression of CANT1 and HSPA5 was determined 
by qRT-PCR and Western Blot analysis. EtOH = ethanol, Thg = thapsigargin, Tu = 
tunicamycin. 
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Fig. 41 CANT1 expression upon ER stress induction in PC-3 cells. 
PC-3 cells were treated with thapsigargin (n=3) and tunicamycin (n=2) or ethanol and DMSO 
as negative control, respectively, for the indicated time periods. MRNA expression of CANT1, 
HSPA5, TRIB3 and Herpud1 and protein expression of CANT1 and HSPA5 was determined 
by qRT-PCR and Western Blot analysis. MRNA expression levels were normalized to ALAS1 
and HPRT1. EtOH = ethanol, Thg = thapsigargin, Tu = tunicamycin. 
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4.2 The role of FOXA1 in prostate cancer 
4.2.1 The expression of FOXA1 in human prostatic tissue 
In the before mentioned comparative study of normal and cancerous prostatic tissue, FOXA1 
was a second gene to be identified as upregulated in prostate cancer [15]. Thus, protein 
expression and diagnostic and prognostic value of FOXA1 were analyzed in a TMA format in 
cohort #1.  
4.2.1.1 FOXA1 expression increases with prostate carcinoma progression 
FOXA1 protein levels and the corresponding diagnostic value of FOXA1 were assessed by 
analyzing the staining intensities of FOXA1. FOXA1 was found almost exclusively in nuclei of 
epithelial cells, no stromal immunoreactivity was observed (Fig. 42 a), neither in normal nor 
in tumor tissues. In cases with strong FOXA1 expression, a mild degree of additional 
cytoplasmic staining was noted (Fig. 42 b) but not recorded. In normal prostatic tissues, 
FOXA1 was found in secretory cells, while basal cells were either negative or only weakly 
and inconsistently positive (Fig. 42 a).  
A B
C D
Fig. 42 FOXA1 immunohistochemistry of human prostatic tissues.  
Immunohistochemistry of human prostatic tissues, magnification 200x. (A) Normal prostate 
glands. Note the FOXA1 negative stromal cells. (B) Prostate adenocarcinoma. Note the 
cytoplasmic signal. (C) Prostate cancer metastasis in a lymph node. Note the lymphocytes 
(smaller nuclei) on the left. (D) CRPC. 
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Close to the tumor (adjacent normal, n=204), the distribution of FOXA1 expression was as 
follows: three cases (1.5 %) negative, 42 (20.6 %) staining score 1, 146 (71.6 %) staining 
score 2 and 13 (6.4 %) staining score 3. The mean expression score was 1.83 (Fig. 42 a, 
Fig. 43). In primary carcinomas, FOXA1 was expressed as follows: 22 cases (10.6 %) 
negative, 56 (27.1 %) staining score 1, 114 (55.1 %) staining score 2 and 15 (7.2 %) staining 
score 3. The mean expression score was 1.59 (Fig. 42 b, Fig. 43). In metastases, FOXA1 
was expressed as follows: seven cases (17.9 %) negative, four (10.3 %) staining score 1, ten 
(25.6 %) staining score 2 and 18 (46.2 %) staining score 3. The mean expression score was 
2.0 (lymph node metastasis in Fig. 42 c, Fig. 43). In CRPC, FOXA1 was expressed as 
follows: two cases (3.9 %) negative, two (3.9 %) staining score 1, 23 (45.1 %) staining score 
2 and 24 (47.1 %) staining score 3. The mean expression score was 2.35 (Fig. 42 d, Fig. 
43).  
In summary, little differences were seen between normal tissue and primary carcinomas, 
although a tendency to slightly decreased FOXA1 levels in primary carcinomas was 
observed. Significant upregulation of FOXA1 was seen in metastases and even more 
pronounced in CRPC.  
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Fig. 43 FOXA1 staining intensity in human prostatic tissue samples. 
Mean FOXA1 staining intensity during neoplasia progression. Ca = carcinoma. 
 
4.2.1.2 Relationship of FOXA1 staining to clinicopathological parameters and survival 
analysis 
The prognostic value of FOXA1 was determined by analyzing the relationship between 
FOXA1 staining intensities and clinicopathological and survival data. In primary carcinomas, 
FOXA1 expression was significantly associated with pT stage and Gleason score. No 
correlation to age, pre-OP PSA levels and surgical margins were revealed (Tab. 18). 
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Tab. 18 Relationship between FOXA1 expression and clinicopathological data of 
primary prostate carcinoma specimens (RPE) in cohort #1 (n=207). 
* statistically significant 
parameter FOXA1 
low 
FOXA1 
high 
p-value 
age    0.774 
≤ 64 years 37 65  
> 64 years 41 64  
pre-OP PSA    0.779 
≤ 10 ng/ml 35 54  
> 10 ng/ml 40 69  
Gleason score    0.017* 
5-6 20 15  
7 42 77  
8-10 16 37  
pT stage    0.018* 
pT2 57 72  
pT3/4 21 57  
margin status    0.294 
R0 53 78  
R1 24 50   
 
The analysis of patient follow-up data concerning serum PSA levels revealed a significant 
association between high FOXA1 expression levels and shorter relapse free survival times in 
Kaplan Meier analysis (mean 87 vs. 70 months, p=0.018, Fig. 44). However, FOXA1 
expression failed to represent an independent prognostic marker (Cox regression analysis 
including pre-OP PSA level, pT stage, Gleason score, margin status; data not shown).  
Together, a clear prognostic value of FOXA1 was revealed. 
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Fig. 44 Univariate survival analysis dependent on FOXA1 staining intensity. 
Kaplan-Meier curves of FOXA1 expression (dichotomized by the median). 
 
4.2.1.3 Relationship between FOXA1 and steroid hormone receptors. 
Because FOXA1 was shown to cooperate amongst others with ERα and AR to induce gene 
expression [98, 115, 116, 125, 129], the relationship between FOXA1 and steroid hormone 
receptors in prostate cancer was analyzed. Therefore, the TMA slides were additionally 
stained with antibodies against AR, ERα and ERβ. Staining intensities were evaluated 
separately in the nuclei of the stroma and the epithelium. Within the group of primary 
carcinomas, FOXA1 staining intensity was significantly correlated to epithelial and stromal 
AR, stromal ERα and epithelial and stromal ERβ (Tab. 19). 
 
Tab. 19 Bivariate correlations between FOXA1 and steroid hormone receptor staining 
intensities. 
* statistically significant 
  AR epithelium 
AR 
stroma
ERα 
epithelium 
ERα 
stroma
ERβ 
epithelium 
ERβ 
stroma
correlation 
coefficient 
0.534 0.213 0.105 0.444 0.410 0.354 
p-value <0.001* 0.002* 0.145 <0.001* <0.001* <0.001*
FOXA1 
n 200 201 196 196 189 189  
 
Due to the strong correlation of FOXA1 to epithelial AR a double immunofluorescence 
staining of both proteins was conducted in a small subset of cases. This demonstrated a 
strong concordance of immunoreactivity of both markers (Fig. 45). 
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FOXA1 AR Merge
Fig. 45 Colocalization of FOXA1 and AR in prostate cancer. 
Double immunofluorescence of FOXA1 (red) and AR (green) in a human prostate 
adenocarcinoma, magnification 400x. 
 
Further, a stratified Kaplan Meier analysis according to low (staining score 0 to 2) and high 
(staining score 3) AR levels was performed. This demonstrated an even increased 
prognostic significance of FOXA1 in cases with low AR levels (mean 86 vs. 56 months, 
p<0.001), whereas in cases  with high AR levels, no prognostic significance at all was 
discerned (Fig. 46). Cox regression analysis including pre-OP PSA level, pT stage, Gleason 
score and margin status revealed FOXA1 not to be independent also in this patient subgroup 
(data not shown). 
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Fig. 46 Univariate survival analysis dependent on AR and FOXA1 staining intensity. 
Kaplan-Meier curves of FOXA1 expression in patients with low (staining score 0 to 2) and 
high (staining score 3) AR levels. 
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In summary, a strong correlation between FOXA1 and steroid horomone receptor expression 
in primary prostate carcinomas was demonstrated, which is reflected in a coexpression of 
FOXA1 and AR. The prognostic value for FOXA1 staining that was revealed before (see 
chapter 4.2.1.2), was even more pronounced in the patient subgroup with prostate 
carcinomas that express low AR protein. 
4.2.2 The influence of FOXA1 knockdown on in vitro tumorigenicity 
4.2.2.1 Characterization of FOXA1 expression in prostatic cell lines 
To test if FOXA1 overexpression has a functional relevance in prostate cancer cell lines the 
expression on transcript and protein level was determined in the four prostatic cell lines using 
an antibody that detects FOXA1 as well as FOXA2. As observed by Western Blot analysis, 
FOXA1 protein was strongly expressed in LNCaP and PC-3 cells, whereas it was 
undetectable in DU-145 and RWPE-1 cells. FOXA2 was strongly expressed in PC-3 and 
DU-145 cells, less amounts were detected in RWPE-1 and LNCaP cells. FOXA1 mRNA 
expression was strongest in LNCaP cells. Medium levels of FOXA1 mRNA were detected in 
PC-3 and DU-145 cells, whereas mRNA levels in RWPE-1 cells were very low (Fig. 47). 
In summary, a similar expression pattern as for CANT1 was revealed. FOXA1 protein is 
strongly expressed in the prostate cancer cell lines LNCaP and PC-3. In contrast, the 
expression is very low in the third prostate cancer cell line DU-145 and the benign prostatic 
cell line RWPE-1. 
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Fig. 47 Expression of FOXA1 in prostatic cell lines. 
RWPE-1, PC-3, DU-145 and LNCaP cells were cultivated in 75 cm² cell culture flasks to 
70-80 % confluence. FOXA1 mRNA and protein expression was determined by qRT-PCR 
(top) and Western Blot analysis (bottom), respectively. MRNA levels were normalized to that 
of LNCaP cells. 
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4.2.2.2 Transient knockdown of FOXA1 in prostate cancer cell lines with high endogenous 
FOXA1 levels 
According to the strong protein expression of FOXA1 LNCaP and PC-3 cells were chosen for 
tumorigenicity studies. A knockdown protocol based on RNA interference was established for 
both cell lines using three FOXA1-specific siRNAs. QRT-PCR and Western Blot analysis 
revealed a potent FOXA1 knockdown on mRNA and protein level, respectively, 72 h after 
siRNA transfection. The mRNA levels were reduced to 39 %, 57 % and 37 % in LNCaP cells 
and to 22 %, 42 % and 16 % in PC-3 cells using FOXA1 siRNA #1, #2 and #3, respectively. 
Except for siRNA #1 in PC-3 cells, knockdown efficiencies on protein level were similar 
strong. In all samples, only the levels of FOXA1 protein were reduced, while the expression 
levels of FOXA2 remained unchanged, indicating the specificity of the siRNAs used (Fig. 48). 
Summarized, efficient downregulation of FOXA1 expression was achieved in LNCaP and 
PC-3 cells using three specific siRNAs.  
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Fig. 48 Knockdown of FOXA1 in LNCaP and PC-3 cells. 
LNCaP and PC-3 cells were cultivated in 6-well plates and left untreated or transfected with 
unspecific or FOXA1-specific siRNAs as indicated. After 72 h FOXA1 mRNA and protein 
expression was determined by qRT-PCR (top) and Western Blot analysis (bottom), 
respectively. 
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4.2.2.3 FOXA1 knockdown reduces cell proliferation 
To determine if FOXA1 expression has an influence on prostate cancer cell proliferation, 
LNCaP and PC-3 cells were transfected with FOXA1-specific siRNAs and cells were 
counted. Compared to corresponding unspecific siRNA transfected cells, the cell number of 
FOXA1 siRNA #1, #2 and #3 transfected LNCaP cells was reduced significantly by 24 %, 
18 % and 20 %. Although siRNA treatment itself strongly affected the propagation of PC-3 
cells, the number of FOXA1 siRNA #1, #2 and #3 transfected cells was further decreased by 
32 %, 44 % and 36 % compared to cells transfected with control siRNA and untreated cells 
(Fig. 49).  
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Fig. 49 Cell number of LNCaP and PC-3 cells upon FOXA1 knockdown.  
LNCaP and PC-3 cells were seeded in 6-well plates, left untreated or transfected with 
siRNAs as indicated, and counted after 72 h. 
 
To test whether the reduction of cell number after FOXA1 knockdown was caused by a 
reduction of cell proliferation rate, DNA synthesis rate was determined by measuring BrdU 
incorporation. As shown in Fig. 50, 44 %, 47 % and 29 % less BrdU was detected after 
transfection of LNCaP cells with FOXA1 siRNA #1, #2 and #3, respectively. The DNA 
synthesis rate of PC-3 cells was decreased in a highly significant manner by 18 %, 48 % and 
28 % in FOXA1 siRNA #1, #2 and #3 transfected cells compared to unspecific siRNA 
transfected cells.  
Taken together, these results show a significant reduction of LNCaP and PC-3 cell 
proliferation after FOXA1 knockdown. 
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Fig. 50 DNA synthesis rate of LNCaP and PC-3 cells upon FOXA1 knockdown.  
LNCaP and PC-3 cells were seeded in 6 cm-dishes and left untreated or transfected with 
siRNAs as indicated. After 72 h DNA synthesis rate measurement was performed. 
 
4.2.2.4 Reduced cell proliferation is associated with G1-arrest 
To examine whether the observed reduction of proliferation was reflected in a change of cell 
cycle distribution, the proportion of cells in G1-, S-, and G2/M-phase was determined by flow 
cytometry of PI-stained cells. The proportion of LNCaP cells in G1-phase increased from 
65 % in control cells to 70–75 % in FOXA1 knockdown cells, whereas the proportion of cells 
in S-phase declined from 22 % to 15–20 % in the respective groups; the proportion of cells in 
G2/M-phase also decreased slightly from 13 % to 10 % (Fig. 51 a, c, e, g). The differences 
were more pronounced in PC-3 cells. Sixty-three percent of the cells treated with unspecific 
siRNA were in G1-phase in contrast to 72–81 % of the cells treated with FOXA1-specific 
siRNAs. According to this up to 18 % increase of cells in G1-phase, the proportions of S- and 
G2/M-phase cells decreased in FOXA1 knockdown PC-3 cells from 19 % to 6–14 %, and 
from 17 to 10–13 %, respectively (Fig. 51 b, d, f, h). In summary, these data clearly indicate 
G1-arrest upon FOXA1 knockdown, which is very prominent in PC-3 cells.  
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Fig. 51 Cell cycle distribution of LNCaP and PC-3 cells upon FOXA1 knockdown.  
LNCaP (A, C, E, G) and PC-3 (B, D, F, H) cells were left untreated or transfected with 
siRNAs as indicated. After 72 h, cell cycle analysis was performed. (A, B) Representative 
histogram of cells that were treated either with unspecific siRNA (red) or FOXA1 siRNA #3 
(blue); note the higher G1-phase peak and lower S-phase plateau and G2-phase peak in the 
FOXA1 siRNA histogram compared to the unspecific siRNA histogram. (C, D) 
Representative distribution of G1-, S-, and G2/M-phase phase. (E, F) Proportion of cells in 
G1-phase from all replicates. (G, H) Proportion of cells in S-phase from all replicates. 
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4.2.2.5 Cell migration is inhibited upon FOXA1 knockdown 
The relevance of FOXA1 expression during cell migration was elucidated in a transmigration 
assay using fibronectin coated wells. Downregulation of FOXA1 reduced migration of LNCaP 
cells through the porous membrane highly significantly by 18 %, 12 % and 25 % using siRNA 
#1, #2 and #3 compared to control cells. The reduction of PC-3 cell migration accounted for 
12 %, 20 % and 29 % with the respective siRNAs in comparison to corresponding control 
cells (Fig. 52).  
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Fig. 52 Haptotactic transmigration of LNCaP and PC-3 cells upon FOXA1 knockdown.  
LNCaP and PC-3 cells were seeded in 6 cm-dishes and left untreated or transfected with 
siRNAs as indicated. After 72 h, the transmigration assay was performed. Below, 
representative pictures of the DAPI-stained membranes are displayed (magnification 100x). 
 
Migration of PC-3 cells on an uncoated surface was assessed in a scratch wound assay. The 
area, which was not recovered with migrated PC-3 cells within 24 h after introducing the 
wound, was 1.9, 2.1 and 1.6 times larger following FOXA1 downregulation with siRNA #1, #2 
and #3, respectively, compared to unspecific siRNA treatment (Fig. 53), indicating a 
diminished cell motility.  
Altogether, these data show that the reduction of FOXA1 expression induces considerable 
inhibition of LNCaP and PC-3 cell migration. 
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Fig. 53 Wound healing of PC-3 cells upon FOXA1 knockdown. 
PC-3 cells were seeded in 6 cm-dishes and the scratch wound assay was conducted. On the 
right, representative pictures of the wounds are shown (magnification 25x). 
 
4.3 Functional characterization of GOLM1 in vitro 
The third candidate protein for functional analyses is GOLM1, which was also identified from 
our gene array study of matched normal and prostate cancer tissue [15]. Recently, our group 
confirmed overexpression of GOLM1 protein in prostate carcinomas in 92.3 % of the patients 
[16]. 
4.3.1 Characterization of GOLM1 expression in prostatic cell lines 
To test if GOLM1 overexpression has a functional relevance in prostate cancer, the four 
prostatic cell lines were evaluated for endogenous GOLM1 expression levels and selected 
for subsequent functional studies. As observed by Western Blot analysis, GOLM1 protein 
was strongly expressed in LNCaP and DU-145 cells, whereas it was undetectable in PC-3 
cells. A weak band was detected in the lysate of the epithelium derived cell line RWPE-1. 
Similarly, mRNA expression was strongest in DU-145 cells followed by LNCaP and RWPE-1 
cells. In contrast to the protein, GOLM1 mRNA was also detected in PC-3 cells (Fig. 54). 
Thus, the GOLM1 expression pattern in the four analyzed cell lines differs from that of 
CANT1 and FOXA1. Similar to these before analyzed proteins, high expression in LNCaP 
cells and weak expression in RWPE-1 cells was detected. Contrary, DU-145 expressed very 
high levels of GOLM1, whereas the protein was undetectable in PC-3 cells. 
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Fig. 54 Expression of GOLM1 in prostatic cell lines. 
LNCaP, DU-145, PC-3, and RWPE-1 cells were cultivated in 75 cm² cell culture flasks to 
70-80 % confluence. GOLM1 mRNA and protein expression was determined by qRT-PCR 
(top) and Western Blot analysis (bottom). MRNA levels were normalized to LNCaP cells. 
 
4.3.2 Transient knockdown of GOLM1 in prostate cancer cell lines with high 
endogenous GOLM1 levels 
According to the strong GOLM1 expression on mRNA and protein level, LNCaP and DU-145 
cells were chosen for knockdown studies. A knockdown protocol based on RNA interference 
was established for both cell lines. QRT-PCR and Western Blot analysis revealed a potent 
GOLM1 knockdown on mRNA and protein level, respectively, 72 h after siRNA transfection 
(Fig. 55). A reduction of mRNA amounts to ~33 % in LNCaP cells and to 15-26 % in DU-145 
cells was achieved. Protein expression was hardly detectable in any of the GOLM1-specific 
siRNA treated samples. Thus, GOLM1 expression was efficiently downregulated in LNCaP 
and DU-145 cells using three specific siRNAs. 
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Fig. 55 Knockdown of GOLM1 in LNCaP and DU-145 cells. 
LNCaP and DU-145 cells were cultured in 6 cm-dishes and left untreated or transfected with 
unspecific or GOLM1-specific siRNAs as indicated. After 72 h GOLM1 mRNA and protein 
expression was determined by qRT-PCR (top, n=2) and Western Blot analysis (bottom, n=5). 
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4.3.3 GOLM1 knockdown does not change cell proliferation rate 
To determine if GOLM1 expression has an influence on prostate cancer cell proliferation, 
LNCaP and DU-145 cells were transfected with GOLM1-specific siRNAs and cells were 
counted. Transfection of GOLM1 siRNA #2 in DU-145 cells slightly increased the cell 
number, however no significant changes were observed in either of the cell lines using any 
siRNA (Fig. 56).  
LNCaP DU-145
un
tr
un
sp
ec
GO
LM
1 #
1
GO
LM
1#
2
GO
LM
1 #
3
0
1000000
2000000
3000000
4000000
5000000
ce
ll 
nu
m
be
r
un
tr
un
sp
ec
GO
LM
1 #
1
GO
LM
1#
2
GO
LM
1 #
3
0
1000000
2000000
3000000
4000000
5000000
ce
ll 
nu
m
be
r
Fig. 56 Cell number of LNCaP and DU-145 cells upon GOLM1 knockdown.  
LNCaP and DU-145 cells were seeded in 6 cm-dishes, left untreated or transfected with 
siRNAs as indicated, and counted after 72 h. 
 
Further, DNA synthesis rate was determined by measuring BrdU incorporation. As shown in 
Fig. 57, similar amounts of BrdU as in control cells were detected after transfection of 
LNCaP and DU-145 cells with GOLM1 siRNAs. 
Taken together, these results show that proliferation of prostate cancer cell lines is 
independent of GOLM1 expression. 
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Fig. 57 DNA synthesis rate of LNCaP and DU-145 cells upon GOLM1 knockdown.  
LNCaP and DU-145 cells were seeded in 6 cm-dishes and left untreated or transfected with 
siRNAs as indicated. After 72 h DNA synthesis rate measurement was performed. 
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4.3.4 GOLM1 knockdown has no influence on cell cycle distribution  
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Fig. 58 Cell cycle distribution of LNCaP and DU-145 cells upon GOLM1 knockdown.  
LNCaP (A, C, E, G) and DU-145 cells (B, D, F, H) were left untreated or transfected with 
siRNAs as indicated. After 72 h, cell cycle analysis was performed. (A, B) Representative 
histogram of cells that were treated either with unspecific siRNA (red) or GOLM1 siRNA #2 
(blue). (C, D) Representative distribution of G1-, S-, and G2/M-phase cells. (E, F) Proportion 
of cells in G1-phase from all replicates. (G, H) Proportion of cells in S-phase from all 
replicates. 
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To analyze cell cycle distribution upon GOLM1 knockdown the proportion of cells in G1-, S- 
and G2/M-phase was determined by flow cytometry of PI-stained cells. The proportion of 
LNCaP cells in G1-phase ranged from 65 % to 71 % in all groups, the proportion of cells in 
S-phase ranged from 15 % to 20 %. No significant changes were observed. In DU-145 cells 
53 % to 57 % of the cells were in G1-phase and 17 % to 23 % of the cells were in S-phase. 
Only the reduction of S-phase cells between cells that were transfected with unspecific 
siRNA and GOLM1 siRNA #1 from 20.6 % to 17.5 % was significant (Fig. 58). Yet altogether, 
these data show that GOLM1 knockdown has no reproducible effect on cell cycle regulation 
in LNCaP as well as in DU-145 cells. 
4.3.5 Cell migration is not influenced by GOLM1 knockdown 
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Fig. 59 Haptotactic transmigration of LNCaP and DU-145 cells upon GOLM1 
knockdown.  
LNCaP and DU-145 cells were seeded in 6 cm-dishes and left untreated or transfected with 
siRNAs as indicated. After 72 h, the transmigration assay was performed. Below, 
representative pictures of the DAPI-stained membranes are displayed (magnification 100x). 
 
The relevance of GOLM1 expression during cell migration was elucidated in a transmigration 
assay using fibronectin coated wells. Transmigration of LNCaP cells was strongly affected by 
transfection with Lipofectamine 2000 (compared with the effect of transfection using 
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HiPerFect in chapters 4.1.2.5 and 4.2.2.5). The effect of downregulation of GOLM1 differed 
between the siRNAs. The proportion of migrated LNCaP cells was reduced by 18 % upon 
transfection with GOLM1 siRNA #1, whereas transfection with siRNA #2 and #3 increased 
the proportion significantly by 34 % and 23 %. In DU-145 cells, transfection with siRNA #1 
led to a highly significant reduction of migrated cells by 31 %. Upon transfection with siRNA 
#2 migration rate was also reduced by 14 %. The change upon transfection with siRNA #3 
was not significant (Fig. 59). 
Migration of DU-145 cells on an uncoated surface was assessed in a scratch wound assay. 
The area, which was not recovered with migrated cells within 8 h after introducing the wound, 
remained unchanged following GOLM1 downregulation with specific siRNAs (Fig. 60). 
Altogether, these data show that the reduction of GOLM1 expression does not mediate a 
change of cell migration. 
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Fig. 60 Wound healing of DU-145 cells upon GOLM1 knockdown. 
DU-145 cells were seeded in 6 cm-dishes and the scratch wound assay was conducted. On 
the right, representative pictures of the wounds are shown (magnification 25x). 
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5 Discussion  
5.1 The role of CANT1 in prostate cancer 
5.1.1 Expression, relationship to clinicopathological parameters and survival 
analysis of CANT1 in human prostatic tissue 
Previously, our group identified CANT1 as a highly upregulated gene in human prostate 
cancer [15]. Further, CANT1 gene expression has been shown to be significantly higher in 
tumors of the prostate compared to 28 other tumor entities [47]. However, the clinical 
significance of CANT1 expression in prostate cancer tissues has not been investigated yet. 
To study CANT1 protein expression during prostate carcinoma initiation (normal, PIN, 
primary carcinoma) as well as during prostate carcinoma progression (primary carcinoma, 
metastasis, CRPC), two TMAs were constructed including nearly 1.000 prostate tissue 
samples from two different hospitals and a valid immunohistochemistry protocol was 
developed. CANT1 immunoreactivity was detected in secretory epithelial cells in the Golgi 
apparatus region as well as in the cytoplasm. Evaluation of TMA #1 showed ubiquitous 
CANT1 expression in normal prostate epithelial tissue, however, the overall staining 
intensities of the Golgi apparatus and the cytoplasm were generally stronger in cancer, thus 
suggesting CANT1 as a candidate diagnostic marker for prostate carcinomas. Slightly but 
significantly lower levels of CANT1 were noted in CRPC in comparison to primary 
carcinomas and metastases. With regard to normal tissue, the CANT1 levels of CRPC were 
only significantly different for the Golgi immunoreactivity. Similarly, in eleven prostate cancer 
xenografts in mice highest expression rates of CANT1 transcripts including exon 1a were 
detected in more differentiated, androgen-dependent tumors. In contrast, transcripts 
including exon 1 were expressed at variable levels in all xenografts independent of 
differentiation and androgen-dependency [49]. Assuming equal translation efficiency of both 
transcripts, the total amount of CANT1 protein was lower in androgen-independent tumors, 
which resemble CRPC, than in androgen-dependent tumors, which is consistent with our 
data. 
This raises the question how CANT1 expression is regulated. First, it would be interesting to 
analyze if CANT1 transcripts including exon 1 or 1a contribute equally to changes in CANT1 
expression. In any case, both transcripts were shown before to be androgen-regulated [49] 
and AR expression increases and decreases similarly from normal epithelium to primary 
carcinomas and from metastases to CRPC, respectively (data not shown), strongly indicating 
that CANT1 levels depend on AR levels.  
CANT1 intensity levels of Golgi and cytoplasm staining show synchronous changes during 
prostate carcinoma development indicating that localization of the protein does not change. 
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The unique design of TMA #2 with matching normal and cancer tissues allowed to 
individually evaluate the diagnostic value of CANT1. The upregulation of CANT1 in 
carcinomas could be convincingly confirmed in this second independent cohort. Moreover, 
the direct case wise comparison of cancerous and adjacent normal glands revealed a gain of 
CANT1 expression in 97.2 % of the cases, clearly substantiating the applicability of CANT1 
as potentially helpful ancillary marker to ascertain a cancer diagnosis in a suspicious lesion. 
Additionally, elevated expression levels of the protein were already detected in the precursor 
lesion PIN. Statistically, the mean staining intensity of PIN cores was significantly lower 
compared to primary carcinomas, however the absolute difference is too little to distinguish 
these stages in practice.  
 
The initial survival analysis of CANT1 expression categorized into negative, weak, moderate 
or strong expression did not show significant differences in Kaplan-Meier analysis. However, 
a significant impact towards better prognosis in cases with strong CANT1 overexpression 
was noted in univariate and multivariate analyses in the larger study cohort (TMA #2) using a 
sophisticated semiquantitative evaluation scheme, which included area and intensity to 
compensate for expression heterogeneity. This more differentiated analysis allowed the 
separation of the upper quartile in the range of expression values, which was not feasible 
with the simpler three tiered scoring system applied to TMA #1. This finding was further 
substantiated by the association of lower H-scores with higher Gleason scores and pT 
stages, respectively. These results nicely fit to the observation that CANT1 expression is 
lower in the aggressive group of CRPC compared to primary carcinomas. 
 
In summary, CANT1 is weakly expressed in normal prostatic epithelium, upregulation starts 
early in prostate carcinoma initiation (PIN), expression remains high in primary carcinomas 
and metastases before CANT1 levels decline again slightly during development of castration-
resistance. Thus, despite ubiquitous overexpression in primary tumors, which was 
demonstrated in two independent patient cohorts, the diagnostic applicability of CANT1 as a 
prostate cancer marker is hampered by its basal expression in normal glands and its inability 
to discriminate PIN glands from invasive carcinoma glands.  
The prognostic value of CANT1 appears to be limited, since it only became evident upon 
careful consideration of staining heterogeneity. However, if this more elaborate analysis is 
conducted, CANT1 expression is an independent prognostic biomarker for prostate cancer 
following RPE. 
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5.1.2 Functional characterization of CANT1 in vitro 
Since CANT1 upregulation is apparently an early event during prostate carcinoma 
development, it was encouraging to investigate if CANT1 has tumor promoting functions. For 
this, we analyzed CANT1 expression in different prostatic cell lines and set up an in vitro 
system to test cell proliferation and migration behaviour in cells with high and low CANT1 
levels. 
 
In concordance with the TMA data, CANT1 protein levels were low in the benign cell line 
RWPE-1 and high in the metastasis-derived hormone-dependent cell line LNCaP. In the 
hormone-independent metastasis-derived cell lines PC-3 and DU-145, which are a model 
system for the castration-resistant stage of prostate carcinomas, CANT1 expression was 
strong and weak, respectively. Hence, the DU-145 cell line possibly represents a CRPC case 
that already repressed CANT1 expression after the protein had been upregulated during the 
stage of hormone-dependency. The expression differences were not that prominent on RNA 
level indicating post-transcriptional regulation of CANT1 protein expression. In all four 
prostatic cell lines as well as in HEK-293 kidney cells, Western Blot analysis detected one 
major band at ~38 kDa and one or two bands of higher molecular weight, confirming the 
results of Smith et al. [60].  
 
We then investigated, if downregulation of CANT1 influences the tumorigenic potential of 
prostate cancer cells. Indeed, CANT1 knockdown heavily impaired the function of PC-3 and 
LNCaP cells, both being characterized by high endogenous CANT1 protein levels. It was 
shown that suppression of CANT1 expression slowed down propagation of LNCaP and PC-3 
cells, which was caused by a decreased cell proliferation as demonstrated by DNA synthesis 
rate measurement. The reduction of DNA synthesis rate was strikingly stronger than the 
reduction of cell number, which probably was a consequence of the experimental setup. Cell 
counting is an endpoint measurement, which includes the establishment phase of the 
knockdown. In contrast, determination of DNA synthesis rate is a snap-shot measurement at 
the time point when knockdown is most efficient. Cell cycle distribution analysis revealed that 
lower proliferation rate in turn was caused by an arrest in G1-phase. Since DNA synthesis 
takes place during the S-phase [170], changes in BrdU incorporation should be reflected in 
changes in the amounts of cells that are in S-phase according to cell cycle analysis. Actually, 
upon CANT1 knockdown the decrease of S-phase cells was only minimally stronger than the 
decrease of BrdU incorporation in both cell lines. Additionally, a decreased motility of both 
cell lines upon CANT1 downregulation was observed in the transmigration assay, which 
could be verified for PC-3 cells in the scratch wound assay. Thus, in prostate cancer cells, 
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haptotactic cell migration towards fibronectin, which is part of the extracellular matrix [171], 
as well as migration on a non-coated surface is influenced by CANT1 expression. 
In most of the assays, the effect of CANT1 knockdown was stronger in PC-3 cells than in 
LNCaP cells and in both cell lines the effect of transfection with siRNA #1 was stronger than 
the effect using siRNA #2, which was consistent with the efficiency of CANT1 downregulation 
in the respective samples. This dose-dependency underlines the specificity of the observed 
inhibition of cell proliferation and migration being actually related to a decrease of CANT1 
expression. 
 
To analyze, if CANT1 has any transforming capacities, the prostate epithelial cell line 
RWPE-1, which expresses low CANT1 protein levels, was transfected with a CANT1 vector. 
The analysis of cell proliferation rate via DNA synthesis rate measurement as well as the 
analysis of cell migration rate in a transmigration assay revealed no changes upon CANT1 
overexpression. Despite an extremely high expression of CANT1 protein, similar results were 
obtained in transfected HEK-293 cells that as well are benign and endogenously express low 
CANT1 protein but that are derived from embryonic kidney instead of prostate. We next 
tested, if upregulation of CANT1 leads to enhanced in vitro tumorigenicity of prostate cancer 
cell lines. This was not the case for DU-145 cells that are characterized by very low CANT1 
protein levels. Similarly, proliferation and migration rates of PC-3 cells that endogenously 
express abundant CANT1 protein remained constant upon further enhancement of CANT1 
expression although in vitro tumorigenicity was strongly reduced upon CANT1 knockdown. 
To elucidate if the effects of CANT1 knockdown could be rescued by restoration of CANT1 
expression, PC-3 cells were consecutively transfected with CANT1 siRNA and a CANT1-
encoding vector. While endogenous mRNA levels of CANT1 were successfully restored, 
rescue on protein level failed. This was probably due to the potent effect of the siRNA which 
not only induces mRNA degradation but also translation inhibition. Because of the failed 
protein re-expression the effects of siRNA transfection were not reversed.  
 
Altogether, these cell culture studies show that CANT1 downregulation strongly impairs cell 
proliferation and migration. However, CANT1 overexpression alone is not sufficient to induce 
or enhance in vitro tumorigenicity independent of the endogenous levels of CANT1 protein, 
the malignancy status and the prostatic origin of the cells. Accordingly, CANT1 appears not 
to be a driver of prostate cancer initiation, rather, CANT1 upregulation might be a 
consequence. Still, presence of CANT1 is essential to sustain cancer cell proliferation and 
migration. Especially in PC-3 cells, which were employed in CANT1 knockdown as well as in 
overexpression studies, it became clear that this effect of CANT1 expression is saturable. In 
conclusion, CANT1 appears to be relevant for the maintenance of prostate carcinomas. 
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5.1.3 Characterization of CANT1 
The questions arise, what leads to CANT1 upregulation during carcinogenesis and what is 
the reason for CANT1 decline in CRPC? Which mechanisms underly the diminished 
tumorigenic potential of prostate cancer cell lines upon CANT1 knockdown? Why does the 
overexpression of CANT1 not induce an increase of in vitro tumorigenicity of prostatic cell 
lines? To answer these questions, knowledge about CANT1 protein and its cellular function 
would be helpful. Therefore, we characterized CANT1 protein, its glycosylation status and its 
localization within the cell and beyond (secretion).  
 
We and others detected multiple bands in Western Blot analyses using CANT1 antibody [60, 
62]. Possible explanations for this observation are glycosylation, usage of different start 
codons, splicing or other post-translational modifications. Smith et al. demonstrated that 
human CANT1, which is transfected into COS-1 cells, is N-glycosylated. However, since 
after PNGase F treatment two bands still remained visible, they concluded that other 
modifications are also involved [60]. To investigate if endogenously expressed CANT1 is also 
N-glycosylated, lysates of LNCaP and PC-3 cells were treated with PNGase F. Confirming 
the data of Smith et al. a double band was detected before and after treatment with a 
molecular weight difference of ~2 kDa.  
 
Smith et al. further reported that nucleotidase activity was detected in the supernatant of 
COS-1 cells, indicating secretion of CANT1. Correspondingly, a cleavable signal peptide was 
identified (Fig. 61), whose truncation would result in a secreted protein of 333 amino acids. 
Confirming this prediction, Western Blot analysis detected a band in cell supernatants that 
was shifted by 2 kDa compared to cell lysates [60]. In contrast, upon transfection of the rat 
homolog of CANT1 into CHO cells, no CANT1 protein was detected in the supernatants. 
Rather, colocalization of the full-length protein including the predicted transmembrane 
domain with the ER resident protein calnexin was observed. In concordance, an RXR (amino 
acid 38-42 RFRPR, Fig. 61) ER-retention motif was identified in all vertebrate CANT1 
homologs [62]. These amino acids are situated between both hydrophobic stretches. Thus, 
independent of the membrane topology this motif is located in the cytoplasmic domain of 
CANT1 as it was described also for other proteins with RXR ER-retention motif [172-174]. 
However, it was observed that these amino acids are only recognized in a certain distance to 
the membrane [175, 176]. In CANT1, this motif is only two and three amino acids away from 
the strong and weak hydrophobic stretch, respectively (Fig. 61), and is thus unlikely to be 
functional.  
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Fig. 61 CANT1 membrane topology and the sequence of the N-terminus. 
The preferred model of CANT1 membrane topology (type II) is displayed together with the 
N-terminal amino acids 1 to 80. The weak and the strong hydrophobic stretch are framed and 
the strong hydrophobic stretch, which corresponds to the transmembrane domain in this 
model, is highlighted in grey. The alternative start codons (M), the RXR ER-retention motif 
(RFRPR) and the signal peptidase sequence (GR) are underlined, the cleavage site is further 
marked with an arrow. The numbers of the important amino acids are given above the 
sequence. Modified from [62]. N = N-terminus, C = C-terminus. 
 
Here, both options were examined by analysing cell culture supernatants via precipitation 
and ELISA and by immunofluorescence of human tissue and cell lines. 
The double immunofluorescence stainings clearly indicate a Golgi localization of CANT1 in 
normal prostate epithelium and prostate cancer as well as in LNCaP and PC-3 cells. 
Moreover, the diffuse cytoplasmic CANT1 staining, which was observed in the 
immunofluorescence and immunohistochemical stainings of prostatic tissue, might indicate 
additional ER localization. 
 
In confirmation of Smith et al. [60] we further demonstrated secretion of a truncated form of 
CANT1 in wildtype CANT1 positive cells applying Western Blot analysis to precipitates. 
Secretion was further confirmed in an ELISA-assay. Analysis of ultracentrifuged super-
natants that are devoid of vesicles demonstrated that this secreted form of CANT1 is soluble. 
Interestingly, the CANT1 band in supernatants was clearly singular. This indicates that the 
part of the protein, which is responsible for the modification that results in multiple Western 
Blot bands, is located N-terminal to the truncation side. This “responsible part” could either 
be the alternative start codons (amino acids 15 and 31) or amino acids that get glycosylated 
or otherwise modified post-translationally. According to computational analyses, the only 
predicted modification site N-terminal to the signal peptidase sequence is a phosphorylation 
site [60]. Following long exposition of the X-ray film, this truncated band was also detectable 
in the cell lysate of LNCaP cells. This argues that truncation of CANT1 takes already place in 
the ER or Golgi apparatus and export from the cell occurs via vesicles, which might be the 
source of this lower molecular weight band. Further, CANT1 containing vesicles represent 
another explanation for the diffuse cytoplasmic immunoreactivity that was observed in the 
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tissue stainings. Additionally, a full-length CANT1 band was detected in the 
ultracentrifugation pellet of PC-3 cells. As the strong shorter band in the precipitate of 
ultracentrifuged supernatant shows that secreted CANT1 is soluble, this signal in the pellet is 
probably derived from cell debris. Together, these observations support the signal peptidase 
model suggested by Smith et al. [60].  
 
Irrespective of the function of secreted CANT1, we analyzed the applicability of this 
observation to construct a novel diagnostic serum test. In contrast to one predecessor, who 
failed to detect CANT1 in human sera by Western Blot analysis [61], we were able to do so 
using a newly constructed sandwich ELISA assay. In accordance with the overexpression of 
CANT1 in prostate carcinomas, higher CANT1-levels were measured in patient sera 
compared to age matched healthy individuals, although, statistical significance was not 
reached. Unfortunately, serum levels of CANT1 were in the range of the lower detection 
threshold of the assay (detection range from 0.1 to 20 µg/ml), which precluded exact 
quantification. Therfore, further assay optimization is needed before the value of serum 
CANT1 as routine diagnostic biomarker can be determined. 
 
Summarizing the experiments for further characterization of CANT1, it was shown that 
endogenous CANT1 is glycosylated, is mainly localized in the Golgi apparatus and gets 
secreted in a truncated, soluble form. Although the clarification of post-translational 
modifications and the possible ER localization could not be completed, these findings add 
important information to the elucidation of the cellular function of CANT1. 
Further, serum CANT1 is suggested as novel non-invasive biomarker candidate for prostate 
cancer diagnosis, which ought to be considered in future research. 
5.1.4 The cellular function of CANT1 
Having further characterized CANT1 protein, we aimed at determining its cellular function. So 
far, CANT1 was suggested to induce expression of nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκB) and mitogen-activated protein kinase (MAPK) and to be 
involved in protein glycosylation [62, 68, 80]. However, little experimental evidence to support 
these hypotheses exists.  
5.1.4.1 The involvement of CANT1 in protein glycosylation 
As mentioned before in chapter 4.1.4, CANT1 is speculated to be an important player in 
protein glycosylation [62, 68, 80]. In more detail, in its function as NDP-hydrolase, CANT1 is 
suggested to be required for a continuous import of NDP-sugars into the ER or Golgi 
apparatus. The proposed mechanism is that CANT1 hydrolyzes NDP, which is a cleavage 
by-product after transfer of the sugar to the glycosylated protein, and thus promotes protein 
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glycosylation in two ways: Firstly, the NDP, which inhibits glycosyltransferases, is removed. 
Secondly, the corresponding NMP drives antiporters that exchange one NMP for one NDP-
sugar molecule. Hence, product inhibition of the transferases is prevented and sugar supply 
is assured [62, 68, 177].  
In this function, CANT1 may play a role either in glycoprotein or proteoglycan synthesis or 
protein folding, depending on its intracellular localization. Glycoprotein synthesis takes place 
in the ER and in the Golgi apparatus, but only in the Golgi apparatus nucleotides serve as 
sugar donors [156]. Nucleotides are also the sugar donors during proteoglycan synthesis 
which takes solely place in the Golgi apparatus [161]. These donor nucleotides are UDP, 
GDP and CMP, whereof UDP and GDP are the major potential targets of CANT1 according 
to nucleotidase activity measurements [60-62]. The crucial step during the protein folding 
process, where nucleotides (UDP) play a role, is the reglucosylation of misfolded proteins in 
the ER [159].  
Thus, if CANT1 is located in the ER, it might be important for protein folding, whereas Golgi 
apparatus localization would imply involvement in glycoprotein or proteoglycan synthesis. 
The same holds true for NTPDase5, which was shown to hydrolyze UDP and to be located in 
the ER [177]. However, since Fang et al. demonstrated an involvement of NTPDase5 in 
protein folding as well as in glycoprotein synthesis [167], one has to assume that this enzyme 
is also expressed in the Golgi apparatus. 
5.1.4.1.1 The involvement of CANT1 in glycoprotein synthesis 
Immunohistochemistry as well as immunofluorescence of human tissue and cell blocks 
revealed CANT1 to be mainly localized in the Golgi apparatus. Therefore, it was planned to 
analyze the glycoprotein pattern of CANT1 knockdown cells by Western Blot analysis using 
the lectin Phaseolus vulgaris Erythoragglutinin (PHA-E), which specifically binds to complex-
type N-glycans [178]. As positive control, LNCaP and PC-3 cells were treated with 
tunicamycin, which inhibits synthesis of the core oligosaccharide [169]. Thus, no N-
glycosylation can take place and the bands that are stained by PHA-E are expected to be 
weaker. As this was not clearly the case, these experiments had to be cancelled and the 
question if CANT1 is involved in glycoprotein synthesis cannot be unambiguously answered 
in this experimental setup. Disturbance of glycoprotein synthesis would have broad-ranging 
effects that would probably include inhibition of cell proliferation and migration. 
5.1.4.1.2 The involvement of CANT1 in proteoglycan synthesis 
Two observations from the analysis of the C.elegans homolog of CANT1, apy-1, and patients 
that suffer from Desbuquois dysplasia, which was shown to be caused by CANT1 mutations, 
support an involvement of CANT1 in proteoglycan synthesis. Apy-1 loss-of-function worm 
mutants display pharyngeal alterations resembling mutants defective in proteoglycan 
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synthesis [68] and bone specimens of Desbuquois dysplasia patients are characterized by a 
decreased amount of proteoglycans [79]. An impaired proteoglycan synthesis upon CANT1 
downregulation could imply a miscomposed extracellular matrix and thus affect cell motility. 
5.1.4.1.3 The involvement of CANT1 in the UPR 
Since we speculate that the origin of the additional cytoplasmic immunoreactivity in 
immunohistochemical and immunofluorescent stainings of prostatic tissue samples may be 
derived from ER-located CANT1, the involvement of CANT1 in the UPR was addressed.  
Before, a possible redundancy between CANT1 and the known ER-UDPase NTPDase5 was 
examined by expression analyses in mutual knockdown cells. In LNCaP cells, no changes of 
CANT1 or NTPDase5 expression levels were seen. However, in PC-3 cells a strong 
statistical trend for increased NTPDase5 transcription was revealed in CANT1 knockdown 
cells. Vice versa, average CANT1 mRNA levels were slightly augmented in NTPDase5 
knockdown cells compared to control cells. In both cases no changes in protein levels were 
observed. Steady-state CANT1 as well as NTPDase5 [167] levels are very high in LNCaP 
cells. Reduction of this basic protein amount by 2/3 is apparently not enough to induce 
expression of the second apyrase. In contrast, basic expression of NTPDase5 is very low in 
PC-3 cells [167]. Hence, CANT1 knockdown, which was nearly complete, strongly decreased 
the total amounts of UDPases in the ER. The consequently strong upregulation of 
NTPDase5 mRNA indicates redundant function of these two apyrases and supports an 
involvement of CANT1 in the UPR as it was shown for NTPDase5 [167]. Besides ADP-
hydrolysis in the blood by human NTPDase1 and bed bug apyrase [72, 73], this would be 
another example of analogous function of the two apyrase families. 
Next, the role of CANT1 in the UPR was investigated. We pursued a similar approach as 
Uccelletti et al. applied to analyze apy-1 function in C.elegans [68]. First, activation of the 
UPR following CANT1 and NTPDase5 knockdown was analyzed by expression analyses of 
established UPR target genes. As positive control for the readout, LNCaP and PC-3 cells 
were treated with chemical inducers of the UPR, which resulted in strong increase of HSPA5 
mRNA and protein levels as well as TRIB3 and Herpud1 mRNA levels. Application of this 
sensitive readout to CANT1 and/or NTPDase5 knockdown LNCaP cells revealed no 
activation of the UPR contrasting the observations of Fang et al. [167]. Similar to the 
observations concerning redundancy of CANT1 and NTPDase5, the knockdown might not 
have been strong enough to activate the UPR. However, in PC-3 cells specific changes were 
detected. Upon CANT1 knockdown, TRIB3 mRNA was significantly upregulated, a trend was 
seen for Herpud1 induction. NTPDase5 single knockdown resulted in significantly 
augmented HSPA5 mRNA levels and tended to increase Herpud1 mRNA. Augmented 
mRNA levels of HSPA5 and Herpud1 were also observed following double knockdown of 
both proteins, accompanied by enhanced expression of HSPA5 protein. These data indicate 
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involvement of both proteins in the UPR, thus partly confirming the results of Fang et al. 
[167]. However, concerning redundancy of CANT1 and NTPDase5 our data are not entirely 
conclusive. Knockdown of CANT1 and NTPDase5 was needed to induce elevated 
expression of HSPA5 protein supporting a redundancy. Yet, TRIB3 expression was 
unaffected in the double knockdown cells and no additive effect was seen on Herpud1 
upregulation upon downregulation of both apyrases. Further, in comparison to the positive 
control, the observed upregulation of UPR target genes upon CANT1 and NTPDase5 
knockdown were minimal. Thus, these two proteins do not seem to be essential for protein 
folding. Possibly, the sequence on chromosome 6, which is as well homologous to the bed 
bug apyrase [60], codes for a third hitherto unknown ER-UDPase that cooperates with 
CANT1 and NTPDase5 to regulate protein folding.  
In a second approach, CANT1 expression was measured during chemically induced UPR. In 
the benign RWPE-1 cells with low endogenous CANT1 levels, the total amount of the protein 
further decreased after 24 h of treatment consistent with a general translation inhibition 
during UPR. In contrast, increased mRNA levels were detected at the beginning similar to 
Herpud1. In the malignant DU-145 cells with similarly low endogenous CANT1 levels, the 
total amount of the protein was as well decreased during the whole kinetics, while mRNA 
expression was not affected by any treatment. Finally, CANT1 protein expression was also 
reduced upon ER stress induction in the malignant cell line PC-3 with high endogenous 
CANT1 levels. In contrast, CANT1 mRNA expression increased over time during 
thapsigargin and tunicamycin treatment and was also elevated 48 h after ethanol and 
especially DMSO treatment, similar to the selected known UPR target genes. In conclusion, 
DU-145 cells generally do not depend on CANT1 expression, regardless of the treatment. 
However, the striking similarity of CANT1 mRNA expression pattern with that of established 
UPR target genes in RWPE-1 and PC-3 cells suggests CANT1 to be a novel cell-type-
specific UPR target gene. In RWPE-1 cells the changes on protein level were either too little 
to be detectable by Western Blot analysis or the time point was missed. In PC-3 cells, 
CANT1 mRNA levels were increasing towards the end of the experiment, maybe this would 
have been reflected on protein levels at later time points. Indeed, in one experiment 
upregulation of the CANT1 protein was observed after 48 h. 
Together, these results indicate that CANT1 plays a role in protein folding, which is 
supported by further published observations. As already mentioned in chapter 4.1.4, apy-1 is 
induced upon ER stress triggered by tunicamycin or high temperature and knockdown of 
apy-1 leads to constitutive activation of the UPR only in the presence of functional ER stress 
sensors [68]. Furthermore, in patients suffering from Desbuquois dysplasia [179], inclusion 
bodies were detected in distended rough ER [70], which might be a hint for impaired protein 
folding and subsequent accumulation of misfolded proteins. A similar skeletal dysplasia was 
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shown to be caused by a functional defect in a nucleotide sugar transporter [180, 181], which 
is also involved in sugar supply of the ER and Golgi apparatus, as explained in the chapters 
1.6.5 and 4.1.4. Hence, by interfering with protein folding, CANT1 knockdown possibly 
causes the disruption of various cellular processes, amongst others cell proliferation and 
migration. It is tempting to speculate that this explains the significantly reduced rate of 
proliferation and migration, which we observed in prostate cancer cell lines upon knockdown 
of CANT1. Since ATP is needed to rephosphorylate the UMP in the cytoplasm to UDP before 
a sugar molecule can be added and imported into the ER, NTPDase5 was shown to promote 
ATP consumption, lower the ATP/AMP ratio and thus to increase glucose uptake, glycolysis 
and provision of intermediates for biomass production and thereby to finally support cell 
proliferation [167, 182]. This might be the mechanism underlying the prostate cancer 
promoting function, which was already assigned repeatedly to NTPDase5. In 2007, it was 
shown that NTPDase5 is upregulated in PIN lesions and prostate carcinomas similar to 
CANT1. Knockdown in LNCaP cells decreased collagen I expression and invasiveness, 
contrary reactions were detected in PC-3 cells upon overexpression of the protein [183]. 
Later, NTPDase5 knockdown was shown to increase the sensitivity to cisplatin, which was 
caused by decreased B-cell leukemia/lymphoma 2 (Bcl2) phosphorylation. [184]. Finally, 
Fang et al. were able to stop progression of LNCaP-derived carcinomas by NTPDase5 
knockdown in mice [167]. These signaling pathways should also be analyzed in CANT1 
knockdown cells in the future. 
 
Having shown that CANT1 mRNA is upregulated following ER stress induction, the promoter 
region of CANT1 was analyzed. However, no corresponding ER-stress response element 
(ERSE) or ERSE II [185, 186] were identified. 
Besides general translation inhibition and upregulation of proteins that assist protein folding 
or degradation, cell cycle arrest in the G1-phase is another feature of the UPR [187]. Thus, 
G1-arrest, which was observed upon CANT1 knockdown in LNCaP and especially in PC-3 
cells, adds further evidence to the putative involvement of CANT1 in protein folding and the 
UPR.  
An impaired protein folding following CANT1 knockdown together with general translation 
inhibition in the context of consequently activated UPR could be another reason for the failed 
rescue of CANT1 protein expression by CANT1 vector transfection in knockdown PC-3 cells 
although mRNA was successfully re-expressed. 
5.1.4.1.4 The role of the UPR in solid tumors 
Solid tumors commonly encounter stressful conditions as hypoxia, nutrient starvation, 
acidosis, disturbance of calcium homeostasis and misfolded mutated proteins. Consequently, 
UPR activation has been detected in various tumor entities. Amongst others, increased 
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expression levels of HSPA5, XBP1 or ATF6 were observed in HCC, breast, colon, gastric 
and esophagal carcinomas. Consisting with these human expression data, overexpression of 
HSPA5 and XBP1 has been shown to act tumor-promoting in mouse models. In contrary, 
suppression of XBP1 and PERK expression inhibited tumor development in animals. 
However, besides cell-protective effects, UPR elicits also cell-destructive pathways. 
Especially long-term activation of the UPR results in apoptosis. Thus, different mechanisms 
are conceivable for the tumor to avoid UPR-induced apoptosis. Either simultaneous 
disruption of the apoptotic machinery is sufficient to inhibit cell death induction, or the tumor 
cells activate specifically the cell-protective pathways of the UPR, or the tumor cell inhibits 
UPR instead of activating the stress response. Activation of single UPR branches has so far 
only been demonstrated in B-cells (reviewed in [188-191]). Evidence for UPR inhibition was 
claimed in mouse prostate cancer models. Indeed, ATF4, ATF6, HSPA5 and Herpud1 were 
downregulated in HGPIN, but the expression levels of PERK, XBP1, IRE1 and HSPA5 were 
either unchanged or increased in HGPIN or prostate cancer. In human prostate carcinomas, 
HSPA5 was reported to be upregulated several times, especially in CRPC [192-194]. Thus, 
the role of the UPR branches in prostate cancer needs to be elucidated in detail. Our data 
about CANT1 suggest at least activation of certain UPR target genes. 
5.1.4.2 The function of secreted CANT1 
The function of truncated CANT1, which was detected in cell culture supernatant by Western 
Blot analysis and ELISA, is currently unknown. Since soluble CANT1 is still enzymatically 
functional [60, 61, 77], it is conceivable that it is involved in the regulation of pyrimidinergic 
signaling of UDP and UTP. These extracellular nucleotides activate the cell-surface 
G-protein coupled receptors P2Y2, P2Y4 and P2Y6, which stimulate Phospholipase (PL) Cβ. 
PLCβ-induced cleavage of phosphatidylinositol bisphosphate (PIP2) into diacylglycerol (DAG) 
and inositol tri-phosphate (IP3) finally triggers intracellular calcium release mainly from the 
ER (reviewed in [195]). Via calcium/calmodulin and calcium/calmodulin dependent kinases, a 
complex, cell-type-specific signaling involving phosphorylation cascades and gene 
transcription is then initiated [196], which would be prevented by the degradation of UDP and 
UTP by CANT1. Moreover, it has been reported recently that IP3-mediated calcium release is 
increased during ER stress [197]. Hence, by hydrolyzing extracellular UDP and UTP and 
thus preventing calcium release from the ER, soluble CANT1 may support intracellular 
CANT1 in coping with ER stress. It is tempting to speculate that upon ER stress induction 
CANT1 expression is increased and newly synthesized CANT1 is secreted to inhibit calcium 
release from the ER. Consequently, CANT1 mRNA would be increased while simultaneously 
intracellular CANT1 protein levels would not change or even decrease because of enhanced  
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secretion of the protein. Increased CANT1 mRNA but decreased CANT1 protein levels were 
indeed observed upon thapsigargin and tunicamycin treatment of RWPE-1 and PC-3 cells, 
decreased protein levels were additionally detected in DU-145 cells. 
5.1.4.3 CANT1 as NFκB and MAPK inducing gene 
A study looking for novel genes that activate MAPK and NFκB signaling offers another 
approach to explain the missing link between CANT1 knockdown and decreased cell 
proliferation and migration. A cDNA library was transfected into HEK293 cells and luciferase-
activity of two reporter constructs, either containing a promoter with an NFκB- binding site or 
a promoter of a MAPK target gene, was measured. Upon transfection with a cDNA clone that 
contained parts of the CANT1 sequence, expression of the reporter constructs increased 19- 
or 15-fold, respectively, indicating that CANT1 activates both pathways, which are frequently 
deregulated in tumorigenesis, including prostate cancer [198-202]. In the NFκB-inducing 
clone, the first 100 amino acids of the CANT1 sequence including the putative ER-retention 
signal and the transmembrane domain were missing. However, to prove biological relevance 
of the NFκB-induction, the cells were simultaneously transfected with dominant-negative 
mutant of IκB kinase β. This kinase phosphorylates inhibitor of kappa B (IκB), which 
subsequently gets ubiquitinated and thus releases NFκB, which can then enter the nucleus 
[196]. The luciferase signal remained stable in this case, which demonstrated that CANT1 
acts upstream of IκB kinase β. Since NFκB is activated in the course of the UPR, a link to 
CANT1 is reasonable. The MAPK activating clone encoded the first 219 amino acids of 
CANT1, however nearly half of the protein was missing, giving rise to doubts if full-length 
CANT1 is also able to activate MAPK [203]. 
5.1.4.4 A model of CANT1’s cellular function 
Collectively, involvement of CANT1 in glycoprotein and proteoglycan synthesis, protein 
folding or NFκB, MAPK or pyrimidinergic signaling was proposed. Activation of NFκB and 
MAPK signaling was only detected in a screen with sequence fragments of CANT1 [203], a 
confirmation with full-length protein is lacking. Participation of CANT1 in pyrimidinergic 
signaling or glycoprotein synthesis was considered because of its enzymatic function in 
combination with the ascertained secretion or Golgi localization, respectively, but was not 
substantiated experimentally so far. Concerning proteoglycan synthesis, supportive 
observations were reported from C.elegans and Desbuquois dysplasia patients [68, 79]. Yet, 
experimental evidence was only demonstrated for protein folding. Additionally to previous 
analyses in C.elegans [68], we showed partially significant upregulation of established UPR 
target genes upon CANT1 knockdown accompanied by G1-arrest in PC-3 cells and an 
increase of CANT1 mRNA in a similar pattern as UPR target genes upon ER stress induction 
in RWPE-1 and PC-3 cells. These data are substantiated by matching cellular changes in the  
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Fig. 62 A hypothetical model of CANT1’s cellular function. 
In a CANT1 positive cell (upper left), CANT1 is localized in the ER and is secreted via the 
Golgi apparatus and vesicles. Soluble CANT1 hydrolyzes UTP and UDP to UMP and 
inorganic phosphate [60, 61, 77]. Through degradation of extracellular UTP and UDP, 
pyrimidinergic signaling is interrupted [195]. In the ER (lower left) CANT1, whose enzymatic 
activity is calcium dependent [60, 61] similar to other ER proteins, hydrolyzes UDP, which is 
a by-product of reglucosylation of misfolded proteins, to UMP and inorganic phosphate [157]. 
By degradation of UDP, product inhibition of UGGT is prevented [62, 68, 177]. The resulting 
UMP is exchanged for another UDP-Glc via the corresponding antiporter [163]. The 
reglucosylated protein is recognized by calnexin or calreticulin, which assist folding. After 
successful folding, the native protein can exit the ER [157]. 
In a CANT1 negative cell (upper right) no soluble CANT1 exists in the extracellular space to 
degrade UTP and UDP. Thus, pyrimidinergic signaling is active. The P2Y receptor activates 
PLCβ, which cleaves PIP2 into DAG and IP3. The latter intracellular signaling molecule 
triggers calcium release from the ER [195], which impairs the function of several ER proteins. 
Addtionally, UDP accumulates in the ER (lower right) because it is not hydrolyzed by CANT1. 
This inhibits UGGT, so that no Glc can be transferred to misfolded proteins [62, 68, 177]. 
Hence, these are not recognized by calnexin or calreticulin [157]. Further, no UDP-Glc 
molecules can be imported into the ER due to missing UMP, which drives the antiporter 
[163]. The consequent accumulation of misfolded proteins induces the UPR. The 
transcription factors ATF4, ATF6 and XBP1 are activated and promote transcription of UPR 
target genes, whose promoters contain special sequences, for example ERSE elements. 
Amongst others HSPA5 expression is increased [160]. CANX = calnexin. 
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bones of Desbuquois dysplasia patients [70]. A prerequisite for a nucleotidase to be involved 
in protein folding however is localization in the ER [159], which could neither be convincingly 
demonstrated nor excluded for CANT1. The fact that CANT1 overexpression in contrast to 
knockdown does not influence cell proliferation or migration indicates that the amount of 
CANT1 protein is tightly regulated and its function is saturable. Combining all observations 
from the current study with previous results, we propose a hypothetical model for CANT1’s 
cellular function, which suggests an interplay between intracellular and secreted CANT1 
(Fig. 62). 
To completely elucidate CANT1’s cellular function, the mode of secretion and the relevance 
of CANT1 in pyrimidinergic, NFκB and MAPK signaling as well as in glycoprotein and 
proteoglycan synthesis ought to be clarified in future studies. 
5.1.5 Conclusion about the role of CANT1 in prostate cancer 
This study is the first to depict a functional relevance of the apyrase CANT1 in a human 
neoplasia. CANT1 expression is ubiquitously increased not only in primary prostate 
carcinomas, but also in the precursor lesion PIN. Further, CANT1 is essential for maintaining 
tumorigenic potential. Thus, although CANT1 overexpression does not actively induce or 
increase in vitro tumorigenicity, CANT1 upregulation seems to be an important event during 
prostate cancer initiation and primary prostate carcinomas rely on CANT1 expression. We 
added further evidence to the putative involvement of CANT1 in protein folding and thus 
propose that increased expression of CANT1 is a consequence of increased protein turnover 
within a cancer cell, which warrants higher folding capacity to avoid accumulation of 
misfolded proteins (Fig. 62). Augmented CANT1 mRNA levels following chemical ER stress 
induction suggests active induction of CANT1 expression rather than passive upregulation by 
selection for cells with high CANT1 levels. 
Given the proposed importance of CANT1 expression in prostate cancer cells for the 
reduction of ER stress, it appears illogical that progression to castration-resistance is 
accompanied by a loss of CANT1. Thus, the mechanisms behind this as well as the 
consequences for the CRPC need to be clarified in future studies. 
Clinically, the good prognosis for patients with very high CANT1 protein levels, who barely 
experience disease progression, is maintained in multivariate analysis. Thus, CANT1 is a 
novel independent prognostic factor for prostate cancer. Yet, on account of the virtually 
equally intensive upregulation in PIN, CANT1 is not recommended as a diagnostic tool for 
the surgical pathologist. 
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5.2 The role of FOXA1 in prostate cancer 
5.2.1 Expression, relationship to clinicopathological parameters and survival 
analysis of FOXA1 in human prostatic tissue 
To my knowledge, this study is the largest yet to analyze the role of FOXA1 in prostate 
tissues including benign tissue, a large set of clinically characterized primary prostate cancer 
cases, metastases and for the first time advanced CRPC. In general, FOXA1 
immunoreactivity was mainly detected in nuclei, which was expected as FOXA1 is a 
transcription factor that was not described to cycle in and out of the nucleus as it is for 
example the case for AR [36]. Only in strongly stained cases, additional weak cytoplasmic 
staining was observed, which is either unspecific immunoreactivity or derived from newly 
synthesized FOXA1 molecules that have not yet been imported into the nucleus.  
 
Paradoxically, the overexpression of FOXA1 in tumor tissue in comparison to normal tissue, 
which was found on RNA level before [15], could not be confirmed. Rather, we report similar 
expression levels of FOXA1 in normal epithelium and primary carcinomas. Actually, at first 
analysis of the TMA, lower FOXA1 expression in benign tissue (mean staining intensity: 
1.48) compared to prostate cancer tissue was found. Further, a high variability of FOXA1 
expression levels in benign tissue was noted. During the consequently performed re-analysis 
of the cases, it turned out that the zonal origin of the benign tissue determines FOXA1 
expression levels. Tissue cores from the transitional zone, where BPH occurs, showed very 
low levels of FOXA1 whereas tissue cores from the peripheral zones, where primary 
carcinomas mostly arise, showed levels comparable to those of primary carcinomas. Many of 
the benign cases that were included on this TMA as well as in the previous gene array study 
[15], which was the basis of this work, were derived from BPH, which resolves the apparent 
discrepancy between our results of FOXA1 mRNA and protein expression in normal and 
prostate cancer. Hence, we decided to evaluate the staining intensity of adjacent normal 
tissue, which was present in nearly every core of primary carcinomas, instead of the BPH 
cores. To support the zonal model of FOXA1 expression, twelve additional RPE specimens 
with transitional zone carcinomas were included and indeed very low FOXA1 expression was 
noticed, comparable to the expression levels of the adjacent transitional zone glands. Thus, it 
was confirmed that FOXA1 expression does not increase during tumor initiation, which was 
already reported before by Mirosevich et al., who probably used normal and cancerous 
tissue from the peripheral zone to compare FOXA1 expression levels [109]. Similar results 
were obtained in mouse models of prostate cancer [204, 205]. However, one study analyzing 
FOXA1 expression in mouse models reported a consistent upregulation of FOXA1 in PIN 
and prostate adenocarcinoma [109]. 
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In concordance with the first study that dealt with FOXA1 expression in prostate cancer 
tissues so far [110], we found an upregulation of the protein between primary carcinomas 
and metastases. As this upregulation of FOXA1 was also indicated in the 27 CRPC cases 
that were included in the TMA (mean staining intensity 2.19), additional 24 cases were 
included from the archives to substantiate this interesting finding. Thus, in a cohort of 
together 51 cases, strong FOXA1 expression in the group of CRPC, which have not been 
looked at so far, was demonstrated.  
A growing stock of literature underscores the importance of FOXA1 in human neoplasia. 
Gene amplification and protein overexpression were observed in Barrett’s and lung 
adenocarcinomas [206, 207].  
 
Higher levels of FOXA1 in prostate cancer metastases and CRPC than in primary 
carcinomas indicate a role of the protein in prostate cancer progression. Accordingly, FOXA1 
correlates positively to conventional parameters of tumor progression, in particular higher 
Gleason scores and higher pT stages within the group of primary carcinomas. Although Jain 
et al. did not reveal correlations with these two parameters, they detected correlations with 
other progression parameters [110]. These results are reflected in a prognostic relevance, 
which we assigned to FOXA1 expression. High expression of the transcription factor in 
primary prostate carcinomas was associated with short times to PSA-relapse. This is in 
contrast to the prognostic value of FOXA1 in breast cancer, where a favourable prognosis 
has been related to high FOXA1 levels, particularly in estrogen receptor positive cases [208-
211].  
 
Main findings of the TMA-based analysis of FOXA1 staining intensity in different stages of 
prostate carcinoma development are a zonal dependence of FOXA1 expression in normal 
and tumor tissues, increasing FOXA1 levels with tumor progression with highest rates in 
CRPC and a prognostic value in primary tumors. The different expression levels of FOXA1 in 
the transitional and peripheral zone of the prostate underscore the importance to more 
accurately define the origins of normal tissue for comparative analyses. The more 
appropriate normal tissue to compare to peripheral zone prostate carcinomas ought to be 
normal tissue of the very same zone. This observation should be considered for future 
assembly of patient cohorts as well as for evaluation of existing studies.  
5.2.2 Relationship between FOXA1 and steroid hormone receptors 
Functional interactions between FOXA1 and ERα as well as AR have been reported before 
in breast and prostate cell lines and tissues [114-116, 125, 129, 130, 132, 133]. Therefore, 
AR and ERα and additionally ERβ were analyzed in parallel in this study. Close and 
significant correlation with FOXA1 was found for all three steroid hormone receptors, which 
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was strongest for AR. The coexpression of FOXA1 and AR could further be verified on single 
cell level by double immunofluorescence. A correlation with AR expression in prostate tissue 
was also found by Jain et al. [110], correlation with ERα expression was reported manifold in 
breast tissues, whereas a correlation between FOXA1 and ERβ is novel.  
 
Coexpression of FOXA1 and AR was also reported in a subset of ERα negative breast 
carcinomas. In these cases FOXA1 expression was probably induced via heregulin and 
v-erb-b2 erythroblastic leukemia viral oncogene homolog (ERBB) 2. [212-214]. The 
consequences of FOXA1-AR-interaction on androgen-dependent gene transcription have 
been studied in detail for PSA: Gao et al. showed that mutations in the FOXA1 binding sites 
inhibit maximal androgen induction of PSA [115]. In contrast, Lee et al. observed that 
overexpression of FOXA1 reduced androgen induced PSA expression, probably by 
competition of FOXA1 and other transcriptional coactivators [133]. Further analyses including 
more androgen-regulated genes are required to unravel the relationship between FOXA1 
and AR. 
Further, this is the first study that demonstrated a prognostic value of FOXA1 in prostate 
cancer. Interestingly, the association between strong FOXA1 expression and shorter relapse 
free survival was particularly significant in the subgroup of primary prostate carcinomas with 
low (staining score 1) and moderate (staining score 2) AR expression levels. In contrast, 
relapse free survival did not depend on FOXA1 expression levels in the subgroup of 
carcinomas with high AR levels (staining score 3). 
These findings might indicate that high AR expression promotes prostate cancer progression 
in a FOXA1 independent way, whereas in carcinomas with low AR expression, FOXA1 is 
needed to maintain AR signaling and thus to promote prostate cancer progression.  
 
As mentioned in the introduction, estrogens were shown to be important for complete 
prostate cancer development. Treatment of rats with testosterone alone resulted in HGPIN in 
40 % of the animals. Additional administration of estradiol led to the development of prostate 
carcinomas in nearly all treated animals. However, no HGPIN or neoplasias were detected in 
ERα knockout rats. Similarly, less carcinomas were detected in rats lacking aromatase, the 
enzyme that converts testosterone to estradiol. In line with these animal studies, expression 
of aromatase is augmented in human prostate carcinomas. Also, ERα expression rises from 
low-grade tumors via high-grade tumors to metastases and CRPC and high expression of 
ERα in prostate carcinomas is associated with progression. Consequently, treatment of 
HGPIN patients with the ERα antagonist toremifene led to a 50 % reduction of carcinoma 
development (reviewed in [40, 41]). By virtue of the strong correlation between FOXA1 and 
ERα in primary prostate carcinomas, FOXA1 is probably involved in the transcription of ERα 
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target genes, which mediate the above described effects of estrogen treatment. One 
potential target is the fusion gene TMPRSS2:ERG, which is frequently detected in prostate 
cancer, and was shown to be inducible by ERα agonists [41]. Although a transcription 
promoting interaction between FOXA1 and ERα was not yet examined in prostatic cells, it 
was convincingly demonstrated several times in breast cells [114, 125, 129, 130]. 
 
Since we identified FOXA1 as an unfavourable prognostic factor, the correlation between 
FOXA1 and ERβ expression contradicts the current assumption that ERβ is the “good” 
estrogen receptor in prostate cancer development. However, also other recent studies 
question this hypothesis. So far, four studies investigated expression of ERβ and association 
with aggressiveness in human prostate carcinomas. Three reported a general loss of ERβ 
mRNA and/or protein expression in prostate carcinomas [215-217], one of these revealed 
upregulation of ERβ in metastases [216]. The fourth study showed a decreased expression 
of ERβ in 40 % of HGPIN compared to normal tissue, high expression in hormone-dependent 
carcinomas and their metastases and again a loss of ERβ expression in CRPC [218]. Poor 
prognosis was associated with low [215] as well as with high [219, 220] ERβ expression.  
Two cell culture studies dealing with the role of ERβ in prostate cancer cells, however 
support the theory of ERβ being the “good guy” as seen from the perspective of the patient. 
Induction of apoptosis and downregulation of the fusion protein TMPRSS2:ERG upon 
treatment with ERβ agonists were reported [221]. Further, it was shown that ERβ together 
with its ligand 3β-adiol maintains the epithelial phenotype and represses epithelial-
mesenchymal transition. Conversely, ERβ expression was reduced upon epithelial-
mesenchymal transition induction by TGFβ or hypoxia [222].  
Analysis of ERβ expression in various independent patient cohorts is needed to clarify the 
role of this steroid hormone receptor in prostate cancer development. 
 
In summary, FOXA1 expression strongly correlates with expression of AR, ERα and ERβ 
indicating that opening of the chromatin by FOXA1 might be important for transcription of 
steroid hormone receptor target genes in prostate carcinomas. The impact of FOXA1 
interaction with steroid hormone receptors needs to be further elucidated. Survival analyses 
performed here added already one piece to that puzzle: FOXA1’s influence on progression 
free survival interestingly depends on the expression level of AR suggesting that the 
presence of FOXA1 is especially important for the survival of prostate cancer cells with lower 
amounts of AR. 
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5.2.3 Functional characterization of FOXA1 in vitro 
The apparent connection between FOXA1 expression and prostate cancer progression 
prompted the question if FOXA1 can directly enhance tumorigenicity of prostate cancer cells. 
For this, expression of FOXA1 in prostatic cell lines was analyzed and in vitro experiments 
were set up in the same way as for CANT1 to study the influence of FOXA1 knockdown on 
cell migration and proliferation.  
 
As for immunohistochemistry, an antibody that reacts with FOXA1 as well as FOXA2 was 
used for Western Blot analyses. Although RWPE-1 cells originate from the peripheral zone 
according to the information of the distributor, very little FOXA1 mRNA and no protein was 
detected, which contradicts TMA expression data. In accordance with the TMA data that 
were obtained from analysis of human tissue, strong expression was noticed in the 
metastatic cell line LNCaP and in the hormone-independent cell line PC-3. In addition, 
FOXA1 protein level is unexpectedly undetectable in the second hormone-independent cell 
line DU-145. The expression levels of FOXA1 mRNA clearly differed from these of FOXA1 
protein, suggesting post-transcriptional regulation. Especially the comparison between these 
levels in PC-3 and DU-145 cells indicates suppression of FOXA1 protein expression in the 
latter cell line. 
High levels of FOXA2 were detected in PC-3 and DU-145 cells, whereas expression of this 
transcription factor was low in RWPE-1 and LNCaP cells. Strong expression of both, FOXA1 
and FOXA2, in PC-3 cells was already described before, as well as strong expression of 
FOXA1 in LNCaP. However, the previous expression analyses of these two proteins 
revealed absence of FOXA2 in DU-145 cells, contrasting our observation [109]. 
 
To further investigate FOXA1’s role in prostate cancer, in vitro tumorigenicity assays were 
performed using wildtype and FOXA1 knockdown cells. These studies demonstrated that, 
similar to CANT1 knockdown, also FOXA1 knockdown slowed down propagation of LNCaP 
and PC-3 cells, which was caused by a reduced cell proliferation rate, which was in turn 
caused by an arrest in G1-phase as demonstrated by DNA synthesis rate measurement and 
cell cycle analysis. Also, a reduction of the S-phase cell population was observed in the cell 
cycle study. FOXA1 was shown before to promote expression of the negative cell cycle 
regulator p27 as well as of the cell cycle promoter cyclin D1 and thus suggested to balance 
cell proliferation and maintenance of differentiation [96]. Upon FOXA1 knockdown this 
balance is probably disrupted and other cell cycle arresting pathways are predominant. 
Similar to our observations, strong expression of FOXA1 was also detected in ERBB2 
positive breast cancer cell lines, which are a model of aggressive (ERBB2 positive) breast 
cancer. In these cells, knockdown of FOXA1 inhibited cell proliferation and promoted 
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response to trastuzumab (Herceptin) by induction of apoptosis [214]. In contrast, forced 
expression of FOXA1 in estrogen receptor-positive breast cancer cell lines inhibited clonal 
growth and FOXA1 expression levels correlated negatively with growth stimuli [208]. These 
results indicate different roles of FOXA1 in ERBB2- and estrogen receptor-positive breast 
cancer cells. Considering the proliferation promoting effect of FOXA1 expression, prostate 
cancer cells resemble more the ERBB2-positive breast cancer cells although a strong 
correlation between FOXA1 and estrogen receptor expression was demonstrated in parallel.  
Additionally, a decreased motility of both cell lines upon FOXA1 downregulation was 
observed in a haptotactic transmigration assay, which could be verified for PC-3 cells in the 
scratch wound assay. 
 
Together, these data show an enhanced mitotic activity and augmented migration rates of 
prostate cancer cells with high FOXA1 levels and hence endorse a functional relevance of 
FOXA1 expression during progression of prostate carcinomas.  
5.2.4 Is it FOXA1 or FOXA2, which is involved in prostate cancer progression? 
One drawback of this study is the FOXA1-antibody, which was used for immuno-
histochemistry and Western Blot analyses, due to its crossreactivity with FOXA2. The cell 
culture studies were performed using FOXA1-specific siRNAs as confirmed by Western Blots 
analyses with this antibody. Therefore all effects that were observed upon FOXA1 
knockdown were actually related to differences in FOXA1 expression levels. However, in 
immunohistochemistry, a distinction between immunoreactivity with FOXA1 or FOXA2 was 
not possible. Other groups that investigated FOXA2 expression in prostate cells, reported 
that FOXA2 is expressed in the prostate only during development [99], whereas in the 
urogenital tract of adult mice, FOXA2 was only detected in the epididymis [116]. One group 
detected FOXA2 in early PIN lesions [223], whereas expression of FOXA2 mostly in 
neuroendocrine carcinomas was shown repeatedly [109, 223, 224]. On our TMA, FOXA1/2 
staining does not correlate with chromogranin, which is a strong marker of neuroendocrine 
differentiation, indicating that the FOXA2 signal is not predominant. 
Mirosevich et al. speculated that FOXA2 is involved in the progression of prostate cancer to 
castration-resistance, because FOXA2 induced expression of androgen-dependent prostate-
specific genes independent of AR and hormone [109]. Accordingly, an association between 
FOXA2 expression and the invasive type of prostate cancer was revealed [225] and FOXA2 
expression was detected in some prostate carcinomas with high Gleason score [109]. 
Further supporting a relation between FOXA2 expression and castration-resistance, both 
hormone-independent cell lines that were analyzed in the here described work displayed 
strong FOXA2 expression.  
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Unfortunately, Jain et al., who as well revealed a strong increase of FOXA1 expression in 
advanced prostate carcinomas, did not explicitly state if they used the FOXA1-specific 
antibody, which is meanwhile offered by Santa Cruz Biotechnologies, or the antibody that we 
were using. In any case, taking into account our definitely FOXA1-specific cell culture data 
and the absence of a correlation between FOXA1/2 staining and neuroendocrine 
differentiation, we are convinced that the upregulation of FOXA1/2 in metastases and CRPC, 
the prognostic value of FOXA1/2 expression and the resultant importance for prostate cancer 
progression is at least in part, if not mainly, caused by FOXA1 expression. 
5.2.5 Conclusion about the role of FOXA1 in prostate cancer 
Collectively, it emerges that the pioneer transcription factor FOXA1 is functionally relevant 
during the progression of prostate carcinomas from primary, hormone-dependent carcinomas 
to end-stage hormone-independent CRPC. This is probably mediated by the steroid hormone 
receptors ERα, ERβ and especially AR. Since carcinomas from the transitional zone showed 
invariably low FOXA1 expression, a FOXA1 independent development of this subtype of 
cancer can be assumed. Clinically, this study added another prognostic biomarker, although 
this was not maintained in multivariate analysis. 
5.3 The role of GOLM1 in prostate cancer  
5.3.1 Functional characterization of GOLM1 in vitro 
Previously, our group showed that GOLM1 expression is stronger in primary prostate 
carcinomas compared to normal prostate epithelium, both on RNA and on protein level. In 
PIN lesions intermediate levels were detected [15, 16]. The analysis of GOLM1 expression in 
advanced carcinomas of the prostate is a matter of future research. 
 
Another hitherto not pursued question is the functional relevance of GOLM1 overexpression 
in prostate cancer cells. To address this question, an expression analysis of GOLM1 in 
prostatic cell lines was conducted. Fitting to the expression data in human tissue, protein 
expression was detectable but low in the benign cell line RWPE-1. As no data for advanced 
carcinoma exist, the expression levels of GOLM1 in the metastatic cell lines, being high in 
the hormone-dependent cell line LNCaP as well as the hormone-independent cell line DU-
145 and low in the second hormone-independent cell line PC-3, cannot be evaluated in 
comparison to tissue expression levels.  
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Next, a protocol to efficiently downregulate GOLM1 expression in LNCaP and DU-145 cells 
was established. In certain knockdown cells, cell proliferation or migration changed 
significantly in comparison to control cells. However, no consistent tendency for all three 
different GOLM1-specific siRNAs was observed in any of the conducted experiments. 
 
Hence, despite of high expression differences on RNA and especially on protein level that 
were achieved between control and GOLM1 knockdown cells, in vitro tumorigenicity was not 
affected. 
5.3.2 Conclusion about the role of GOLM1 in prostate cancer 
Clinically, GOLM1 is a valuable diagnostic marker, which can be applied immuno-
histochemically to tissue samples [16] as well as for non-invasive diagnosis of prostate 
cancer in the patients’ urine [147, 149]. However, tumorbiologically it is unlikely that GOLM1 
is functionally implicated in prostate cancer development, because neither an association 
with prognosis was found in the previous TMA-study of our group [16] nor a reduction of 
tumorigenicity was observed in in vitro assays. Thus, GOLM1 upregulation in primary 
prostate carcinomas is most probably a side-effect of tumor initiation without any functional 
relevance for the cancer cells. Still analyses of GOLM1 protein expression in advanced 
prostate carcinomas and of GOLM1 regulation in prostatic tissues are required. 
5.4 The molecular biology of prostate cancer 
A major goal in the field of molecular biology of prostate cancer is to unravel the mechanisms 
of castration-resistance. A better knowledge of the underlying mechanisms is crucial for the 
development of more efficient therapies for end-stage carcinomas. 
5.4.1 Gene and protein expression in prostate cancer 
This study revealed the expression course of two proteins during prostate cancer initiation 
and progression. CANT1, whose expression had not been analyzed in any human neoplasia 
so far, was detected weakly in normal prostate epithelium. Its expression increased during 
tumor initiation and decreased again during progression to castration-resistance. The case-
wise comparison of CANT1 expression in tumor glands with adjacent normal glands revealed 
an upregulation of the protein in the vast majority (97.2 %) of the cases. 
FOXA1 expression was studied for the first time in a large cohort of prostate carcinomas 
including 51 CRPC cases. Being not affected during initiation of prostate cancer 
development, FOXA1 expression clearly increased in metastases and even more 
pronounced in CRPC. 
Thus, in primary prostate carcinomas, the overexpression of the first candidate CANT1, 
which was identified within the initial gene array study [15], was confirmed, whereas 
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overexpression of the second candidate FOXA1 was contradicted. This discrepancy could be 
traced back to usage of tissue from different prostatic zones as benign control tissue. While 
the former study used samples from different zones of normal epithelium and primary 
carcinomas, samples from the same zonal origin were used in the current study. Thus, the 
finding that FOXA1 expression levels are similar in normal epithelium and primary 
carcinomas is correct. 
5.4.2 Different ways to overcome castration 
Following hormonal therapy most of the tumors regress initially, accompanied by a decline of 
serum PSA levels. However, after a certain period of quiescence, PSA levels rise again 
indicating relapse of the tumor, which is then castration-resistant. Various mechanisms have 
been described that enable the tumor to overcome androgen blockage. Frequently, the AR 
gene is amplified or mutated, which leads to overexpression or functional changes of the 
receptor. Overexpression allows the tumor cells to survive despite minimal extracellular 
androgen levels. Further, it was reported that overexpression of AR turns therapeutic 
antagonists into agonists. Treatment of cells with high AR levels with bicalutamide induces 
DNA binding of the AR, recruitment of coactivators and expression of target genes, while 
bicalutamide treatment of cells with low AR levels inhibits expression of androgen dependent 
genes. Various mutation variants of AR are known. These either can be activated by other 
endogenous steroids and antiandrogens, or have different binding characteristics to 
coactivators and corepressors, or lack the ligand binding domain and are constitutively 
active. The latter mutants cannot be targeted by any antiandrogens that interact with the 
ligand binding domain [226]. Further, AR can be activated independent of androgens via 
growth factor receptor signaling pathway, PKA pathway, interleukin (IL) 6 or bone-derived 
factors, for which the N-terminal domain of AR is important. Alternatively, ubiquitination of AR 
by RNF6 was reported, which results in modulation of the activity and specificity of the 
steroid hormone receptor. RNF6 was shown to be overexpressed selectively in CRPC and to 
promote prostate cancer cell growth especially under androgen depletion conditions [227]. 
Other resistence mechanisms involve upregulation of transcriptional AR coactivators or of 
androgen synthesis enzymes. Indeed, intratumoral testosterone concentrations were shown 
to be equal in primary tumors and CRPC (reviewed in [35, 38, 41], summarized in Fig. 63). 
The novel agent EPI-001 that interacts with the N-terminal domain of AR is currently under 
investigation [226]. Great expectations are connected with this molecule, because it prevents 
transactivation of gene transcription independent of AR activation. 
Given that FOXA1 is upregulated during establishment of castration-resistance and that 
FOXA1 epxression is needed for the progression of carcinomas with low and moderate AR 
expression levels in contrast to carcinomas with high AR expression levels, this thesis 
suggests expression of this transcription factor as a novel mechanism of castration-
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resistance in the category of upregulation of coactivators (Fig. 63). This enables the cancer 
cells to sustain androgen signaling despite shortage of androgens. In the case of high AR 
expression, the additive support on transcription of androgen-regulated genes by FOXA1 is 
not needed. 
One potential target gene is anterior gradient homolog (AGR) 2, whose regulation by 
androgens as well as by FOXA1 was demonstrated and which was shown to promote motility 
and invasiveness of prostate cancer cells [228, 229]. 
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Fig. 63 Mechanisms of castration-resistance in prostate cancer. 
 
5.5 The clinical aspects of prostate cancer 
As outlined in detail in the introduction, three major clinical aims are connected to prostate 
cancer: specific and sensitive non-invasive diagnosis, prognosis of disease course and life-
prolonging treatment of CRPC. 
5.5.1 Diagnosis 
In most cases, prostate cancer can be diagnosed correctly using the current methods of 
DRE, serum PSA measurement, and most important, histology. However, some unclear 
cases remain, where immunohistochemical markers help to ascertain the diagnosis. Since 
FOXA1 expression levels are similar in normal prostate epithelium and in primary prostate 
carcinomas, it is ineligible for this application. Also, analysis of tissue CANT1 levels does not 
help in diagnosing prostate cancer, because this marker cannot discriminate between PIN 
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and cancer lesions, which would be important to determine the treatment modality for the 
patient.  
In any case, currently needle biopsies are needed to make a definite diagnosis following 
initial suspicion of prostate cancer due to positive DRE or elevated serum PSA levels. Since 
increased secretion of PSA into the blood occurs also in other benign prostate diseases [8], 
many healthy individuals undergo invasive diagnostics (biopsies). To reduce the number of 
unnecessary biopsies, a more specific non-invasive diagnostic tool is desirable. Hence, 
biomarkers that are evaluable in patient serum or urine would represent an ideal alternative. 
Hitherto, the non-coding RNA PCA3 has been identified with an increased specificity in 
comparison to PSA. Further, PCA3 seems to be independent of the prostate volume in 
contrary to PSA [230]. Consequently, urine-detection of this gene was approved for the 
diagnosis of prostate cancer in Europe in 2006 [20, 231]. However, the test is expensive and 
is therefore not widely applied in the clinic.  
Further improved statistical values that characterize specificity of biomarkers were revealed 
for a multiplex analysis of PCA3, TMPRSS2:ERG, GOLM1 and SPINK1 gene expression in 
post-DRE urine [149] as well as for a multiplex analysis of glutathione S-transferase pi 
(GSTP) 1, Ras association (RalGDS/AF-6) domain family member (RASSF) 1A, retinoic acid 
receptor (RAR) β2, and adenomatous polyposis coli (APC) methylation [232]. 
In this study, CANT1 was proven to be detectable in serum samples in contrary to a previous 
statement [61]. With the newly designed sandwich ELISA assay higher serum CANT1 levels 
were measured in prostate cancer patients in comparison to healthy individuals. Although 
this difference was not significant and CANT1 amounts were just below the detection 
threshold of the assay, CANT1 is a potential novel candidate as serum biomarker for the 
diagnosis of prostate cancer. Beneficial to PCA3, conduction of a serum ELISA assay is 
more economic than RNA-based diagnostic. However, since CANT1 upregulation in tissue 
was already detectable in the precursor lesion PIN, CANT1 serum levels need to be 
analyzed in PIN patients, before the optimization of CANT1 measurement in serum can 
proceed. 
5.5.2 Prognosis 
An early prognosis of the disease course is highly relevant for the prevention of 
overtreatment. Two major disease courses exist for prostate cancer. Either the (insignificant) 
carcinoma grows slowly, does not extend through the prostate capsule and never threatens 
the patients’ life or the (aggressive) carcinoma relapses after primary treatment, gets 
inevitably castration-resistant within two years after hormonal therapy and finally involves 
death of the patient. To avoid treatment-associated side-effects [30] for patients with 
insignificant carcinomas, prognosis of the disease course ought to be carried out ideally with 
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help of blood serum, urine or needle biopsies. Classical analysis of histology is a strong 
prognostic factor in prostate cancer (Fig. 64).  
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Fig. 64 Univariate survival analysis dependent on Gleason scoring. 
Note the different survival curves of patients with Gleason score 7 dependent on the 
dominant Gleason pattern. Modified from [233]. 
 
However, as already mentioned in the introduction, especially for the intermediate risk group 
with Gleason score 7, novel biomarkers that are able to predict the risk of recurrence, are 
needed. Potential candidates with some superiority to Gleason score have been identified, 
amongst others increased detection of U-plasminogen activator (uPA) or uPA-receptor 
(uPAR), TGFβ, ILg-R and Endoglin in serum and increased immunohistomchemical staining 
of prostate-specific membrane antigen (PSMA), Ki67, AR, p53, HSP60, TATI (the protein of 
the SPINK1 gene), PTEN, SMAD4, cyclin D1 and secreted phosphoprotein (SPP)1 [234]. 
Furthermore, hypermethylation of CD44 and cyclin D2 that can be detected in tissue or 
serum, the overall number of DNA copy number alterations [53] or an increased number of 
circulating tumor cells have been suggested. In general, combinations of these candidates 
amongst themselves or with classical clinicopathological parameters increase the 
performance of the markers (reviewed in [232, 235-237]).  
This study adds two further biomarker candidates for the prognosis of prostate cancer. 
Patients with very high expression levels of CANT1, which can only be identified using the 
more differentiated H-score, have a very good prognosis (5-year survival rate 93 %) 
compared to patients with lower CANT1 expression levels (5-year survival rate 81 %). In 
contrast, patients with high FOXA1 expression levels have a poor prognosis (5-year survival 
rate 55 %) compared to patients with low FOXA1 expression levels (5-year survival rate 
68 %). This difference is even more pronounced in the subgroup of patients with low or 
moderate AR expression levels (5-year survival rate 68 % and 40 % for patients with high 
and low FOXA1 expression levels, respectively). The prognostic value of CANT1 is also 
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maintained in a multivariate analysis, which means that CANT1 is independent of Gleason 
score and other clinicopathological parameters. Thus, CANT1 expression adds further  
information to the prognosis of the disease course. Since these analyses were conducted on 
RPE specimens, these markers can only be applied in the clinic if the prognostic relevance is 
maintained in a large cohort of needle biopsies. 
5.5.3 Treatment 
Whereas the majority of prostate cancer patients can be cured by either surgery or 
radiotherapy [238] and hormonal therapy reduces disease symptoms successfully in the 
beginning, a significant fraction of patients experiences disease progression to CRPC. For 
these, treatment options are limited and survival rates are low [31, 32, 239, 240]. Thus, novel 
therapies urgently need to be developed to at least prolong the life-expectancy of CRPC 
patients. However, the final goal must be to keep the carcinoma in its hormone-dependent 
state to achieve a persistent control of the disease.  
Concerning prolongation of the life-expectancy of CRPC patients, CANT1 is a potential 
target. Although CANT1 protein levels decline from primary prostate carcinomas to CRPC, 
proliferation of the hormone-independent cell line PC-3 was markedly reduced by 
transfection of CANT1-specific siRNA #1. Hence, CANT1 downregulation by RNA 
interference represents a promising approach to prevent growth of castration-resistant 
prostate cancer cells. A technically easier approach would be a small molecular inhibitor of 
CANT1 enzymatic activity. In the context of UPR, inhibition of CANT1 would be equal to 
induction of UPR, which was suggested as possible therapeutic approach for solid tumors, 
possibly in combination with overload of the protein folding machinery so that cells cannot 
handle the bulk of misfolded proteins, leading to death of the cancer cell [188]. 
In patients with low to moderate expression levels of AR, FOXA1 might be the target of 
choice to prevent the carcinoma from growing independent of androgens. Especially in this 
group, patients’ prognosis was highly dependent on FOXA1 expression levels. However, 
further experimental evidence is needed to directly show that FOXA1 is required for the 
progression of primary carcinomas with low AR levels before a treatment based on FOXA1 
inhibition is developed. 
5.6 Final Conclusion 
Within this study, the expression patterns of two proteins were analyzed in detail in large 
patient cohorts. CANT1 is upregulated during prostate cancer initiation, whereas FOXA1 is 
upregulated during cancer progression. Due to the importance of FOXA1 for the progression 
of carcinomas with low AR levels, we suggest overexpression of FOXA1 in its function as AR 
coactivator as novel mechanism of castration-resistance for prostate cancer. 
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Both proteins are not suitable as immunohistochemical diagnostic biomarkers. However, 
under certain conditions both proteins have a prognostic value. Very strong CANT1 levels in 
RPE specimens identified the upper quartile of patients with a good prognosis. In contrast, 
the prognosis for patients with high FOXA1 expression is poor, especially in combination with 
low or moderate AR levels. Thus, FOXA1 might be a target for a treatment to prevent 
castration-resistance. Downregulation of CANT1 potentially impairs proliferation of prostate 
cancer cells during the whole tumor development. 
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7.1 Abbreviations 
a.u. arbitrary unit 
ABCC ATP-binding cassette sub-family C member 
ACTH adrenocorticotropic hormone 
ADAM a disintegrin and metallopeptidase domain 
ADP adenosine diphosphate 
AFP alpha-fetoprotein 
AGR anterior gradient homolog 
ALAS aminolevulinate, delta-, synthase 
AMACR alpha-methylacyl-CoA racemase 
AMP adenosine monophosphate 
APC adenomatous polyposis coli 
APS ammonium persulfate 
apy APYrase 
AR androgen receptor 
ARA70 70 kDa AR-activator 
ARE androgen responsive element  
ATF activating transcription factor 
ATP adenosine triphosphate 
 
Bcl2 B-cell leukemia/lymphoma 2 
BPH benign prostatic hyperplasia 
BRCA breast cancer 
BrdU bromodeoxyuridine 
BSA bovine serum albumine 
 
Ca carcinoma 
CANT calcium-activated nucleotidase 
CANX calnexin 
CD44 cluster of differentiation 
CHOP CCAAT/enhancer-binding protein homologous protein 
CMP cytidine monophosphate 
CRH corticotropin-releasing hormone 
CRPC castration-resistant prostate carcinoma 
C-terminus carboxy-terminus 
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CTFC CCCTC-binding Factor 
CTP cytidine triphosphate 
CXCL chemokine (C-X-C motif) ligand 
 
DAG diacylglycerol 
DAPI 4′,6-Diamidino-2-phenylindole dihydrochloride 
DHEA dehydroepiandrosterone 
DHEA-S DHEA-sulphate 
DHT dihydrotestosterone 
DMSO dimethylsulfoxid 
DNA deoxyribonucleic acid 
Dol dolichol 
DRE digital rectal examination 
 
E2 estradiol 
EDEM ER degradation enhancer, mannosidase alpha-like 
EDTA ethylenediaminetetraacetic acid  
EGF epidermal growth factor 
eIF eukaryotic translation initiation factor 
ELISA enzyme-linked Immunosorbent assay 
ER endoplasmic reticulum 
ERAD ER-associated degradation 
ERBB v-erb-b2 erythroblastic leukemia viral oncogene homolog 
ERE estrogen responsive element 
ERSE ER-stress response element 
ERα/β estrogen receptor α/β 
ETS avian erythroblastosis virus E26 (v-ets) oncogene homolog 
 
FASN fatty acid synthase 
FBS fetal bovine serum 
FGF fibroblast growth factor 
FOX forkhead box 
Fuc fucose 
 
G1/2 gap 1/2-phase 
Gal galactose 
GATA GATA binding protein  
GDP  guanosine diphosphate 
GFP green fluorescent protein 
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GH globular domain of linker histone 
Glc glucose 
GlcA glucuronic acid 
GlcNAc N-acetylglucosamine 
GM-CSF granulocyte-macrophage colony-stimulating-factor 
GMP guanosine monophosphate 
GnRH gonadotropin releasing hormone 
GOLM Golgi membrane protein 
GOLPH Golgi phosphoprotein 
GPP130 130 kDa Golgi-localized phosphoprotein 
GSTP glutathione S-transferase pi 
 
HCC hepatocellular carcinoma 
Herpud homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like  
domain member 
HGF hepatocyte growth factor 
HGPIN high grade PIN  
Hn histone n 
HNF hepatocyte nuclear factor 
HPRT hypoxanthine phosphoribosyltransferase 
H-score histochemical score 
HSP heat-shock protein 
HX homeobox 
 
IDP inosine diphosphate 
IF immunofluorescence 
IGF insulin-like growth factor 
IHC immunohistochemistry 
IL interleukin 
IP inositol phosphate 
IRE inositol-requiring protein 
ITP inosine triphosphate 
IκB  inhibitor of kappa B 
 
Kn lysine n 
 
LH  luteinizing hormone 
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M metastasis 
Man mannose 
MAPK mitogen-activated protein kinase 
men methylated n-times 
miRNA microRNA 
M-phase mitotic phase 
mRNA messenger RNA 
 
N  node 
NDP nucleoside diphosphate 
NFκB nuclear factor kappa-light-chain-enhancer of activated B cells 
NKn NKn homeobox 
NMP nucleoside monophosphate 
N-terminus amino-terminus 
NTP nucleoside triphosphate 
 
OD optical density 
 
PAP prostatic acid phosphatase 
PBS phosphate buffered saline 
PCA prostate cancer antigen 
pcr polymerase chain reaction  
PDGF platelet-derived growth factor 
PERK protein kinase RNA-like endoplasmic reticulum kinase 
PHA-E Phaseolus vulgaris Erythoragglutinin 
PI propidium iodide 
PIN prostatic intraepithelial neoplasia 
PIP phosphatidylinositol bisphosphate 
PK protein kinase 
PL phospholipase 
PNGase  peptide: N-glycosidase 
pre-OP pre-operative 
PSA prostate-specific antigen 
PSGR prostate-specific G-protein coupled receptor 
PSMA prostate-specific membrane antigen 
pT(NM) pathological T(NM) 
PTEN phosphatase and tensin homolog  
 
qRT-PCR quantitative real-time PCR 
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RAR retinoic acid receptor 
RASSF Ras association (RalGDS/AF-6) domain family member 
RNA ribonucleic acid 
RPE radical prostatectomy 
RPMI Roswell Park Memorial Institute 
RT room temperature 
 
SDS sodium dodecyl sulphate 
Sia sialic acid 
siRNA small interfering RNA 
SOX SRY (sex determining region Y)-box 
S-phase synthesis phase 
SPINK serine peptidase inhibitor, Kazal type 
SPP secreted phosphoprotein 
 
T  tumor  
TARP T-cell receptor gamma alternate reading frame protein 
TEMED tetramethylethylenediamine 
TGF transforming growth factor 
TLE transducin-like enhancer of split 
TMA tissue microarray 
TMPRSS transmembrane protease, serine 
TRIB tribbles homolog 
 
UDP uridine diphosphate 
UGGT UDP-Glc glycoprotein glucosyltransferase 
UMP uridine monophosphate 
unspec unspecific 
untr untreated 
uPA u-plasminogen activator 
uPAR uPA receptor 
UPR unfolded protein response 
UTP uridine triphosphate 
 
VEGF vascular endothelial growth factor 
 
WB Western Blot 
 
Xyl xylose
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